Document:

EX-10.47

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 EXHIBIT 10.47 

AMENDED AND RESTATED LICENSE AGREEMENT 

This AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”), effective as of January 8, 2014 (the “Amendment Effective
Date”), is made by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (“Sunesis”), and Millennium
Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 40 Landsdowne Street, Cambridge, Massachusetts 02139 (“Millennium”). Sunesis and Millennium are sometimes referred to herein individually as a
“Party” and collectively as the “Parties”. 
 BACKGROUND 

A. Sunesis has developed proprietary technology and know-how for the discovery and optimization of small molecules that bind to enzyme targets
and protein-protein interfaces, with special expertise towards kinases. 
 B. Pursuant to a Collaboration Agreement (the “Original
Agreement”) effective as of August 27, 2004 (the “Original Agreement Effective Date”) by and between Sunesis and Biogen Idec MA Inc. (“Biogen Idec”), as amended, Sunesis and Biogen Idec collaborated on the discovery and
development of small molecules that modulated Collaboration Targets (as defined in the Original Agreement), and discovered and commenced development of several compounds, including compounds designated as BIIB024 and [ * ], it being understood that
BIIB024 has been designated as a “Development Candidate” under the terms of the Original Agreement. 
 C. Pursuant to a Termination
and Transition Agreement (the “Three Party Agreement”) dated as of March 31, 2011 (the “Effective Date”), Sunesis, Biogen Idec and Millennium agreed that (i) Millennium shall succeed to the rights of Biogen Idec under
the Original Agreement with respect to the Licensed Compounds and certain other compounds and, in order to effectuate the foregoing, (ii) Sunesis and Millennium shall enter into that certain License Agreement, dated the Effective Date (the
“License Agreement”), Sunesis and Biogen Idec shall enter into an amendment and restatement of the Original Agreement (the “New Sunesis-Biogen Agreement”), and Millennium and Biogen Idec shall enter into an asset transfer
agreement (the “Millennium-Biogen Agreement”). 
 D. Pursuant to the License Agreement, Millennium has been developing BIIB024 and designated small
molecules that bind to two different targets, the Raf Target and the PDK Target, and Sunesis granted Millennium a license to its interest in the jointly owned intellectual property to develop and commercialize certain of such compounds. 

E. The Parties now desire for Millennium to grant Sunesis rights to develop and commercialize compounds binding the PDK Target (but not compounds binding the
Raf Target), and certain other rights with respect to such compounds. Accordingly, the Parties are amending and restating the License Agreement as this Agreement in accordance with Section 15.11 of the License Agreement. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 NOW, THEREFORE, for and in consideration of the covenants, conditions and undertakings
hereinafter set forth, it is agreed by and between the Parties as follows: 
 ARTICLE 1 

DEFINITIONS 
 As used
herein, the following terms will have the meanings set forth below: 
 1.1.”Affiliate” of a Person shall mean any
corporation or other business entity that during the Term of this Agreement controls, is controlled by or is under common control with such Person but only for so long as such entity controls, is controlled by, or is under common control with such
Person. With respect to a particular entity, “control” shall mean the ownership directly or indirectly of fifty percent (50%) or more of the stock entitled to vote for the election of directors, and for nonstock organizations, of the
equity interests entitled to control the management of such entity. [ * ]. 
 1.2. “Biogen Idec Collaboration Technology”
shall mean all Biogen Idec Collaboration Patents and Biogen Idec Collaboration Know-How. 
 1.2.1 “Biogen Idec
Collaboration Patents” shall mean (a) those Patent Rights set forth on Exhibit 1.4(a), the subject of which is an invention: (i) conceived in the course of performing the Research Program during the Research Term and
reduced to practice prior to the Effective Date solely by or under authority of personnel of Biogen Idec or any of its controlled Affiliates; or (ii) conceived and reduced to practice solely by or under authority of personnel of Biogen Idec or
any of its controlled Affiliates after the Original Agreement Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or
development of Licensed Compounds or Licensed Products; and (b) all Patent Rights that arise during the Term that claim or cover any Biogen Idec Collaboration Know-How. Notwithstanding the foregoing, Biogen Idec Collaboration Patents shall in
all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen Collaboration Patents and Sunesis Collaboration Patents. 

1.2.2 “Biogen Idec Collaboration Know-How” shall mean any Know-How: (i) made or developed solely by or
under authority of personnel of Biogen Idec or any of its controlled Affiliates in the course of performing the Research Program during the Research Term; or (ii) made or developed solely by or under authority of personnel of Biogen Idec or any
of its controlled Affiliates after the Original Agreement Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or
development of Licensed Compounds or Licensed Products. Notwithstanding the foregoing, Biogen Idec Collaboration Know-How shall in all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen Collaboration Know-How and Excluded Compounds (as
defined in the Original Agreement). 

  
 -2- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.3. “Co-Funding Option” shall mean the
option of Sunesis to fund a portion of the post-Phase I Development Costs of a Licensed Product in the Co-Funded Territory as provided in Section 2.2. The “Co-Funded Territory” shall have the meaning set forth in Section 2.2.1.

 1.4. “Collaboration Technology” shall mean all Collaboration Patents and Collaboration Know-How. 

1.4.1 “Collaboration Patents” shall mean all Biogen Idec Collaboration Patents, Sunesis Collaboration Patents
and Joint Sunesis-Biogen Collaboration Patents. Exhibit 1.4(a) sets forth the Collaboration Patents existing as of the Amendment Effective Date. 

1.4.2 “Collaboration Know-How” shall mean all Biogen Idec Collaboration Know-How, Sunesis Collaboration
Know-How and Joint Sunesis-Biogen Collaboration Know-How. 
 1.5. “Combination Product” shall mean any of (i) a
Licensed Product that incorporates two or more active drug substances including a Licensed Compound, or (ii) a PDK Product that incorporates two or more active drug substances including a PDK Compound; or (iii) a Reverted Licensed Product
that incorporates two or more active drug substances including a Reverted Compound; in each case where at least one of the active drug substances is not a Licensed Compound, PDK Compound or Reverted Compound, respectively. 

1.6. “Commercially Reasonable and Diligent Efforts” shall mean the level of effort and resources normally used by a Party for
a product or compound owned or controlled by it, which is of similar market potential and at a similar stage in its development or product life, taking into account, without limitation, with respect to a product issues of safety and efficacy,
product profile, the proprietary position of the product, the then current competitive environment for the product and the likely timing of the product’s entry into the market, the regulatory environment of the product, and other relevant
scientific, technical and commercial factors. Notwithstanding the foregoing, to the extent that the performance of a Party’s responsibilities hereunder is adversely affected by the other Party’s failure to perform its responsibilities
hereunder, such Party shall not be deemed to have failed to use its Commercially Reasonable and Diligent Efforts in performing such responsibilities. Notwithstanding, but not in limitation of the foregoing, Millennium shall be deemed to be using
Commercially Reasonable and Diligent Efforts for a Co-Funded Product specifically directed at a particular Designated Target if it is using Commercially Reasonable and Diligent Efforts with respect to a Licensed Compound specifically directed at
such Designated Target. 
 1.7 “Confidential Information” shall mean, with respect to a Party, all information (and all
tangible and intangible embodiments thereof), which is owned or controlled by such Party, and is disclosed by such Party to the other Party pursuant to this Agreement. Notwithstanding the foregoing, Confidential Information of a Party shall not
include information which, and only to the extent, the receiving Party can establish by written documentation (a) has been generally known prior to disclosure of such information by the disclosing Party to the receiving Party; (b) has
become generally known, without the fault of the receiving Party, subsequent to disclosure of such information by the disclosing Party to the receiving Party; 

  
 -3- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
(c) has been received by the receiving Party at any time from a source, other than the disclosing Party, rightfully having possession of and the right to disclose such information free of
confidentiality obligations; (d) has been otherwise known by the receiving Party free of confidentiality obligations prior to disclosure of such information by the disclosing Party to the receiving Party; or (e) is independently developed
without reference to or use of the Confidential Information of the disclosing Party. For clarity, except as otherwise expressly provided in this Agreement, Sunesis Collaboration Technology and Joint Sunesis-Biogen Collaboration Technology shall be
deemed Confidential Information of both Millennium and Sunesis. For clarity, Biogen Idec Collaboration Technology and Development Technology shall (i) if related to any of the Raf Target, Licensed Compounds or Licensed Products, be deemed
Confidential Information solely of Millennium (unless and until such time as such Licensed Compound becomes a Reverted Compound or such Licensed Product becomes a Reverted Licensed Product in accordance with the Agreement, in which case it shall be
deemed Confidential Information solely of Sunesis); and (ii) if related to any of the PDK Target, PDK Compounds or PDK Products, be deemed Confidential Information solely of Sunesis, and PDK Technology shall be deemed Confidential Information
solely of Sunesis, in each case unless and until such time as such PDK Compound becomes a Licensed Compound or such PDK Product becomes a Licensed Product in accordance with the Agreement, in which case it shall be deemed Confidential Information
solely of Millennium. 
 1.8 “Control” or “Controlled” shall mean, with respect to any Patent Rights or
Know-how and with respect to any Person, possession (whether by ownership or license, other than a license granted pursuant to this Agreement) by such Person or its Affiliate of the ability to grant the licenses or sublicenses as provided for herein
without violating the terms of any agreement or other arrangement with any Third Party. 
 1.9 “Covered” shall mean, with
respect to a compound and a Valid Claim, that the manufacture, use, sale, offer for sale or importation of such compound, but for the licenses or ownership rights granted herein, would infringe such Valid Claim. 

1.10 “Designated Targets” shall mean (i) the Raf Target and (ii) the PDK Target. 

1.11 “Development” shall mean all research, development and regulatory activities regarding the Licensed Products.
“Development” shall include all activities related to research, optimization and design of the appropriate molecule and identification of back-ups, preclinical testing, test method development and stability testing, toxicology,
formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, manufacturing clinical supplies, regulatory affairs, statistical analysis and report writing, technology
transfer, market research and development, and all other pre-approval and related post-approval activities. When used as a verb, “Develop” shall mean to engage in Development. 

1.12 “Development Candidate” shall mean any Licensed Compound that enters into GLP clinical toxicology testing or GMP
manufacturing. 

  
 -4- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.13 “Development Costs” shall mean the costs and expenses associated with
Development activities actually incurred by Millennium or its Affiliates for a particular Licensed Product during the measurement period and in the territories described in Section 2.2.4(c). The costs and expenses associated with Development
activities shall include [ * ]. In determining “Development Costs” chargeable under this Agreement, Millennium will use its project accounting systems, and will review its project accounting systems and methodologies with Sunesis. The
Parties hereby agree that efforts of the employees of Millennium or its Affiliates in performing its activities hereunder shall be charged as Development Costs at the FTE Rate. Notwithstanding anything in this Section 1.13 to the contrary, only
those Development Costs that are contemplated by the Co-Development Plan and Budget or were otherwise approved by the Joint Steering Committee shall be chargeable by Millennium as Development Costs. It is further understood that the activities of
the following groups or functions shall not be chargeable as Development Costs: [ * ]. All payments made by Millennium to a Third Party in connection with the performance of its activities under the Co-Development Plan and Budget shall be charged as
Development Costs at Millennium’s actual out-of-pocket cost. Expenses incurred by Millennium for equipment, materials and supplies utilized in performing its activities under the Co-Development Plan and Budget shall not be separately charged as
Development Costs, except for those expenses incurred by Millennium, with the prior written consent of the Joint Steering Committee as set forth in the Co-Development Plan and Budget, in the purchase or making of [ * ], and the like) that are to be
used exclusively in connection with the performance of Millennium’s activities under the Co-Development Plan and Budget (e.g., [ * ], etc.), which expenses shall be charged as Development Costs at Millennium’s actual out-of-pocket expense
incurred in purchasing or making such [ * ]. 
 1.14 “Development Technology” shall mean any Know-How that is made or
developed solely by or under authority of either Party or its Affiliates, or jointly by or under authority of both Parties or their respective Affiliates, in the course of performing any activity under (a) the License Agreement that is [ * ] to
a Designated Target or [ * ] to the Development, manufacturing or commercialization of a Licensed Compound, Licensed Product, PDK Compound or PDK Product, or (b) this Agreement that is [ * ] to the Raf Target or [ * ] to the Development,
manufacturing or commercialization of a Licensed Compound or Licensed Product, and in each case (a) and (b) all Patent Rights that claim or cover any such Know-How. Development Technology shall in all cases exclude Biogen Idec
Collaboration Technology, Sunesis Collaboration Technology, Sunesis Core Technology, Joint Sunesis-Biogen Collaboration Technology and PDK Technology. 

1.15 “Diligence Summary” shall mean, with respect to a particular Product, a summary of Development and commercialization
activities with respect to such Product, that (i) were performed by the reporting Party or its Third Party collaborators in the previous [ * ] period (or shorter period from the prior Diligence Summary, if applicable), and (ii) as of the
date of the Diligence Summary, are planned in good faith for the following [ * ] period. For clarity, it is understood and acknowledged that in providing a Diligence Summary, a Party shall not be required to disclose scientific results, specific
research activities or the identity of any Third Party collaborator or potential collaborator, but shall at a minimum provide a summary of the total number of FTEs dedicated or planned to be dedicated to the Development and commercialization of such
Product, and a summary of the functional allocation of such FTEs. 

  
 -5- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.16 “Field” shall mean the treatment, prevention or diagnosis of disease in
humans and animals. 
 1.17 “FTE” shall mean, with respect to a Party, the equivalent of the work time of a full-time
clinician, regulatory or other qualified person over a twelve-month period (including normal vacations, sick days and holidays), equal to at least [ * ] ([ * ]) weeks of work. In the case of less than a full-time person, the portion of an FTE year
devoted by such person to Development activities shall be determined by dividing the number of days during any twelve-month period devoted by such person to Development activities by the total number of working days of such person during such
twelve-month period. “FTE Rate” for Millennium shall mean $[ * ] per annum per FTE from the Effective Date through December 31, 2011. Thereafter, the FTE Rate will be adjusted by the Inflation Index. As used herein, “Inflation
Index” shall mean the percentage increase in the Consumer Price Index for all Urban Consumers, as published by the U.S. Department of Labor, Bureau of Statistics, since the Effective Date. For clarity, the FTE rate for sales representatives
involved in co-promotion shall be determined in accordance with Section 3.2.3. 
 1.18 “Governmental Authority” shall
mean any multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other
tribunal). 
 1.19 “Gross Sales” shall mean the gross amount invoiced by either Party or its Affiliates or permitted
Sublicensees for sales of a Product. However, Gross Sales shall not include amounts received by such Party (or any of its Affiliates) from transactions with an Affiliate or Sublicensee, where the Product in question will be resold by such Affiliate
or Sublicensee to an independent Third Party distributor, agent or end user and such amounts received by the Affiliate or Sublicensee from such resale is included in Gross Sales. 

1.20 “Joint Sunesis-Biogen Collaboration Technology” shall mean all Joint Sunesis-Biogen Collaboration Patents and Joint
Sunesis-Biogen Collaboration Know-How. 
 1.20.1 “Joint Sunesis-Biogen Collaboration Patents” shall mean (a) those
Patent Rights set forth on Exhibit 1.4(a), the subject of which is an invention: (i) conceived in the course of performing the Research Program during the Research Term and reduced to practice prior to the Effective Date jointly by, or
under authority of, both Sunesis and Biogen Idec; (ii) conceived and reduced to practice jointly by, or under authority of, Sunesis and Biogen Idec after the Original Agreement Effective Date but prior to the Effective Date, in the case of
either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or development of Licensed Compounds or Licensed Products; or (iii) conceived in the course of performing the Research
Program during the Research Term and reduced to practice prior to the Effective Date using Joint Sunesis-Biogen Collaboration Know-How, Sunesis Collaboration Know-How or Sunesis Core Technology by or under authority of personnel of Biogen Idec or
any of its controlled Affiliates; and (b) all Patent Rights that arise during the Term that claim or cover any Joint Sunesis-Biogen Collaboration Know-How. For clarity, the inventions described in subsection (a)(iii) above are limited to those
inventions [ * ] or comprising compositions of matter that modulate Designated Targets or methods of use thereof in modulating Designated Targets. Notwithstanding the foregoing, Joint Sunesis-Biogen Collaboration Patents shall in all cases exclude
Sunesis Core Technology, Biogen Idec Collaboration Patents and Sunesis Collaboration Patents. 

  
 -6- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.20.2 “Joint Sunesis-Biogen Collaboration Know-How” shall mean any Know-How:
(i) made or developed jointly by, or under authority of, both Sunesis and Biogen Idec in the course of performing the Research Program during the Research Term; (ii) made or developed jointly by, or under authority of, both Sunesis and
Biogen Idec after the Original Agreement Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or development of
Licensed Compounds or Licensed Products. 
 1.21 “Know-How” shall mean any data, inventions, invention disclosures, methods,
proprietary information, processes, techniques, technology, or material (including biological or other materials). 
 1.22 “Licensed
Compounds” shall mean (i) BIIB024, (ii) the other compounds set forth on Exhibit G of the Millennium-Biogen Agreement, (iii) all other compounds that were Synthesized in the course of performing the Research Program
during the Research Term in connection with activities relating to the Raf Target, (iv) all other compounds claimed or covered by a Collaboration Patent that are [ * ] to the Raf Target (including Collaboration Patents listed under “Raf
Portfolio” in Exhibit 1.4(a) attached hereto, which has been updated as of the Amendment Effective Date), (v) all other compounds claimed or covered by an invention disclosure within the Collaboration Know-How that are [ * ] to the
Raf Target, and (vi) all salts, prodrugs, esters, metabolites, solvates, stereoisomers and polymorphs of any of the foregoing. As from the Amendment Effective Date, Licensed Compounds excludes all PDK Compounds. 

1.23 “Licensed Product” shall mean a pharmaceutical preparation for sale by prescription, over-the-counter, or any other
method for all uses in humans or animals, which incorporates one or more Licensed Compounds as an active drug substance, but excluding Reverted Licensed Products. It is understood that Licensed Products containing different active ingredient(s)
(i.e., a different active ingredient or an additional active ingredient) or a different formulation shall be deemed different “Licensed Products”. 

1.24 “Major Market” means any of [ * ]. 

1.25 “Millennium Licensed Technology” shall mean Millennium Licensed Patents and Millennium Licensed Know-How. 

1.25.1 “Millennium Licensed Patents” shall mean Millennium’s interest in the Patent Rights to the PDK
Compounds or PDK Products that were acquired from Biogen pursuant to the Millennium-Biogen Agreement, all of which are listed under the “PDK Portfolio” in Exhibit 1.4(a) to this Agreement. 

1.25.2 “Millennium Licensed Know-How” shall mean Millennium’s interest in Biogen Idec Collaboration
Know-How that was acquired from Biogen pursuant to the Millennium-Biogen Agreement [ * ] to the PDK Target or [ * ] to the PDK Compounds or PDK Products. 

  
 -7- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.26 “NDA” shall mean a New Drug Application (or its equivalent), as defined in
the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any jurisdiction for marketing authorization of a Product. 

1.27 “Net Sales” shall mean, with respect to a Product, Gross Sales less applicable Sales Returns and Allowances. 

If a sale, transfer or other disposition with respect to a Product is made for consideration other than cash or is not at arm’s length,
then the Net Sales from such sale, transfer or other disposition shall be the arm’s length fair market value thereof. For purposes of this Agreement, “sale” shall mean any transfer or other distribution or disposition, but shall not
include transfers or other distributions or dispositions of Product, at no charge, for pre-clinical, clinical or regulatory purposes or in connection with patient assistance programs or other charitable purposes or to physicians or hospitals for
promotional purposes. 
 In the event that a Product is sold in the form of a Combination Product, Net Sales for the Product shall be
determined by multiplying actual Net Sales of the Combination Product (determined by reference to the definition of Net Sales set forth above) during the royalty payment period by the fraction A/(A+B) where A is the average sale price of the Product
as the sole active drug substance when sold separately in finished form, and B is the average sales price of products containing only the other active ingredients when sold separately in finished form, in each case during the applicable royalty
payment period in the country in which the sale of the Combination Product was made, or if sales of both types of products did not occur in such period, then in the most recent royalty payment period in which sales of both occurred. Where the
Product is sold separately in finished form but the other ingredients are not, Net Sales for the Product shall be determined by multiplying actual Net Sales of the Combination Product (determined by reference to the definition of Net Sales set forth
above) during the royalty payment period by the ratio of the average per-unit sale price of the Product when sold separately in finished form to the average per-unit Net Sales of the Combination Product, in each case during the applicable royalty
payment period in the country in which the sale of the Combination Product was made. Where the other active ingredients are sold separately in finished form but the Product is not, Net Sales for the Product shall be determined by multiplying actual
Net Sales of the Combination Product (determined by reference to the definition of Net Sales set forth above) during the royalty payment period by the difference obtained by subtracting from one (1) the ratio of the average per-unit sale price
of products containing only the other active ingredient when sold separately in finished form to the average per-unit Net Sales of the Combination Product, in each case during the applicable royalty reporting period in the country in which the sale
of the Combination Product was made. In the event that such average sales price cannot be determined for either of the Product or for products containing only the other active ingredient included in the Combination Product, Net Sales for purposes of
determining payments under this Agreement shall be determined by good faith negotiations between the Parties. 

  
 -8- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.28 “Patent Rights” shall mean all patents and patent applications in any
country in the world, including any continuations, continuations-in-part, divisionals, provisionals or any substitute applications, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension
(including any supplemental protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all non-United States counterparts of any of the foregoing. 

1.29 “PDK Compounds” shall mean (i) [ * ], (ii) [ * ], (iii) [ * ], (iv) [ * ], (v) the other
compounds set forth on Exhibit F of the Millennium-Biogen Agreement, (vi) all other compounds that were Synthesized in the course of performing the Research Program during the Research Term in connection with activities [ * ] to the PDK
Target, (vii) all other compounds claimed or covered by a Collaboration Patent that are [ * ] the PDK Target (including Collaboration Patents listed under “PDK Portfolio” in Exhibit 1.4(a) hereinunder), (viii) all other compounds
claimed or covered by an invention disclosure within the Collaboration Know-How that are [ * ] the PDK Target, and (ix) all salts, prodrugs, esters, metabolites, solvates, stereoisomers and polymorphs of any of the foregoing. 

1.30 “PDK Product” shall mean a pharmaceutical preparation for sale by prescription, over-the-counter, or any other method for
all uses in humans or animals, which incorporates one or more PDK Compounds as an active drug substance. It is understood that PDK Products containing different active ingredient(s) (i.e., a different active ingredient or an additional active
ingredient) or a different formulation shall be deemed different “PDK Products”. For clarity, any product that does not contain a PDK Compound shall not be considered a PDK Product. 

1.31 “PDK Target” shall mean human 3-phosphoinositide-dependent protein kinase-1. 

1.32 “Person” shall mean any natural person, corporation, general partnership, limited partnership, joint venture,
proprietorship or other business organization or a Governmental Authority. 
 1.33 “Phase I” shall mean human clinical
trials, the principal purpose of which is the preliminary evaluation of safety in healthy individuals as more fully defined in 21 C.F.R. §312.21(a) or similar clinical study in a country other than the United States. An initial study in
patients where the primary purpose is the preliminary evaluation of safety will be considered a Phase I study. 
 1.34 “Phase
II” shall mean human clinical trials conducted on a limited number of patients for the primary purpose of evaluation of both clinical efficacy and safety, or to obtain a preliminary evaluation of the dosage regimen, as more fully defined in
21 C.F.R. §312.21(b). 
 1.35 “Phase III” shall mean human clinical trials, the principal purpose of which is to
establish substantial evidence of both safety and efficacy in patients with the disease or condition being studied, as more fully defined in 21 C.F.R. §312.21(c) or similar clinical study in a country other than the United States. Phase III
shall also include any other human clinical trial intended to serve as a pivotal trial to support the submission of an application for regulatory approval. 

  
 -9- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.36 “Product” shall mean a Licensed Product, Reverted Licensed Product
or PDK Product, as applicable. 
 1.37 “Raf Target” shall mean the human Raf protein together with the Raf protein family
members [ * ]. 
 1.38 “Regulatory Approval” shall mean approval of the health regulatory agency in a country (FDA in the
U.S. and comparable authority outside the U.S.) necessary for the marketing and sale of a product in the applicable country. As used herein, “Regulatory Approval” shall not include pricing or reimbursement approval. 

1.39 “Research Program” shall mean the activities undertaken by Sunesis and Biogen Idec pursuant to the Original Agreement
during the Research Term. 
 1.40 “Research Term” shall mean the period of time beginning on the Original Agreement
Effective Date and ending on June 30, 2008. 
 1.41 “Reverted Compound” shall mean, with respect to a Reverted Licensed
Product, any Licensed Compound included in such Reverted Licensed Product. 
 1.42 “Sales Returns and Allowances” shall
mean, with respect to a specific Product, the sum of (a) and (b), where: (a) is a provision, determined by a Party under U.S. GAAP for sales of such Product for (i) trade, cash and quantity discounts on such Product (other than price
discounts granted at the time of invoicing and which are already included in the determination of Gross Sales), (ii) credits or allowances given or made for rejection or return of, and for uncollectable amounts on, previously sold product or
for rebates or retroactive price reductions (including Medicare, Medicaid and similar types of rebates and chargebacks), (iii) taxes, duties or other governmental charges levied on or measured by the billing amount for such Product, as adjusted
for rebates and refunds (excluding income and franchise taxes), (iv) charges for freight and insurance directly related to the distribution of such Product, to the extent included in Gross Sales, and (v) credits for allowances given or
made for wastage replacement, indigent patient and any other sales programs agreed to by the Parties for such Product; and (b) is a periodic adjustment of the provision determined in (a) to reflect amounts actually incurred by a Party for
items (i), (ii), (iii), (iv) and (v) in clause (a). 
 1.43 “Sublicensee” shall mean a Third Party expressly
licensed by a Party or its Affiliate to make, use, import, offer for sale or sell a Product. The term “Sublicensee” shall not include distributors (i.e., a Third Party who purchases Product from a Party for resale). 

1.44 “Sunesis Collaboration Technology” shall mean all Sunesis Collaboration Patents and Sunesis Collaboration Know-How. 

1.44.1 “Sunesis Collaboration Patents” shall mean (a) those Patent Rights set forth on Exhibit 1.4(a), the subject
of which is an invention: (i) conceived in the course of performing the Research Program during the Research Term and reduced to practice prior to the Effective Date solely by or under authority of personnel of Sunesis or any of its controlled
Affiliates or (ii) conceived and reduced to practice solely by or under authority of personnel of 

  
 -10- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
Sunesis or any of its controlled Affiliates after the Original Agreement Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [
* ] to the Designated Targets or to the discovery, research, or development of Licensed Compounds or Licensed Products; and (b) all Patent Rights that arise during the Term that claim or cover any Sunesis Collaboration Know-How. Notwithstanding
the foregoing, Sunesis Collaboration Patents shall in all cases exclude Sunesis Core Technology and Joint Sunesis-Biogen Collaboration Patents. 

1.44.2 “Sunesis Collaboration Know-How” shall mean any Know-How: (i) made or developed solely by or under authority of
personnel of Sunesis or any of its controlled Affiliates in the course of performing the Research Program during the Research Term; or (ii) made or developed solely by or under authority of personnel of Sunesis or any of its controlled
Affiliates after the Original Agreement Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or development of Licensed
Compounds or Licensed Products. Notwithstanding the foregoing, Sunesis Collaboration Know-How shall in all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen Collaboration Know-How and Excluded Compounds (as defined in the Original
Agreement). 
 1.45 “Sunesis Core Technology” shall mean all Patent Rights (all as listed on Exhibit 1.41) and all
information, materials and other subject matter, and improvements thereof, relating to (i) mutants or the use thereof in screening, (ii) the use of novel protein engineering techniques and their application in drug discovery,
(iii) target-directed fragment discovery and maturation to produce drug leads, including monophores, extenders and fragments and monophore, extender and fragment libraries for such purposes, or (iv) covalent tethering and techniques
related thereto (e.g., NMR, X-ray, mass spec. AUC, Biacore) and its use to discover fragments and test binding hypotheses of fragments and leads: (a) Controlled by Sunesis or its controlled Affiliates prior to the Original Agreement Effective
Date or during the Research Term; or (b) made by Biogen Idec in the course of activities directed to the discovery, research, or development of Licensed Compounds and PDK Compounds; provided, in the case of (b) that such item was made
using or derived from Sunesis Core Technology. 
 1.46 “Sunesis Licensed Technology” shall mean Sunesis Licensed Patents and
Sunesis Licensed Know-How. 
 1.46.1 “Sunesis Licensed Patents” shall mean (i) Sunesis’s interest in Collaboration
Patents, (ii) the Patent Rights Controlled by Sunesis as of the Effective Date that claim or cover the Designated Targets, Licensed Compounds or Licensed Products, and (iii) all Patent Rights that arise during the Term that claim or cover
any Know-How Controlled by Sunesis as of the Effective Date that relates to a Designated Target, Licensed Compound or Licensed Product. 

1.46.2 “Sunesis Licensed Know-How” shall mean (i) Sunesis Collaboration Know-How, (ii) Sunesis’s interest in
Joint Sunesis-Biogen Collaboration Know-How and Biogen Idec Collaboration Know-How, (iii) with respect to any Licensed Product that is not a Co-Funded Product, any Know-How Controlled by Sunesis as of the Effective Date that relates to a
Designated Target, Licensed Compound or Licensed Product, and (iv) with respect to any Licensed Product that is a Co-Funded Product, any Know-How Controlled by Sunesis that relates to a Designated Target, Licensed Compound or Licensed Product.

  
 -11- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.47 “Synthesize”, “Synthesis” or
“Synthesized” shall mean, with respect to a chemical composition, the act of (i) first physical synthesis of such chemical composition, or (ii) if such composition had previously been first actually synthesized, first
physically establishing, in a relevant assay, that such composition is Target Selective against a specific Designated Target. For avoidance of doubt Synthesize shall not include chemical compositions synthesized in vivo. 

1.48 “Target Selective” shall mean, when used to describe a chemical compound with respect to a specified Designated Target,
that such compound exhibits [ * ] cell-based assay, and [ * ] (i) [ * ] enzyme assay [ * ] or (ii) [ * ]. For the purposes of the foregoing, the relevant cell-based and enzyme assays shall be as specified in Exhibit 01.44, and the [
* ] in (ii) shall be measured in the same enzyme assay as (i). 
 1.49 “Third Party” shall mean any person or entity
other than Sunesis and Millennium, and their respective Affiliates. 
 1.50 “Valid Claim” shall mean [ * ]. 

1.51 Additional Terms. In addition to the foregoing, the following terms shall have the meaning defined in the corresponding Section
below: 
  

							
	 Term
	  	 Section

Defined
	  	 Term
	  	 Section

Defined

	 Agreement
	  	Preamble	  	Key Subsidiary	  	2.2.4(a)
	 Annual Net Sales
	  	6.3.1	  	Liabilities	  	12.1
	 Biogen Idec
	  	Background	  	Licensed Compound Joint Technology	  	9.1.1(c)
	 Change in Control
	  	2.2.4(a)	  	Licensed Product Team	  	2.3
	 Co-Development Plan and Budget
	  	2.2.2	  	Millennium	  	Preamble
	 Co-Funded Product
	  	2.2.1	  	Millennium-Biogen Agreement	  	Background
	 Co-Funded Territory
	  	2.2.1	  	Millennium Competitor	  	2.2.4(b)
	 Co-Funding Percentage
	  	2.2.3	  	New Sunesis-Biogen Agreement	  	Background
	 [ * ]
	  	15.3	  	Notice Period	  	2.2.1
	 Controlling Party
	  	9.3.4	  	Original Agreement	  	Background

  
 -12- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

							
	 Term
	  	 Section

Defined
	  	 Term
	  	 Section

Defined

	 Cooperating Party
	  	9.3.4	  	Original Agreement Effective Date	  	Background
	 Co-Promoted Licensed Product
	  	3.2	  	Other Joint Technology	  	9.1.1(c)
	 Co-Promotion Option
	  	3.2	  	Other Millennium Technology	  	5.1.3
	 Election Notice
	  	2.2.1	  	Party, Parties	  	Preamble
	 Election Percentage
	  	3.2.1	  	Phase II Drug Collaboration	  	5.3
	 Indemnitee
	  	12.3	  	Phase II Notice	  	2.2.1
	 Indemnitor
	  	12.3	  	post Phase I Development Costs	  	2.2.4(c)
	 Indication
	  	6.2.2(b)	  	Projected Start Date	  	2.2.1
	 Initial Development Plan
	  	2.2.1	  	Raf Patents	  	9.1.1(a)
	 Initial Territory
	  	2.2	  	Reverted Licensed Product	  	8.2
	 Infringement Action
	  	9.3.4	  	Sales and Marketing Plan	  	4.4.2
	 JCC
	  	4.4.1	  	Sunesis	  	Preamble
	 JDC
	  	4.3.1	  	Subject Infringement	  	9.3.1
	 Joint Steering Committee
	  	4.1	  	Term	  	13.1
	 Joint Sub-Committee
	  	4.2	  	Three Party Agreement	  	Background

 1.52 Construction. In construing this Agreement, unless expressly specified otherwise: 

1.52.1 references to Sections, Articles and Exhibits are to sections and articles of, and exhibits to, this Agreement; 

1.52.2 except where the context otherwise requires, use of any gender includes any other gender, and use of the singular includes the plural
and vice versa; 
 1.52.3 any list or examples following the word “including” shall be interpreted without limitation to the
generality of the preceding words; 
 1.52.4 except where the context otherwise requires, the word “or” is used in the inclusive
sense; and 
 1.52.5 all references to “dollars” or “$” herein shall mean U.S. Dollars. 

  
 -13- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 ARTICLE 2 

PRODUCT DEVELOPMENT 
 2.1.
Development by Millennium. Commencing on the Effective Date, Millennium shall be responsible for undertaking a development program aimed at ultimately seeking Regulatory Approval for Licensed Products. 

2.2. Co-Funding Option. Sunesis shall have the right, on a Licensed Product-by-Licensed Product
basis, to elect to fund a portion of post Phase I Development Costs of a Licensed Product in all countries worldwide other than Japan (the “Initial Territory”); provided, however, that Sunesis shall not have the Co-Funding Option with
respect to any Licensed Product directed against a Designated Target for which Sunesis has entered into a Phase II Drug Collaboration. In the event that Sunesis elects to exercise its Co-Funding Option with respect to the Initial Territory for a
particular Licensed Product pursuant to the preceding sentence, then Sunesis shall have the right to elect to fund a portion of post Phase I Development Costs of such Licensed Product in Japan, all in accordance with this Section 2.2. 

2.2.1 Election. For so long as Sunesis continues to have a Co-Funding Option for a Licensed Product, Millennium shall notify Sunesis [ *
] for each Licensed Product in each of the applicable territories described above in Section 2.2 where the primary endpoint of such trial involves a preliminary determination of efficacy. For clarity, for purposes of this Section 2.2.1, [
* ] for each Licensed Product shall mean [ * ], and elsewhere in this Agreement, [ * ] of a trial (regardless of phase) or clinical study shall mean [ * ]. Such notice shall include the date [ * ]. Sunesis may elect, by so notifying Millennium in
writing [ * ] (the “Notice Period”), to participate in funding the further development of such Licensed Product in the applicable territory, as described in this Section 2.2 (such notice, the “Election Notice”). [ * ] and
until the end of the Notice Period, Millennium shall cooperate fully with Sunesis, and shall promptly provide Sunesis with access to such material information, to the extent such information is not included in the Initial Development Plan or
otherwise has not been communicated previously to Sunesis, as Sunesis may reasonably request to enable Sunesis to make an informed decision whether to exercise its Co-Funding Option under this Section 2.2
with respect to such Licensed Product. Such cooperation shall include consulting with Sunesis in good faith regarding the Initial Development Plan, and the financial, scientific and regulatory assumptions reflected therein. In the event Sunesis
exercises its Co-Funding Option with respect to a particular Licensed Product (such Licensed Product, a “Co-Funded Product”), the provisions of Sections 2.2.2 through 2.2.4 below shall apply with
respect to such Co-Funded Product in the Co-Funded Territory. The “Co-Funded Territory” shall consist of the Initial Territory for each Co-Funded Product, and in the event Sunesis elects to exercise its Co-Funding Option for Japan with
respect to a particular Co-Funded Product, the Co-Funded Territory shall mean all territories worldwide for such Co-Funded Product. In the event that Sunesis elects not to exercise the Co-Funding Option with respect to a Licensed Product or fails to
provide an Election Notice within the applicable Notice Period, Sunesis shall no longer have the right to exercise the Co-Funding Option, and Millennium shall have no further obligations under this Section 2.2.1, with respect to such Licensed
Product. 

  
 -14- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 2.2.2 JDC. For each Co-Funded Product, the Parties shall establish and maintain a JDC in
accordance with Section 4.3 below, which shall be responsible for establishing the plan and budget for the development of each Co-Funded Product (each, a “Co-Development Plan and Budget”) and overseeing the implementation of such
plan. Such Co-Development Plan and Budget shall be comprehensive (as of the time of preparation and delivery hereunder) and shall fully describe at least the proposed activities and data related to [ * ], and other activities and timelines directed
to obtaining the initial and subsequent Regulatory Approvals in each applicable country. Unless otherwise specified in a Co-Development Plan and Budget amounts reflected for a full year shall be deemed budgeted in equal amounts for each calendar
quarter of such year. 
 2.2.3 Co-Funding Obligation. In the event Sunesis exercises its Co-Funding Option with respect to a Licensed Product, Sunesis shall be obligated to reimburse Millennium for a percentage (the “Co-Funding Percentage”) of post Phase I Development Costs for such Licensed
Product, subject to the provisions of this Section 2.2. It is understood and agreed that the Co-Funding Percentage shall initially be [ * ] percent ([ * ]%) for each Co-Funded Product. In addition the following shall apply: 

(a) The Co-Development Plan and Budget will be updated on a quarterly basis. Millennium shall provide to Sunesis its then current estimates
for each upcoming budget year for each Co-Funded Product by November 15 of each year. Promptly following April 1 of each calendar year during the development activities for a particular Co-Funded Product or such other date as is mutually
agreed by the Parties, the JDC shall update and amend the Co-Development Plan and Budget for such Co-Funded Product for the period ending March 31 of the subsequent calendar year. Millennium shall provide
Sunesis with reasonable opportunity to provide input into each Co-Development Plan and Budget, and, subject to Article 4, Millennium shall reasonably consider Sunesis’s comments in establishing and updating each Co-Development Plan and Budget.

 (b) Within thirty (30) days after the end of each calendar quarter, Millennium shall provide to Sunesis a statement reflecting the
total post Phase I Development Costs incurred by Millennium in accordance with the then-current Co-Development Plan and Budget during such calendar quarter with respect to each Co-Funded Product. Within thirty (30) days after Sunesis’s
receipt of such statement, Sunesis shall reimburse Millennium for the applicable Co-Funding Percentage of the post Phase I Development Costs incurred by Millennium during such calendar quarter for such Co-Funded Product. 

(c) Upon [ * ] days written notice to Millennium, Sunesis may terminate its Co-Funding Option for a
particular Co-Funded Product. In such event, Sunesis’s funding obligation under this Section 2.2.3 above shall apply only with respect to post Phase I Development Costs for activities conducted with respect to such Co-Funded Product prior
to the effective date of such termination. Should Sunesis terminate its Co-Funding Option under this Section 2.2.3(c) with respect to a particular Co-Funded Product, (i) any royalties payable to
Sunesis on such Co-Funded Product shall be paid in accordance with Section 6.3.1, subject to Section 6.3.2(b), and (ii) Sunesis shall relinquish its right to participate in the JDC pursuant to Section 4.3 and any right to its Co-Promotion Option under Section 3.2 for such Co-Funded Product. 

  
 -15- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (d) Upon written notice to Millennium at least ninety (90) days prior to the end of a
budget year, Sunesis may elect to [ * ], by so notifying Millennium in writing, referencing this Section 2.2.3(d) and specifying [ * ]. In such event, Sunesis shall receive a [ * ] in accordance with the schedule set forth in
Section 6.3.2(c) below [ * ]. Upon such election, Sunesis’s previous Co-Funding Percentage under this Section 2.2.3 shall apply only with respect to post Phase I Development Costs for activities conducted with respect to such
Co-Funded Product [ * ] with respect to such Co-Funded Product. Sunesis may [ * ], provided that (i) Sunesis shall not be permitted [ * ] its Co-Funding Percentage for such Co-Funded Product, and (ii) Sunesis may [ * ]. As used herein,
“budget year” shall mean April 1 through March 31, provided that Millennium shall have the right to change the budget year to coincide with Millennium’s annual budget cycle, provided that Millennium provides Sunesis with at
least one hundred twenty (120) days notice of such change. 
 (e) Notwithstanding the foregoing, in the event that Sunesis experiences
a Change in Control, then Sunesis’s Co-Promotion rights under Section 3.2, the right to participate in the JDC under Section 4.3, the right to participate in the JCC under Section 4.4, and any Licensed Product Teams under
Section 2.3 shall terminate. In addition: 
 (i) With respect to any Co-Funded Product for which Sunesis has exercised its Co-Funding
Option prior to such Change of Control, Sunesis’s rights and obligations under this Section 2.2.3 shall continue, provided that Millennium shall no longer be obligated to provide the detailed plans required of a Co-Development Plan and
Budget to Sunesis (or its successor entity), but shall provide Sunesis (or its successor entity) with annual budgets of post Phase I Development Costs for such Co-Funded Product. 

(ii) Sunesis’s Co-Funding Option with respect to future Licensed Products shall continue as well (i.e., with respect to Licensed Products
that are not Co-Funded Products as of the date of such Change of Control), provided that Millennium shall no longer be obligated to provide for each Licensed Product the detailed plans and clinical data required of an Initial Development Plan and
Phase II Notice. Millennium shall, however, provide Sunesis (or its successor entity) with annual budgets of post Phase I Development Costs for such Co-Funded Product in accordance with the timetable for a Phase II Notice set forth in
Section 2.2.1, and shall provide reasonable cooperation to Sunesis (or its successor entity) in evaluating such Licensed Product and the post Phase I Development Costs related thereto, including consulting with Sunesis (or its successor entity)
in good faith regarding such annual budgets and the financial, scientific and regulatory assumptions reflected therein. 
 2.2.4 Certain
Terms. As used in this Section 2.2, the following terms shall have the meanings set forth below: 
 (a) “Change in
Control” shall mean, [ * ]. 
 (b) “Millennium Competitor” shall mean [ * ]. 

  
 -16- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (c) “post Phase I Development Costs” shall mean, with respect to a particular
Co-Funded Product, the Development Costs incurred by Millennium or its Affiliates following Sunesis’s exercise of the Co-Funding Option for such Co-Funded Product in the Co-Funded Territory for such Co-Funded Product. For the avoidance of
doubt, (i) post Phase I Development Costs shall not include any Development Costs incurred by Millennium or its Affiliates for any subsequent Phase I trials, and (ii) Development Costs relating to activities directed at obtaining
Regulatory Approval in Japan for a Co-Funded Product shall not be considered post Phase I Development Costs to the extent such Development Costs are incurred (A) prior to completion of the Phase I trials for such Co-Funded Product in Japan, or
(B) if no Phase I trials are necessary or performed for such Co-Funded Product in Japan, then prior to initiation of any clinical trial other than a Phase I trial. 

2.3. Licensed Product Team. Upon identification of a Development Candidate for any Licensed Compound other than BIIB024, the Parties
shall form a product team with respect to such Licensed Compound that is a Co-Funded Product (which team shall report to the JDC if Sunesis exercises its Co-Funding Option with respect to such Licensed Compound), comprised of Millennium and Sunesis
personnel, that will share all relevant information and implement the further development and regulatory affairs with respect to that Co-Funded Product (each a “Licensed Product Team”) in accordance with the Co-Development Plan and Budget.
It is understood that both Millennium and Sunesis shall have the opportunity for meaningful participation in the activities of a Licensed Product Team commensurate with their respective levels of funding participation; it being further understood
that Millennium shall control the Development of the Licensed Product. Sunesis shall be notified at least two weeks in advance of the date of each Licensed Product Team meeting, which meetings shall be held quarterly by in-person meetings or
electronic conference, and shall have the opportunity to have its representatives attend such meeting. Millennium shall provide such Sunesis representatives with all information distributed to Millennium members of the Licensed Product Team, and
such other material information as Sunesis may reasonably request from time to time, in each case related to the Development and commercialization of Licensed Product. With respect to [ * ], within thirty (30) days after the Effective Date, the
Parties shall establish a Licensed Product Team for [ * ] as a Licensed Product (i.e., even though the such Licensed Product is not yet a Co-Funded Product). The Parties shall maintain any such Licensed Product Team under this Section 2.3 until
the Co-Funding Option lapses or is declined with respect to such Licensed Product. For clarity, it is understood that the establishment of a Licensed Product Team hereunder for a Licensed Product directed at the Raf Target shall not obligate Sunesis
to subsequently exercise the Co-Funding Option with respect to such Licensed Product. The Licensed Product Team will be composed of three (3) representatives of Millennium (at Millennium’s discretion) and three (3) representatives of
Sunesis, who shall be appointed (and may be replaced at any time) by the respective Party on written notice to the other Party in accordance with this Agreement. The Parties may invite additional employee observers based on the subject matter of the
meeting, who shall be able to participate in such meetings. The Sunesis representatives shall not be entitled to vote on any Licensed Product Team matters. In any event, the Licensed Product Team shall terminate in the event that Sunesis does not
exercise its Co-Funding Option. 
 2.4. Regulatory Matters. Millennium shall file and be the owner of all regulatory filings for
Licensed Compounds or Licensed Products (including Co-Funded Products) developed pursuant to this Agreement, including all NDAs and Regulatory Approvals, unless otherwise agreed by the Parties. 

  
 -17- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 2.5. Records; Inspections. 

2.5.1 Research Records. Sunesis shall maintain records of the Research Program relating to the Licensed Compounds and Designated Targets
(or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in such performance of the Research Program. 

2.5.2 Inspections. During the one-year period following the Effective Date, Sunesis shall provide Millennium with access to the records
referred to in Section 2.5.1, upon reasonable request, during ordinary business hours and subject to appropriate confidentiality agreement in the event that Third Party confidential information is involved. 

ARTICLE 3 
 PRODUCT
COMMERCIALIZATION 
 3.1. Commercialization Rights. Subject to the provisions of Section 3.2, Millennium shall be
responsible for the establishment and implementation of the strategy, plans and budgets for marketing and promotion of the Licensed Products. 

3.2. Co-Promotion Option. Sunesis will have an option (the “Co-Promotion Option”) to co-promote each Co-Funded Product in the
Co-Funded Territory (excluding [ * ]), according to the terms and conditions set forth in this Section 3.2. [ * ]. This Co-Promotion Option may be exercised at Sunesis’s discretion on a Co-Funded Product-by-Co-Funded Product and
territory-by territory basis [ * ] for any Co-Funded Product, such [ * ], by so notifying Millennium in writing within [ * ] for such Co-Funded Product in such territory. Each such Co-Funded Product for which Sunesis exercises the Co-Promotion
Option being referred to as a “Co-Promoted Licensed Product.” [ * ], Millennium shall provide Sunesis with a good faith estimate of the number of field force personnel to be deployed for such Co-Funded Product in the applicable territory
for [ * ], together with a then-current Sales and Marketing Plan for such Co-Funded Product. The estimate of the number of field force personnel to be deployed shall be prepared by the JCC, and shall take into consideration the then-current
marketing and promotion practices in the relevant markets and the number and nature of other products, if any, including the detail position, if applicable, that such field force personnel will be selling. In situations where field force personnel
will be selling multiple products, the JCC shall make a good faith allocation of the field force personnel’s time to be spent on each product. Once Sunesis has exercised the Co-Promotion Option for a Co-Funded Product in a particular territory,
the JCC shall discuss in good faith [ * ]. In the event that Sunesis elects not to exercise the Co-Promotion Option with respect to a Co-Funded Product or fails to notify Millennium in writing of its election within the applicable [ * ] in any
territory, Sunesis shall no longer have the right to exercise the Co-Promotion Option with respect to such Co-Funded Product in such territory. 

  
 -18- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 As used in this Agreement, “co-promote” or “co-promotion” shall mean to
promote jointly or joint promotion of a Licensed Product through Millennium’s and Sunesis’s respective sales forces under the same brand name, with Millennium booking all sales of such Co-Promoted Licensed Product, all as shall be more
specifically set forth in a co-promotion agreement for each of the territories in which Sunesis co-promotes, such agreement to be negotiated in good faith as soon as practicable following the exercise by Sunesis of the Co-Promotion Option for a
Co-Promoted Licensed Product and reflecting the terms set forth in this Article 3 and other customary terms and provisions. A co-promotion agreement shall include the following provisions: (a) Sunesis shall, within thirty (30) days of the
end of each calendar quarter, send a written report to Millennium setting out for each applicable territory and each Co-Promoted Licensed Product, the number of field sales force representatives performing co-promotion activities hereunder, and the
number and nature of other products, if any, that such field force personnel promoted during such calendar quarter. (b) In the event that [ * ] that are allocated to Sunesis in the applicable Sales and Marketing Plan, Millennium may terminate
Sunesis’s right to co-promote such Co-Promoted Licensed Product in such territory upon written notice to Sunesis. 
 3.2.1 Scope and
Coordination of Co-Promotion. Upon exercise of its Co-Promotion Option with respect to a Co-Promoted Licensed Product, Sunesis shall have the right to field [ * ] (the “Election Percentage”) of the field force efforts, as such field
force is determined in good faith by the JCC, with respect to the Co-Promoted Licensed Product in the applicable territory. The JCC shall be responsible for coordinating the co-promotion activities under this Section 3.2, and shall develop the
strategies and programs to optimally carry out marketing and promotional activities, including the assignment of sales force responsibilities in accordance with the Sales and Marketing Plan. It is understood that Sunesis may use one or more contract
service organizations for its activities under this Section 3.2, provided that with respect to each Co-Promoted Licensed Product, Sunesis [ * ] for such Co-Promoted Licensed Product. Sunesis field sales force representatives will be employed by
Sunesis and Sunesis shall be responsible for the payment of all such representatives’ salary, out-of pocket expenses (other than for promotional materials), bonus (Sunesis shall adopt reasonable bonus plans/systems to reward sales of the
Co-Promoted Licensed Product) and benefits, pension, insurance, social security and any other related obligations. 
 3.2.2 Co-Promotion
Obligations. Sunesis shall employ a professional and trained sales force to co-promote the Co-Promoted Licensed Product, and such sales force shall meet standards of competence and professionalism as are common in the pharmaceutical industry. In
all events, Sunesis’s co-promotion shall be conducted as directed by the JCC and in accordance with the then current Sales and Marketing Plan and in accordance with all applicable laws. Millennium shall provide to Sunesis’s sales personnel
[ * ] any Co-Promoted Licensed Product-specific training and promotional materials (including samples), and shall permit Sunesis’s sales personnel to attend and participate in any Co-Promoted Licensed Product-specific seminars and sales
training programs [ * ] Sunesis, in each case as reasonably necessary to effectively promote the particular Co-Promoted Licensed Product consistent with the Sales and Marketing Plan. 

3.2.3 Reimbursement. For the performance of the obligations of Sunesis under this Section 3.2 and the co-promotion agreement,
Millennium shall reimburse Sunesis as described herein. [ * ]. In the event that Sunesis sales representatives promote any other products other than such Co-Promoted Licensed Product, then Millennium shall only reimburse Sunesis for the pro rata
share of the cost of such Sunesis sales representatives. 

  
 -19- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 3.2.4 Right to Terminate Co-Promotion. Sunesis shall have the right, on a
territory-by-territory basis, to terminate its co-promotion of any Co-Promoted Licensed Product, and its obligations under this Section 3.2 with respect to such Co-Promoted Licensed Product, on a Co-Promoted Licensed Product-by-Co-Promoted
Licensed Product basis, upon [ * ] prior written notice to Millennium. Millennium shall have the right, on a territory-by territory basis, to terminate Sunesis’s co-promotion of any Co-Promoted Licensed Product, and Millennium’s
obligations under this Section 3.2 with respect to such Co-Promoted Licensed Product, on a Co-Promoted Licensed Product-by-Co-Promoted Licensed Product basis, (a) [ * ] after written notice to Sunesis following any material breach of any
applicable law, rule or regulation with respect to the co-promotion of such Co-Promoted Licensed Product, or (b) [ * ] after written notice to Sunesis following any other material breach by Sunesis relating to the co-promotion of such
Co-Promoted Licensed Product in such territory if Sunesis does not cure such breach within the applicable specified cure period in Section 3.2.4(a) or (b). Upon termination of co-promotion under this Section 3.2.4 or the co-promotion
agreement, Sunesis shall have no right to reimbursement by Millennium under Section 3.2.3 for services provided in the applicable territory after the effective date of such termination. 

3.3. Amendment of Sales and Marketing Plan. Promptly upon exercise of Sunesis’s Co-Promotion Option hereunder, the JCC shall meet
to revise the Sales and Marketing Plan to reflect the sales activities to be undertaken by Sunesis, including the formulation of a mechanism to establish and adjust cost allocation, and the definition of a relevant field sales force promotional
activity metric for purposes of allocating the activities of sales representatives. 
 3.4. Sunesis [ * ]. To the extent consistent
with applicable law, the [ * ] Sunesis shall [ * ], on all [ * ] for all [ * ] Licensed Products in the applicable country. 
 3.5.
Sunesis Insurance. In the event that Sunesis exercises its Co-Promotion Option, Sunesis shall procure and continue to maintain, at its own cost, the following insurance coverage: Commercial General Liability, including coverage for products
and completed operations (maintained for a period of at least five (5) years after expiration or termination of this Agreement) and contractual liability (including coverage for advertising and personal injury). The JCC shall set commercially
reasonable and appropriate minimum terms and conditions for such insurance coverage, consistent with then-current pharmaceutical industry practice for commercialization efforts of similar scope to the co-promotion activities undertaken hereunder.
Sunesis shall provide Millennium with a certificate of insurance reflecting such coverage. 
 ARTICLE 4 

MANAGEMENT 
 4.1. Joint
Steering Committee. Within thirty (30) days of the Effective Date, the Parties shall establish a joint steering committee (“Joint Steering Committee”) to provide oversight and management of the activities undertaken under this
Agreement. The Joint Steering Committee will be composed of two (2) representatives of each Party who shall be appointed (and may be replaced at any time) by such Party on prior written notice to the other Party in accordance with this
Agreement. At least one (1) representative of a Party on the Joint Steering Committee shall be a vice president or more senior officer of such Party, and the representatives shall have relevant experience and expertise in research, development
and commercialization of biopharmaceuticals. 

  
 -20- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 4.1.1 Responsibilities. The Joint Steering Committee shall be responsible for
(i) reviewing the efforts of the JDC in the conduct of ongoing development activities and regulatory affairs with respect to Co-Funded Products under Article 2, and resolving disputes as to matters to be decided by the JDC under this Agreement;
(ii) reviewing the efforts of the JCC in the conduct of promotional activities of the Parties with respect to Co-Promoted Licensed Products under Article 3, and resolving disputes as to matters to be decided by the JCC under this Agreement; and
(iii) taking such other actions as are specifically allocated to the Joint Steering Committee under this Agreement. 
 4.1.2
Meetings. The Joint Steering Committee shall meet quarterly, or at such frequency as agreed by the respective committee members. Meetings of the Joint Steering Committee shall be at such locations as the Parties agree, and will otherwise
communicate regularly by telephone, electronic mail, facsimile or video conference. With the consent of the Parties, other representatives of Sunesis or Millennium may attend the Joint Steering Committee meetings as nonvoting observers based on the
subject matter of the meeting. 
 4.1.3 Decisions. Any approval, determination or other action of the Joint Steering Committee shall
require agreement of the members of the Joint Steering Committee, with each Party having one (1) vote. Action that may be taken at a meeting of the Joint Steering Committee also may be taken without a meeting if a written consent setting forth
the action so taken is signed by all members of the Joint Steering Committee. 
 4.1.4 Disputes. In the event the Joint Steering
Committee is unable to reach consensus on a particular matter within its jurisdiction or that of the JDC or JCC, the matter shall be referred to executives of the Parties in accordance with Section 14.1, and if such referral does not resolve
such matter, then Millennium shall have the right to cast a deciding vote on the Joint Steering Committee. Notwithstanding the foregoing, Millennium shall not have the right to exercise [ * ] of this Agreement or that [ * ] Sunesis. In the
evaluation of a Diligence Summary pursuant to Section 8.5, any decision of the Joint Steering Committee shall be binding on the Parties, but in the event the Joint Steering Committee is unable achieve agreement with respect to such evaluation,
then such dispute shall be resolved as set forth in Section 8.5. 
 4.2. Joint Sub-Committees. The Parties shall form the JDC and
JCC (each, a “Joint Sub-Committee”) in accordance with the terms set forth in Sections 4.3 and 4.4. 
 4.2.1 Generally. Each
Joint Sub-Committee shall meet at such locations as the Parties agree, and will otherwise communicate regularly by telephone, electronic mail, facsimile or video conference. Each Party shall be responsible for all of its own expenses associated with
attendance of such meetings, and either Party may replace its respective representatives to each Joint Sub-Committee at any time, with prior written notice to the other Party. Other representatives of Sunesis or Millennium may attend the Joint
Sub-Committee meetings as nonvoting observers based on the subject matter of the meeting. From time to time, each Joint Sub-Committee may establish further subcommittees to oversee particular projects or activities, and such further subcommittees
will be constituted as such Joint Sub-Committee approves. 

  
 -21- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 4.2.2 Decision Making. Decisions of each Joint Sub-Committee shall be made by unanimous
approval of the team leaders from each Party present in person or by other means (e.g., teleconference) at any meeting; provided that at least one member from each Party must be so present and voting. In the event that unanimity is not achieved
within a Joint Sub-Committee on a decision required to be made by such Joint Sub-Committee, the matter will be referred to the Joint Steering Committee, which in each case shall promptly meet and endeavor in good faith to resolve such matter in a
timely manner. In the event the Joint Steering Committee is unable to reach consensus on a particular matter, such matter shall be resolved in accordance with Section 4.1.4 above. 

4.3. Joint Development Committee. 

4.3.1 Formation. Promptly following notice from Sunesis that it is exercising its Co-Funding Option, the Parties shall establish a Joint
Development Committee (“JDC”) with respect to the development of the applicable Co-Funded Product. The JDC will be composed of three (3) representatives of Millennium (at Millennium’s discretion) and three (3) representative
of Sunesis who shall be appointed (and may be replaced at any time) by the respective Party on written notice to the other Party in accordance with this Agreement. In the event that Sunesis undergoes a Change of Control (as that term is defined in
Section 2.2.4(a) above), the JDC shall be dissolved in accordance with Section 2.2.3(e). 
 4.3.2 Responsibilities. The
responsibilities of the JDC shall consist of (i) overseeing the ongoing development of Co-Funded Product(s), (ii) establishing Co-Development Plans and Budgets for Co-Funded Products, (iii) monitoring and approving development
activities under such Co-Development Plans and Budgets, (iv) reviewing and approving regulatory correspondence, final study reports and submissions to Regulatory Authorities relating to Co-Funded Products, and (v) making such decisions as
are expressly provided in Article 2. 
 4.3.3 Meetings and Information. The JDC shall meet at least quarterly. Millennium shall
notify Sunesis at least two weeks in advance of the date of each JDC meeting. 
 4.4. Joint Commercialization Committee. 

4.4.1 Formation. Upon request by either Party following [ * ] for a Co-Funded Product and the election to co-promote by Sunesis, the
Parties shall establish a Joint Commercialization Committee (“JCC”) with respect to commercialization of such Co-Funded Product(s). The JCC will be composed of three (3) representatives of Millennium (at Millennium’s discretion)
and three (3) representative of Sunesis who shall be appointed (and may be replaced at any time) by the respective Party on written notice to the other Party in accordance with this Agreement. In any event, the JCC shall terminate upon the
expiration of all Co-Promotion Options or termination of all co-promotion by Sunesis. 
 4.4.2 Responsibilities. The JCC shall have
responsibility to monitor the conduct and progress of the commercialization strategy, plans, and budgets, including establishment of a plan and budget for the marketing, promotion, sale and distribution of such Co-Funded Product (each a “Sales
and Marketing Plan”) and managing the promotional activities of the Parties with respect to Co-Promoted Licensed Products under Article 3 above. The JCC shall update the Sales and Marketing Plan periodically, and no less often than annually,
and shall include therein detailed plans and budgets for the marketing, promotion, sale and distribution of each Co-Funded Product. 

  
 -22- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 4.4.3 Meetings and Information. The JCC shall meet at least quarterly. Millennium shall
notify Sunesis at least two weeks in advance of the date of each JCC meeting. 
 ARTICLE 5 

LICENSES 
 5.1.
Development and Commercialization Licenses. 
 5.1.1 License under the Sunesis Licensed Technology to Licensed Products.
Subject to the terms and conditions of this Agreement, Sunesis hereby grants to Millennium a worldwide, exclusive license under the Sunesis Licensed Technology, with the right to grant and authorize sublicenses as provided in Section 5.2, to
Develop, make, have made, use, import, offer for sale, sell and otherwise exploit Licensed Compounds and Licensed Products in the Field. 

5.1.2 License under the Sunesis Core Technology to Licensed Products. Subject to the terms and conditions of this Agreement, Sunesis
hereby grants to Millennium a worldwide, non-exclusive license under the Sunesis Core Technology to make, have made, use, import, offer for sale and sell Licensed Compounds and Licensed Products in the Field. It is understood that the foregoing
license to Sunesis Core Technology shall not include the right to practice Sunesis Core Technology to discover novel compositions. 
 5.1.3
License for Reverted Licensed Products. Subject to the terms and conditions of this Agreement (including Sections 5.1.1 and 5.1.2 above), with respect to each Reverted Licensed Product Millennium hereby grants to Sunesis a worldwide,
exclusive license under Millennium’s interest in the Biogen Idec Collaboration Technology, Joint Sunesis-Biogen Collaboration Technology, Development Technology and other Patent Rights and Know How [ * ] the relevant Licensed Product becomes a
Reverted Licensed Product (“Other Millennium Technology”), with the right to grant and authorize sublicenses as provided in Section 5.2, to develop, make, have made, use, import, offer for sale, sell and otherwise exploit such
Reverted Licensed Product. It is understood and acknowledged that the licenses granted with respect to Biogen Idec Collaboration Technology, Development Technology and Other Millennium Technology in this Section 5.1.3 extend solely to that
technology that is being used on that Reverted Licensed Product as of the date of such reversion to Sunesis, and solely to the extent necessary for Sunesis to continue development and commercialization of such Reverted Licensed Product in the form
in which such Reverted Licensed Product existed as of the date of such reversion to Sunesis. 
 5.2. Grant of Sublicenses. Within a
reasonable period of time following grant of any sublicense, to the extent sublicensing is permitted under Section 5.1, 9.1.3 and 16.1, the sublicensing Party shall provide the other Party with a summary of such sublicense, including the
identity of the Sublicensee (including any Affiliate) and the rights granted with respect thereto for each product and territory, sufficient to allow such other Party to verify any amounts then or subsequently due under Articles 6, 7 and 17 below;
provided that such summary may redact 

  
 -23- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
confidential information that the sublicensing Party is reasonably prohibited from disclosing under the sublicense agreement. Any sublicense granted under this Section 5.2 shall be
consistent with all of the terms and conditions of this Agreement, and subordinate thereto, and the sublicensing Party shall remain responsible to the other Party for the compliance of each such Sublicensee with the obligations due under this
Agreement. 
 5.3 Covenants [ * ] 

5.3.1. Sunesis Covenant [ * ] Notwithstanding the foregoing, Sunesis shall not be prohibited from collaborating with a Third Party on
the development and commercialization of chemical compounds in-licensed from or controlled by such Third Party [ * ]; provided that Sunesis has not exercised the Co-Funding Option with respect to a Licensed Product [ * ] and such compounds are in
Phase II clinical trials or later stage of development or commercialization at the time of initiation of such collaboration (a “Phase II Drug Collaboration”). Sunesis shall notify Millennium in writing upon entering into a Phase II
Drug Collaboration. Nothing in this Section 5.3.1 is intended as the grant of a license by Millennium to Sunesis. 
 5.3.2. Sunesis
Covenant [ * ] 
 5.3.3. Millennium Covenant [ * ] To clarify, notwithstanding the foregoing, Millennium is free to research,
develop, market, sell, promote, exploit or license, alone or in collaboration with others, any pharmaceutical compound that is [ * ] so long as none of them use any Millennium Licensed Technology, Sunesis Licensed Technology (as in effect prior to
the Amendment Effective Date) or Collaboration Technology. 
 5.4 Assay License. Millennium hereby grants to Sunesis a fully-paid,
royalty-free worldwide, non-exclusive, perpetual, irrevocable license under Millennium’s rights in the assays set forth on Exhibit 1.44 for use by Sunesis solely to comply with Sunesis’s obligations under this Agreement. 

5.5 No Other Rights; No Implied Licenses. Only the licenses granted or retained pursuant to the express terms of this Agreement shall be
of any legal force or effect. No other license rights shall be created by implication, estoppel or otherwise. 
 ARTICLE 6 

PAYMENTS 
 6.1. Research
Milestones. Millennium shall pay to Sunesis the following amounts within thirty (30) days following the first achievement of the following research milestones: 
  

					
	 Research Milestones
	  	Payment Amount	 
	 1. Identification of the second Development Candidate directed against the Raf Target (it being acknowledged and agreed that [ * ] is
the first such Licensed Compound for the Raf Target):
	  	$	[ 	* ] 

  
 -24- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 6.2. Development Milestones. 

6.2.1 Development Milestone Payments. 

(a) [ * ] 
 (b)
With respect to each Licensed Product, Millennium shall pay to Sunesis on a Licensed Product-by-Licensed Product basis the following amounts within thirty (30) days following the first achievement by Millennium, its Affiliates or Sublicensees,
as the case may be, of each of the following milestones with respect to such Licensed Product: 
  

									
	 	  	Payment Amount	 
	Development Milestones	  	[1st Indication	 	  	2nd Indication]	 
	 [1. Initiation of the first Phase II trial for such Licensed Product in any country:
	  	 	N/A	  	  	$	750,000	  
	 2. Initiation of the first Phase III trial for such Licensed Product in any country:
	  	$	3,000,000	  	  	$	2,250,000	  
	 3. Filing of an NDA in the U.S. for such Licensed Product:
	  	$	5,000,000	  	  	$	3,750,000	  
	 4. Filing of an NDA with EMEA for such Licensed Product:
	  	$	4,000,000	  	  	$	3,000,000	  
	 5. Filing of an NDA in Japan for such Licensed Product:
	  	$	2,000,000	  	  	$	1,500,000	  
	 6. Regulatory Approval in the U.S. of such Licensed Product:
	  	$	8,000,000	  	  	$	6,000,000	  
	 7. Regulatory Approval by EMEA of such Licensed Product:
	  	$	6,000,000	  	  	$	4,500,000	  
	 8. Regulatory Approval in Japan of such Licensed Product:
	  	$	4,000,000	  	  	$	3,000,000	] 

 Such milestone payments shall be non-refundable and non-creditable against other amounts due Sunesis
hereunder. 

  
 -25- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 6.2.2 Certain Additional Terms. 

(a) Licensed Product-by-Licensed Product Milestones. It is understood that, subject to Section 6.2.2(b), the payments under this
Section 6.2 shall be due only once with respect to each Licensed Product. 
 (b) Multiple Indications. With respect to a
particular Licensed Product, [ * ] 
 (c) Discontinued Licensed Products. If Millennium ceases all clinical development of a
particular Licensed Product, after having made one or more of the payments due under Section 6.2.1 above on the achievement of a particular milestone by such Licensed Product, there shall be no payment due upon the accomplishment of that same
milestone with respect to the next Licensed Product that is specifically directed at the same Designated Target to achieve such milestone. 

(d) Accrued Milestones. If a development milestone for a Licensed Product under Section 6.2.1 above is achieved with respect to
such Licensed Product before a prior development milestone under Section 6.2.1 for such Licensed Product, then the earlier milestone payments shall then also be due with respect to such Licensed Product. 

6.2.3 Reports; Payments. Within ten (10) business days of the occurrence of any event which would trigger a milestone payment
according to Section 6.2, Millennium shall inform Sunesis of such occurrence. The corresponding payment shall be due thirty (30) days after the occurrence of such event. 

6.3. Royalties on Annual Net Sales of Licensed Products. 

6.3.1 Licensed Products Generally. Subject to Sections 6.3.2, 6.3.3 and 6.3.4, Millennium shall pay to Sunesis a royalty on Net Sales by
Millennium, its Affiliates and their Sublicensees of Licensed Products (other than Net Sales of Co-Funded Products in the Co-Funded Territory) on a Licensed Product-by-Licensed Product basis, equal to the percentage of such Net Sales set forth
below: 
  

					
	Annual Net Sales	  	Royalty on Net Sales	 
	Portion of Annual Net Sales of such Licensed Product up to $[ * ]:	  	 	[ * ]	% 
	 Portion of Annual Net Sales of such Licensed Product

between $[ * ] and $[ * ]:
	  	 	[ * ]	% 
	 Portion of Annual Net Sales of such Licensed Product

between $[ * ] and $[ * ]:
	  	 	[ * ]	% 
	Portion of Annual Net Sales of such Licensed Product over $[ * ]:	  	 	[ * ]	% 

  
 -26- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 For purposes of the foregoing and Section 6.3.2 below, “Annual Net Sales” shall
mean, for a particular Licensed Product, the worldwide Net Sales of such Licensed Product for the particular calendar year. In the event that in a calendar quarter portions of the worldwide Net Sales of a particular Licensed Product are subject to
royalty obligations under both Sections 6.3.1 and 6.3.2, the applicable royalty rate under Section 6.3.2 shall be applied to worldwide Net Sales based on the proportion of worldwide Net Sales generated in the Co-Funded Territory. 

6.3.2 Compensation for Co-Funded Products. 

(a) Subject to Sections 6.3.2(b), 6.3.2(c), 6.3.3 and 6.3.4, in consideration for the co-funding by Sunesis, Millennium shall pay to Sunesis
an amount [ * ]. 
 (b) [ * ] 

[ * ] 
 6.3.3 Third Party
Patents. 
 (a) If: (i) a [ * ] of a Third Party should be in force in any country during the Term of this Agreement covering the
practice of the Sunesis Licensed Technology or Sunesis Core Technology as licensed to Millennium under Section 5.1 with respect to the manufacture, use or sale of any Licensed Product, (ii) it should prove in Millennium’s reasonable
judgment, after consultation with Sunesis, [ * ] for Millennium to commercialize such Licensed Product without obtaining a royalty bearing license from such Third Party [ * ] (with such agreement not to be unreasonably withheld or delayed), and
(iii) the royalty paid to such Third Party is directed to the practice of rights granted to Millennium under Section 5.1 with respect to such Licensed Product, then Millennium shall be entitled to a credit against the royalty payments due
under the other provisions of this Section 6.3 with respect to the same Licensed Product in such country of an amount equal to [ * ] of the royalty paid to such Third Party for such Licensed Product in such country, arising from the practice of
such Sunesis Licensed Technology or Sunesis Core Technology with respect to the manufacture, use or sale of the Licensed Product in said country, with such credit not to exceed [ * ] of the royalty otherwise due under this Agreement for such
Licensed Product in such country. 
 (b) If: (i) a [ * ] of a Third Party should be in force in any country during the Term of this
Agreement covering the practice of the Biogen Idec Collaboration Technology, Joint Sunesis-Biogen Collaboration Technology, Development Technology or Other Millennium Technology licensed to Sunesis under Section 5.1.3, in each case with respect
to the manufacture, use or sale of any Reverted Licensed Product, (ii) it should prove in Sunesis’s reasonable judgment, after consultation with Millennium, [ * ] for Sunesis to commercialize such Reverted Licensed Product without
obtaining a royalty bearing license from such Third Party [ * ] (with such agreement not to be unreasonably withheld or delayed), and (iii) the royalty paid to such Third Party is directed to the practice of rights granted to Sunesis under
Section 5.1.3 with respect to such Reverted Licensed Product, then Sunesis shall be entitled to a credit against the royalty payments due under Section 6.4 with respect to the same Reverted Licensed Product in such country of an amount
equal to [ * ] of the royalty paid to such Third Party for such Reverted Licensed Product in such country, arising from the practice of the intellectual property described above with respect to the manufacture, use or sale of the Reverted Licensed
Product in said country, with such credit not to exceed [ * ] of the royalty otherwise due under this Agreement for such Reverted Licensed Product in such country. 

  
 -27- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 6.3.4 Royalty Reduction. The royalty rates set forth in Sections 6.3.1 (but not 6.3.2)
used to calculate royalties payable on Net Sales of a Licensed Product (excluding a terminated PDK Product) in a country shall be [ * ] by [ * ] with respect to sales in the U.S. or Japan during any portion of the applicable period under
Section 6.5 in which [ * ] the Sunesis Licensed Patents or Sunesis Core Technology Covers the sale or use of such Licensed Product in such country. 

6.4. Royalties on Net Sales of Reverted Licensed Products. Sunesis shall pay Millennium at a royalty rate equal to the royalty rate
provided under Section 6.3.1 with respect to Net Sales of Reverted Licensed Products by Sunesis, its Affiliates and their Sublicensees; provided, however, that such royalty rate shall be [ * ] by [ * ] with respect to sales in the U.S. or Japan
during any portion of the applicable period under clause (ii) in Section 6.5.1 in which [ * ] the Biogen Idec Collaboration Patents, Joint Sunesis-Biogen Collaboration Patents, Development Technology or Other Millennium Technology Covers
the sale or use of such Reverted Licensed Product in such country. 
 6.5. Royalty Term. 

6.5.1 The royalties due pursuant to Section 6.3 and Section 6.4 above shall be payable on a country-by-country and Product-by-Product
basis commencing on the first commercial sale in a country and continuing until the later of: (i) the expiration of the last Valid Claim of (a) the Sunesis Licensed Patents or Sunesis Core Technology Covering the sale or use of the
relevant Licensed Product in such country or (b) the Biogen Idec Collaboration Patents, Joint Sunesis-Biogen Collaboration Patents, Development Technology or Other Millennium Technology Covering the sale or use of the relevant Reverted Licensed
Product in such country, or (ii) the tenth (10th) anniversary of the first commercial sale of such Product in such country. 

6.5.2 Millennium acknowledges that it will continue to benefit from its license under, and the transfer to Millennium of certain elements of,
the Sunesis Collaboration Technology and Sunesis Core Technology, the co-funding payments pursuant to this Agreement and Millennium’s own development of Know-How derived from the practice of such Sunesis licenses and Millennium’s use of
such Sunesis Collaboration Technology and Sunesis Core Technology, even after the expiration of all Patent Rights that claim a Licensed Product in a particular country. In addition, Millennium and Sunesis acknowledge the application of a uniform
royalty structure and compensation to Sunesis for its co-funding payments in the form of an additional royalty payment amount throughout the period under clause (ii) in Section 6.5.1. The Parties acknowledge that such structure is more
convenient to the Parties, facilitates the payment of compensation between the Parties for co-funding commitments and access to Know How and reduces accounting burdens on the Parties. Accordingly, the Parties have agreed to apply the royalty
structure as provided in this Article 6. 

  
 -28- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 ARTICLE 7 

PAYMENTS, BOOKS AND RECORDS 

7.1. Royalty Reports and Payments. After the first sale of a Product on which royalties are payable by a Party hereunder, such Party
shall make quarterly written reports to the other Party within sixty (60) days after the end of each calendar quarter, stating in each such report, separately the number, description, and aggregate Net Sales, by territory, of each such Product
sold during the calendar quarter upon which a royalty is payable under Section 6.3 or Section 6.4 above, as applicable. Concurrently with the making of such reports, such Party shall pay to the other Party royalties due at the rates
specified in Section 6.3 or Section 6.4 above, as applicable. 
 7.2. Payment Method. All payments due under this Agreement
shall be made by bank wire transfer in immediately available funds to a bank account designated by the Party owed such payment. All payments hereunder shall be made in U.S. dollars. Any payments that are not paid on the date such payments are due
under this Agreement shall bear interest to the extent permitted by applicable law at a rate equal to the 3-month LIBOR rate at the close of business on the date such payment is due, plus an additional two percent (2%), calculated on the number of
days such payment is delinquent. 
 7.3. Place of Royalty Payment; Currency Conversion. The functional currency for accounting will be
U.S. dollars. Except as the Parties otherwise mutually agree, for billing and reporting, Development Costs and Net Sales will be translated, if necessary, into U.S. dollars using the currency exchange rates quoted by Bloomberg Professional, a
service of Bloomberg L.P., or in the event Bloomberg Professional is not available, then the Eastern U.S. edition of The Wall Street Journal on the last business day of the applicable calendar quarter. 

7.4. Records; Inspection. Each Party shall keep, and shall ensure that its Affiliates keep, complete, true and accurate books of account
and records for the purpose of determining the amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of such Party, for at least three (3) years following the end of the calendar quarter
to which they pertain. Such records will be open for inspection by a public accounting firm to whom the audited Party has no reasonable objection and subject to such accounting firm entering into a satisfactory confidentiality agreement, solely for
the purpose of determining the payments to the other Party hereunder. Such inspections may be made no more than twice each calendar year, at reasonable times and on reasonable notice. Inspections conducted under this Section 7.4 shall be at the
expense of the auditing Party, unless a variation or error producing an increase exceeding [ * ] percent ([ * ]%) of the amount stated for the period covered by the inspection is established in the course of any such inspection, whereupon all
reasonable costs relating to the inspection for such period and any unpaid or overpaid amounts that are discovered will be promptly paid or refunded by the appropriate Party, in each case together with interest noted in Section 7.2 thereon from
the date such payments were due (if underpaid) or paid (if overpaid). 
 7.5. Withholding Taxes. Each Party shall pay any and all
taxes levied on account of amounts payable to it under this Agreement. If laws or regulations require that taxes be withheld, the paying Party will (i) deduct those taxes from the remittable payment, (ii) timely pay the taxes to the proper
authority, and (iii) send proof of payment to the other Party within sixty (60) days following that payment. 

  
 -29- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 ARTICLE 8 

DILIGENCE 
 8.1.
Diligence; Reports. Millennium shall use Commercially Reasonable and Diligent Efforts to develop and commercialize Co-Funded Products within the Field. Millennium agrees to keep Sunesis fully informed regarding the Development and
commercialization activities with respect to each Co-Funded Product by providing reports to Sunesis at least quarterly regarding ongoing activities being undertaken with respect to Co-Funded Products. In addition, Millennium shall provide Diligence
Summaries to Sunesis with respect to each [ * ]. This Section 8.1 shall not limit other provisions of this Agreement that address the provision of information regarding Licensed Products. 

8.2. Reversion of a Co-Funded Product. If Millennium fails to use Commercially Reasonable and Diligent Efforts to develop and
commercialize a Co-Funded Product, and Millennium shall continue to fail to use Commercially Reasonable and Diligent Efforts to develop and commercialize such Co-Funded Product for [ * ] after written notice thereof from Sunesis, or in the event
that Sunesis terminates this Agreement pursuant to Section 13.2 for Millennium’s breach, pursuant to Section 13.3 for Millennium’s bankruptcy or in the event that Millennium terminates this Agreement pursuant to Section 13.4
for convenience with respect to a Co-Funded Product, Sunesis shall have the right to assume the development and commercialization of such Co-Funded Product, subject to the terms and conditions of this Section 8.2, upon written notice to
Millennium. Upon the effective date of such notice from Sunesis, such Co-Funded Product shall be designated a “Reverted Licensed Product”, the terms set forth in Section 1 of Exhibit 8.2 attached hereto shall thereafter apply, and
Sunesis shall pay royalties to Millennium as provided under Section 6.4 on Net Sales of such Reverted Licensed Product by Sunesis, its Affiliates or Sublicensees. 

8.3. Diligence for a Reverted Licensed Product. Sunesis shall use Commercially Reasonable and Diligent Efforts to develop and
commercialize each Reverted Licensed Product. Sunesis agrees to keep Millennium fully informed regarding the development and commercialization activities with respect to each Reverted Licensed Product, including by providing Millennium with reports
at least quarterly regarding ongoing activities being undertaken with respect to Reverted Licensed Products. In addition, Sunesis shall provide Millennium with a Diligence Summary with respect to each Reverted Licensed Product on a semi-annual basis
during the Term of this Agreement. 
 8.4. Termination of a Reverted Licensed Product. If Sunesis fails to use Commercially Reasonable
and Diligent Efforts to develop and commercialize a Reverted Licensed Product, and Sunesis shall continue to fail to use Commercially Reasonable and Diligent Efforts to develop and commercialize such Reverted Licensed Product for sixty
(60) days after written notice thereof from Millennium, then such Reverted Licensed Product shall cease to be a Reverted Licensed Product, and the license granted to Sunesis under Section 5.1.3 shall terminate with respect to such Reverted
Licensed Product. Thereafter, such Reverted Licensed Product shall be a Licensed Product and subject to Millennium’s licenses under Section 5.1 and obligations to pay royalties and milestones to Sunesis pursuant to Article 6. In addition,
the terms set forth in Section 2 of Exhibit 8.2 shall apply to such Reverted Licensed Product. 

  
 -30- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 8.5. Disputes. In the event that there is a good faith dispute as to whether the
activities described in a Diligence Summary constitute Commercially Reasonable and Diligent Efforts to develop and commercialize the applicable Co-Funded Product or Reverted Licensed Product, then either Party may refer the dispute for a prompt
determination by the Joint Steering Committee. In the event that the Joint Steering Committee is unable to reach consensus on such determination, then the matter shall be referred to the Parties’ respective Chief Medical Officers (or the
equivalent if there is no such Chief Medical Officer of a Party). Upon such request, the Chief Medical Officers shall make themselves reasonably available to meet, and shall meet either by telephone or if, specifically requested, in person, to
attempt to resolve such matter, and shall thereafter continue to use good faith efforts to attempt to resolve such matter unless it becomes clear that the matter cannot be resolved by mutual agreement. Thereafter either Party may pursue such legal
process as is otherwise available under applicable law. 
 ARTICLE 9 

INTELLECTUAL PROPERTY 

9.1. Ownership; Disclosure. 

9.1.1 Collaboration Technology. 

(a) Raf Technology. All right, title, and interest in and to the Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration
Patents, the subject of which are inventions that were developed in the course of activities directed to the Raf Target or to the discovery, research, or development of Licensed Compounds which are Target Selective to the Raf Target or Licensed
Products incorporating such Licensed Compounds (the “Raf Patents”) were jointly and equally owned by Biogen Idec and Sunesis under the Original Agreement. Pursuant to the Millennium-Biogen Agreement, Biogen Idec has, with the consent of
Sunesis as provided in the Three Party Agreement, assigned all of its right, title and interest in and to the Raf Patents to Millennium; and from and after the Effective Date the Raf Patents shall be jointly owned by Millennium and Sunesis. 

(b) Sunesis Collaboration Technology. Subject to Section 9.1.1(a), all right, title, and interest in and to the Sunesis
Collaboration Technology shall be owned by Sunesis, subject to the licenses granted to Millennium under Article 5. 
 (c) Joint
Sunesis-Biogen Collaboration Technology. Pursuant to the Millennium-Biogen Agreement, Biogen Idec has, with the consent of Sunesis as provided in the Three Party Agreement, assigned to Millennium all of its right, title and interest in and to
the Joint Sunesis-Biogen Collaboration Patents and Joint Sunesis-Biogen Collaboration Know-How that are included in the Assigned IP (as defined in the Millennium-Biogen Agreement) and that, in each case, are [ * ] a Licensed Compound (the
“Licensed Compound Joint Technology”) and has granted a license to Millennium under Biogen Idec’s right, title and interest in and to all other Joint Sunesis-Biogen Patents and Joint Sunesis-Biogen Know-How (the “Other Joint
Technology”). All right, title and interest in and to the Licensed Compound Joint Technology shall be jointly owned by the Parties. All right, title and interest in and to the Other Joint Technology shall be jointly owned by Sunesis and Biogen
Idec (subject to the licenses granted to Millennium). Except as expressly provided in this Agreement, neither Party shall have any 

  
 -31- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
obligation to account to the other for profits, or to obtain any approval of the other Party to license, exploit or enforce the Licensed Compound Joint Technology, by reason of joint ownership
thereof, and each Party hereby waives any right it may have under the laws of any jurisdiction to require any accounting or consent related thereto. It is understood and agreed that all Joint Sunesis-Biogen Collaboration Technology that is jointly
owned pursuant to Section 9.1.1(a) and this Section 9.1.1(c) shall be subject to the licenses granted under Article 5 and Section 16.1. 

(d) Excluded Compounds. For the avoidance of doubt, to the extent a Joint Sunesis-Biogen Collaboration Patent discloses any use of an
Excluded Compound (as defined in the Original Agreement), the composition of matter of which is separately owned by one Party, the other Party shall not have, merely as a result of its joint ownership of such Joint Sunesis-Biogen Collaboration
Patent, any right, title or interest in or to such Excluded Compound. 
 9.1.2 Development Technology. All right, title and interest
in and to the Development Technology shall, as between the Parties, be owned solely by Millennium. Sunesis hereby assigns to Millennium all of Sunesis’s and its Affiliates’ rights in and to the Development Technology (including all patent
and other intellectual property rights therein), subject to the licenses granted to Sunesis under Article 5. 
 9.1.3 PDK Technology.
Sunesis shall solely own all Know-How made or developed after the Amendment Effective Date, solely by or under authority of Sunesis or its Affiliates, in the course of performing any activity under this Agreement directed to the PDK Target or
directly related to the development, manufacturing or commercialization of a PDK Compound or PDK Product, and all Patent Rights that claim or cover any such Know-How (collectively, the “PDK Technology”). To the extent that Millennium
Controls Patent Rights or Know-How that is generated after the Amendment Effective Date [ * ], Millennium [ * ]. 
 9.2. Patent
Prosecution. Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement: 
 9.2.1 Sunesis Core Technology. Sunesis
shall have the right to control the preparation, filing, prosecution and maintenance of patent applications and patents directed to Sunesis Core Technology using patent counsel of Sunesis’s choice, provided that such decisions made by Sunesis
in the preparation, filing, prosecution, and maintenance of such patents and patent applications shall be reasonable and Sunesis shall employ reasonable efforts not to substantially negatively impact Millennium’s rights hereunder. 

9.2.2 Collaboration Patents and Development Patents. 

(a) Millennium shall have the first right, using in-house or outside legal counsel selected by Millennium, subject to approval,
not to be unreasonably withheld, by Sunesis, to prepare, file, prosecute, maintain, and obtain extensions throughout the world of Collaboration Patents and Patent Rights in the Development Technology that claim or cover the Raf Target, Licensed
Compounds or Licensed Products, or the use of manufacture thereof. Millennium shall: (a) ensure that Sunesis receives copies of all 

  
 -32- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
correspondence between Millennium or outside legal counsel or any governmental offices relating to such preparation, filing, prosecution, maintenance, and obtaining of extensions, of such
Collaboration Patents and other Patent Rights under this Section 9.2.2(a), (b) timely consult with Sunesis regarding all substantive matters associated with such activities, (c) use reasonable efforts to periodically advise Sunesis on
such activities and to respond to any reasonable inquiries Sunesis may from time to time raise in respect of such activities, and (d) not substantially negatively impact Sunesis’s rights under such Collaboration Patents. As used in this
Article 9, “prosecution” shall include interferences, re-examinations, reissues, oppositions and the like. 
 (b)
Sunesis shall have the first right, using in-house or outside legal counsel selected by Sunesis, subject to approval, not to be unreasonably withheld, by Millennium, to prepare, file, prosecute, maintain, and obtain extensions throughout the world
of (i) Collaboration Patents and Patent Rights in the Development Technology that claim or cover the PDK Target, PDK Compounds or PDK Products, or the use of manufacture thereof and (ii) Patent Rights in the PDK Technology. Sunesis shall:
(a) ensure that Millennium receives copies of all correspondence between Sunesis or outside legal counsel or any governmental offices relating to such preparation, filing, prosecution, maintenance, and obtaining of extensions, of such
Collaboration Patents and other Patent Rights under this Section 9.2.2(b), (b) timely consult with Millennium regarding all substantive matters associated with such activities, (c) use reasonable efforts to periodically advise
Millennium on such activities and to respond to any reasonable inquiries Millennium may from time to time raise in respect of such activities, and (d) not substantially negatively impact Millennium’s rights under such patents. Promptly
after the Amendment Effective Date, Millennium shall cooperate with Sunesis to promptly transfer relevant prosecution materials for all such Patent Rights to Sunesis. 

9.2.3 Prosecution Costs. All costs [ * ] associated with filing, prosecuting, issuing, maintaining, and extending (i) patent
applications and patents within the Sunesis Core Technology and Patent Rights described in Section 9.2.2(b) shall be borne by Sunesis; and (ii) Patent Rights described in Section 9.2.2(a) shall be borne by Millennium. 

9.2.4 Cooperation. Each Party will cooperate fully with the other Party and provide all information and data, and sign any documents,
reasonably necessary and requested by the other Party for the purpose of preparing, filing and prosecuting patent applications pursuant to this Section 9.2. 

9.2.5 Abandonment. 

(a) Millennium may elect to decline to file or, having filed, decline to further prosecute and maintain any Collaboration
Patent or other Patent Right under Section 9.2.2(a), in which event Millennium shall provide Sunesis with written notice thereof prior to the expiration of any deadline, without considering any possible extensions thereof, relating to such
activities, but in any event at least thirty five (35) business days prior notice. In such circumstances Sunesis shall have the right to decide, with reason and with written notice at least thirty (30) business days prior to the deadline,
that Millennium should continue to file or prosecute such Patent Right. Millennium shall then 

  
 -33- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
have the option to decide, with at least twenty (20) business days notice to Sunesis to: (i) continue to file or prosecute such Patent Right at its cost and expense, or (ii) allow
Sunesis to file or prosecute such Patent Right at its own cost and expense using counsel of its own choice. In the event that Millennium elects option (ii), then Millennium shall cooperate with Sunesis to promptly transfer relevant prosecution
materials to Sunesis. 
 (b) Sunesis may elect to decline to file or, having filed, decline to further prosecute and maintain
any Collaboration Patent or other Patent Right under Section 9.2.2(b), in which event Sunesis shall provide Millennium with written notice thereof prior to the expiration of any deadline, without considering any possible extensions thereof,
relating to such activities, but in any event at least thirty five (35) business days prior notice. In such circumstances Millennium shall have the right to decide, with reason and with written notice at least thirty (30) business days
prior to the deadline, that Sunesis should continue to file or prosecute such Patent Right. Sunesis shall then have the option to decide, with at least twenty (20) business days notice to Millennium to: (i) continue to file or prosecute
such Patent Right at its cost and expense, or (ii) allow Millennium to file or prosecute such Patent Right at its own cost and expense using counsel of its own choice. In the event that Sunesis elects option (ii), then Sunesis shall cooperate
with Millennium to promptly transfer relevant prosecution materials to Millennium. 
 (c) It is understood and agreed that
transfer of prosecution of particular Patent Rights pursuant to subsection (ii) in both Sections 9.2.5(a) and 9.2.5(b) above shall not affect the ownership or licenses otherwise provided in this Agreement. 

9.3. Enforcement. Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement: 

9.3.1 Notice. In the event a Party becomes aware of any actual or potential infringement or misappropriation of the Sunesis Licensed
Technology or Biogen Idec Collaboration Technology that relates to the Raf Target or Licensed Compounds or Licensed Products (a “Subject Infringement”), such Party shall notify the other Party. 

9.3.2 Millennium. Millennium shall have the sole right, but not the obligation, to take legal action to: 

(a) enforce and defend the Sunesis Licensed Technology against Subject Infringements by Third Parties at its sole cost and
expense. If, within [ * ] following a request by Sunesis to do so, Millennium fails to use commercially reasonable efforts to take such action to enforce the Sunesis Licensed Patents with respect to a Subject Infringement, Sunesis or its designee
shall, in its sole discretion, have the right, at its sole expense, to take such action. 
 (b) enforce and defend any actual
or potential infringement or misappropriation of the Biogen Idec Collaboration Technology that relates to the Raf Target or Licensed Compounds or Licensed Products. If, within [ * ] following a request by Sunesis to do so, Millennium fails to use
commercially reasonable efforts to take such action to enforce 

  
 -34- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
and defend any actual or potential infringement or misappropriation of the Biogen Idec Collaboration Technology that relates to the Raf Target or Licensed Compounds or Licensed Products, Sunesis
or its designee shall, in its sole discretion, have the right, at its sole expense, to take such action. 
 9.3.3 Sunesis. To the
extent a Subject Infringement is not covered by Section 9.3.2 above, Sunesis (or its designee) shall have the initial right, but not the obligation, to take reasonable legal action to enforce and defend the Sunesis Licensed Technology against
such Subject Infringements by Third Parties at its sole cost and expense. If, within [ * ] following a request by Millennium to do so, Sunesis fails to take such action to enforce the Sunesis Licensed Patents with respect to such Subject
Infringement, and the Subject Infringement is in a field not then licensed exclusively to Sunesis hereunder, Millennium or its designee shall, in its sole discretion, have the right, at its sole expense, to take such action. 

9.3.4 Cooperation. If a Party (the “Controlling Party”) brings an action in accordance with this Section 9.3 (an
“Infringement Action”), then the other Party (the “Cooperating Party”) shall cooperate as reasonably requested, at such Controlling Party’s expense, in the pursuit of such Infringement Action, including if necessary by
joining as a nominal Party to the Infringement Action. In any case, the Cooperating Party shall have the right, even if not required to be joined, to participate in such Infringement Action with its own counsel at its own expense. The costs and
expenses of the Infringement Action shall be the responsibility of the Controlling Party, and any damages or other monetary rewards or settlement payments actually received and retained by the Controlling Party shall first be applied to reimburse
the Controlling Party’s out-of-pocket expenses directly attributed to the Infringement Action, then the other Party’s out-of-pocket expenses directly attributed to the Infringement Action, then the other Party’s out-of-pocket expenses
directly attributed to the Infringement Action, and the remainder shall be shared as follows: [ * ]. 
 9.3.5 PDK Products. In
the event a Party becomes aware of any actual or potential infringement or misappropriation of the Millennium Licensed Technology or PDK Technology, such Party shall notify the other Party. Sunesis shall have the sole right, but not the obligation,
to take legal action to enforce and defend the Millennium Licensed Technology and PDK Technology against infringement by Third Parties at its sole cost and expense. If, within [ * ] following a request by Millennium to do so, Sunesis fails to use
commercially reasonable efforts to take such action to enforce and defend Millennium Licensed Technology or PDK Technology with respect to such infringement, Millennium or its designee shall, in its sole discretion, have the right, at its sole
expense, to take such action. 
 ARTICLE 10 

CONFIDENTIALITY 
 10.1.
Confidentiality. During the Term of this Agreement and for a period of [ * ] years following the expiration or earlier termination hereof, each Party shall maintain in confidence the Confidential Information of the other Party, shall not use
or grant the use of the Confidential Information of the other Party except as expressly permitted hereby, and shall not disclose the Confidential Information of the other Party (in each case, irrespective of whether such Confidential Information is
also the Confidential Information of the receiving Party), except (i) 

  
 -35- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
on a need-to-know basis to such Party’s directors, officers and employees, (ii) to such Party’s consultants performing work contemplated by the Agreement, and to any bona fide
subcontractor performing work for such Party hereunder, or (iii) to the extent such disclosure is reasonably necessary in connection with such Party’s activities under rights and licenses expressly authorized by this Agreement (including
the permitted sublicensees). To the extent that disclosure to any person is authorized by this Agreement, prior to disclosure, a Party shall obtain written agreement of such person to hold in confidence and not disclose, use or grant the use of the
Confidential Information of the other Party except as expressly permitted under this Agreement. Each Party shall notify the other Party promptly upon discovery of any unauthorized use or disclosure of the other Party’s Confidential Information.

 10.2. Permitted Use and Disclosures. The confidentiality obligations under this Article 10 shall not apply to the extent that
a Party is required to disclose information by applicable law, regulation or order of a governmental agency or a court of competent jurisdiction; provided, however, that such Party shall provide written notice thereof to the other
Party (to the extent not prohibited by law or court order), and consult with the other Party with respect to such disclosure to the extent reasonably protectable and provide the other party reasonable opportunity to object to any such disclosure or
to request confidential treatment thereof. Notwithstanding the provisions of this Section, either Party may, to the extent necessary, disclose Confidential Information of the other Party, to any governmental or regulatory authority in connection
with the development of a product which it has the right to develop under this Agreement. 
 10.3. Nondisclosure of Terms. Each of the
Parties hereto agrees not to disclose the financial terms of this Agreement to any Third Party without the prior written consent of the other Party hereto, which consent shall not be unreasonably withheld, except (a) to such Party’s
attorneys, advisors, investors, potential bona fide collaborators and Sublicensees, and others on a need-to-know basis under circumstances that reasonably protect the confidentiality thereof; (b) or to the extent required by law (and
with appropriate requests made for confidential treatment), including filings required to made by law with the Securities and Exchange Commission or any national securities exchange; provided, however, that, with respect to any filing required to
made by law with the Securities and Exchange Commission or any national securities exchange, the Party subject to such filing requirement shall, at least ten (10) business days in advance of any such filing, provide the other Party with a draft
set of redactions to this Agreement for which confidential treatment will be sought, reasonably incorporate the other Party’s comments as to additional terms it would like to see redacted, and seek confidential treatment for such additional
terms (except only in the limited circumstances where confidential treatment is in the opinion of outside counsel unavailable); or (c) to Biogen Idec, to the extent required under the Three Party Agreement or Millennium-Biogen Agreement.
Notwithstanding the foregoing, (i) Sunesis may issue the press release to be mutually agreed by the Parties, and (ii) each Party may disclose the information contained in such press release (and related Securities and Exchange Commission
filing) without the consent of the other Party. 

  
 -36- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 10.4. Publication. 

10.4.1 By Sunesis. Any manuscript by Sunesis on subject matter in connection with the Research Program relating to the Raf Target or
Licensed Compounds to be published or publicly disclosed shall be subject to the prior review of Millennium at least [ * ] prior to submission. Further, to avoid loss of patent rights as a result of premature public disclosure of patentable
information, Millennium shall notify Sunesis in writing within [ * ] after receipt of any disclosure whether Millennium desires to file a patent application on any invention disclosed in such scientific results. In the event that Millennium desires
to file such a patent application, Sunesis shall withhold publication or disclosure of such scientific results until the earlier of (i) a patent application is filed thereon, (ii) the Parties determine after consultation that no patentable
invention exists, or (iii) [ * ] after receipt by Sunesis of Millennium’s written notice of Millennium’s desire to file such patent application. Further, if such scientific results contain the information of Millennium that is subject
to use and nondisclosure restrictions under this Article 10, Sunesis agrees to remove such information from the proposed publication or disclosure. For clarity, nothing in this Section 10.4 shall be deemed to limit the publication or
disclosure right of Sunesis with respect to a Reverted Licensed Product. Sunesis shall have the right, but not the obligation, to publish or publicly disclose, in its sole discretion, any manuscript containing scientific or clinical results
generated during the Term relating to the PDK Target, PDK Compounds or PDK Products, and shall provide Millennium with a courtesy copy of such manuscript prior to its publication. 

10.4.2 By Millennium. Millennium shall have the right, but not the obligation, to publish or publicly disclose, in its sole discretion,
any manuscript containing scientific or clinical results generated during the Term relating to the Raf Target, Licensed Compounds or Licensed Products, and shall provide Sunesis with a courtesy copy of such manuscript prior to its publication. 

10.4.3 Patent Applications. Following the filing of any patent application within the Collaboration Technology, in the period prior to
the publication of such a patent application, neither Party shall make any written public disclosure regarding any invention claimed in such patent application without the prior consent of the other Party. 

ARTICLE 11 

REPRESENTATIONS AND WARRANTIES 

11.1. Warranty. Each Party represents and warrants on its own behalf and on behalf of its Affiliates that as of the Amendment Effective
Date: 
 (i) Such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized.

 (ii) It has the legal power and authority to enter into this Agreement and to perform all of its obligations hereunder. 

(iii) This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms. 

  
 -37- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (iv) All necessary consents, approvals and authorizations of all governmental authorities and
other persons or entities required to be obtained by such Party in connection with this Agreement have been obtained. 
 (v) The execution
and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies; and (b) do not conflict
with, or constitute a default under, any contractual obligation of such Party. Neither Party will enter into any agreement with any Third Party that conflicts with the terms of this Agreement. 

(vi) Such Party requires, and shall require, that all of its employees and consultants involved in the Development, manufacture or
commercialization of Licensed Compounds, Licensed Products, PDK Compounds, PDK Products, Reverted Compounds or Reverted Licensed Products have entered into written agreements obligating such person to assign any rights s/he may have in any
inventions made during such work to such Party. 
 11.2. Additional Warranty of Sunesis. Sunesis represents and warrants as of the
Effective Date that: 
 (a) to the best of its knowledge, the practice of the Sunesis Core Technology with respect to the
Licensed Compounds is not generally dominated by Patent Rights of a Third Party; 
 (b) Sunesis has not received any notice
of infringement from any Third Party relating to the Sunesis Core Technology or Sunesis Licensed Technology; 
 (c) Sunesis
has not received any notice challenging the validity of the Sunesis Licensed Technology or Sunesis Core Technology; and 

(d) to the best of its knowledge, the Sunesis Licensed Technology and Sunesis Core Technology with respect to Licensed
Compounds is legally possessed by Sunesis and has not been misappropriated from any Third Party. 
 11.3. Disclaimer. EXCEPT AS
OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE COLLABORATION TECHNOLOGY, SUNESIS CORE TECHNOLOGY, DEVELOPMENT TECHNOLOGY, OTHER
MILLENNIUM TECHNOLOGY, LICENSED COMPOUNDS, OTHER COMPOUNDS, LICENSED PRODUCTS, PDK TECHNOLOGY, PDK COMPOUNDS, PDK PRODUCTS, DESIGNATED TARGETS OR CONFIDENTIAL INFORMATION, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
VALIDITY OF ANY COLLABORATION TECHNOLOGY OR PDK TECHNOLOGY, PATENTED OR UNPATENTED, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

  
 -38- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 11.4. Additional Warranties of Millennium. Millennium represents and warrants as of the
Amendment Effective Date that (a) the Millennium Licensed Patents are the only Patent Rights owned or controlled by Millennium or its Affiliates that [ * ] to the PDK Compounds or PDK Products, (b) Millennium has not transferred, whether
by license or otherwise, the Millennium Licensed Technology to any Affiliate, (c) no compounds were Synthesized during the [ * ] by or on behalf of Millennium in the course of activities [ * ] the PDK Target and through the use of the Sunesis
Licensed Technology, and (d) [ * ]. 
 ARTICLE 12 

INDEMNIFICATION 
 12.1.
Millennium. Millennium shall indemnify, defend and hold harmless Sunesis and its Affiliates and their respective directors, officers, employees, agents and their respective successors, heirs and assigns from and against any losses, costs,
claims, damages, liabilities or expense (including reasonable attorneys’ and professional fees and other expenses of litigation) (collectively, “Liabilities”) resulting from any claims, demands, actions or other proceedings by any
Third Party to the extent resulting from: (i) the manufacture, use, sale, handling or storage of Licensed Products by Millennium or its Affiliates or Sublicensees or other designees (except with respect to claims of infringement or violation of
intellectual property rights, which shall be governed solely by clause (iv)); (ii) the breach by Millennium of the representations and warranties made in this Agreement; (iii) [ * ] Millennium or any of its agents or employees or
failure of Millennium or any of its agents or employees to comply with applicable laws and regulations; or (iv) a claim that the use, manufacture, sale or importation of a Licensed Product infringes or violates the intellectual property rights
of a Third Party (other than if such infringement or violation results solely from the practice of any Sunesis Licensed Technology (excluding any Joint Sunesis-Biogen Idec Collaboration Patents and Joint Sunesis-Biogen Idec Collaboration Know-How)
and Sunesis Core Technology in accordance with this Agreement); except, in each of cases (i)–(iv), to the extent such Liabilities result from a material breach of this Agreement by Sunesis, [ * ] Sunesis or any of its agents or employees
(including sales representatives involved in co-promoting any Co-Promoted Licensed Product) or failure of Sunesis or any of its employees or agents to comply with applicable laws or regulations. 

12.2. Sunesis. Sunesis agrees to indemnify, defend and hold harmless Millennium and its Affiliates and their respective directors,
officers, employees, agents and their respective heirs and assigns from and against any Liabilities resulting from any claims, demands, actions or other proceedings by any Third Party to the extent resulting from: (i) the manufacture, use,
sale, handling or storage of Co-Promoted Licensed Products, PDK Products or Reverted Licensed Products by Sunesis or its Affiliates or Sublicensees or other designees, (ii) the breach by Sunesis of its representations and warranties made in
this Agreement or the Original Agreement, (iii) [ * ] Sunesis or any of its agents or employees or failure of Sunesis or any of its agents or employees to comply with applicable laws and regulations; except, in each case, to the extent such
Liabilities result from a breach of this Agreement by Millennium, [ * ] Millennium or any of its agents or employees (including sales representatives involved in co-promoting any Co-Promoted Licensed Product) or failure of Millennium or any of its
employees or agents to 

  
 -39- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
comply with applicable laws or regulations, or (iv) a claim arising after the Amendment Effective Date that the use, manufacture, sale or importation of a PDK Product infringes or violates
the intellectual property rights of a Third Party (other than if such infringement or violation results solely from the practice of any PDK Technology in accordance with this Agreement). 

12.3. Procedure. If a Party (the “Indemnitee”) intends to claim indemnification under this Article 12, it shall promptly
notify the other Party (the “Indemnitor”) in writing of any claim, demand, action or other proceeding for which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to participate in, and, to the
extent the Indemnitor so desires, to assume the defense thereof with counsel mutually satisfactory to the Parties; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the
Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitee and any other Party represented by such counsel in such
proceeding. The obligations of this Article 12 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld
or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation
to the Indemnitee under this Article 12. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this
Article 12. The Indemnitor shall not, without the Indemnitee’s consent, which consent shall not be withheld or delayed unreasonably, consent to the entry of any judgment or accept any settlement with respect to such claim, demand, action or
proceeding which imposes liability not covered by this indemnification or restrictions on the Indemnitee. 
 ARTICLE 13 

TERM AND TERMINATION 

13.1. Term. The Term of this Agreement shall commence on the Amendment Effective Date, and shall continue in full force and effect on a
country-by-country and Product-by-Product basis until expiration of both Parties’ royalty payment obligations in such country with respect to such Products, in each case unless earlier terminated as provided in this Article 13 (the
“Term”). 
 13.2. Termination for Breach. Either Party to this Agreement may terminate this Agreement, with respect to the
applicable compounds and products only, in the event the other Party hereto shall have materially breached or defaulted in the performance of any of its material obligations hereunder with respect to (i) any Licensed Product(s), Licensed
Compound(s) or Reverted Licensed Product(s) or (ii) any PDK Product(s) or PDK Compound(s), and such default shall have continued for [ * ] after written notice thereof was provided to the breaching Party by the non-breaching Party. Such
termination shall be specifically limited to the compounds and products to which the breach or default relates, and this Agreement shall continue in full force and effect with respect to any other Licensed Product, Licensed Compound, Reverted
Licensed Product, PDK Product or PDK Compound. Any termination shall become effective at the end of 

  
 -40- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
such [ * ] period unless the breaching Party has cured any such breach or default prior to the expiration of the [ * ] period. Notwithstanding the foregoing, failure by either Party to use
Commercially Reasonable and Diligent Efforts with respect to the development and commercialization of a Product shall not be deemed a breach of this Agreement. Sunesis hereby waives any breaches or defaults by Biogen Idec under the Original
Agreement and acknowledges and agrees that any future breaches or defaults by Biogen Idec under the New Sunesis-Biogen Agreement shall have no bearing on this Agreement. 

13.3. Termination For Bankruptcy. Either Party hereto shall have the right to terminate this Agreement forthwith by written notice to
the other Party (i) if the other Party is declared insolvent or bankrupt by a court of competent jurisdiction, (ii) if a voluntary or involuntary petition in bankruptcy is filed in any court of competent jurisdiction against the other
Party and such petition is not dismissed within ninety (90) days after filing, (iii) if the other Party shall make or execute an assignment of substantially all of its assets for the benefit of creditors, or (iv) substantially all of
the assets of such other Party are seized or attached and not released within ninety (90) days thereafter. All rights and licenses granted under this Agreement by one Party to the other Party are, and shall otherwise be deemed for purposes of
Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 (56) of the Bankruptcy Code. The Parties agree that the licensing Party under this Agreement shall retain and
may fully exercise all of its rights and elections under the Bankruptcy Code in the event of a bankruptcy by the other Party. The Parties further agree that in the event of the commencement of a bankruptcy proceeding by or against one Party under
the Bankruptcy Code, the other Party shall be entitled to complete access to any such intellectual property pertaining to the rights granted in the licenses hereunder of the Party by or against whom a bankruptcy proceeding has been commenced and all
embodiments of such intellectual property. 
 13.4. Termination for Convenience. Provided that Millennium is not in breach of this
Agreement, Millennium will have the right to terminate this Agreement at any time with respect to any or all of the Licensed Compounds and Licensed Products (including terminated PDK Products), by providing [ * ] prior written notice. In such event,
this Agreement will remain in effect with respect to PDK Compounds, PDK Products, Reverted Licensed Products and any other Licensed Compound or Licensed Product, in each case that has not been terminated. Provided that Sunesis is not in breach of
this Agreement, Sunesis will have the right to terminate this Agreement at any time with respect to any or all of the PDK Products and Reverted Licensed Products, by providing [ * ] prior written notice. In such event, this Agreement will remain in
effect with respect to Licensed Compounds and Licensed Products and any other PDK Products or Reverted Licensed Products, in each case that has not been terminated. 

13.5. Effect of Breach or Termination. 

13.5.1 Accrued Rights and Obligations. Termination of this Agreement for any reason shall not release either Party hereto from any
liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement. 

  
 -41- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 13.5.2 Termination by Millennium for Breach or Bankruptcy of Sunesis. In the event of
termination of this Agreement by Millennium pursuant to Section 13.2 due to Sunesis’s breach (only with respect to the PDK Compounds, PDK Products and PDK Target) or by Millennium pursuant to Section 13.3 for Sunesis’s
bankruptcy, in addition to those provisions surviving under Section 13.8, the following shall apply: 
 (a) Sections 2.5.1 (Research
Records); 2.5.2 (Inspections) (but only with respect to Millennium’s rights and Sunesis’s obligations); 5.1.3 (License for Reverted Licensed Products) (but only with respect to Reverted Licensed Products in existence as of the effective
date of such termination); 6.1 (Research Milestones); 6.2 (Development Milestones); 6.3 (Royalties on Annual Net Sales of Licensed Products) (except that any royalties payable by Millennium thereunder, commencing upon such termination and continuing
thereafter, shall be reduced by [ * ]); 6.4 (Royalties on Net Sales of Reverted Licensed Products); 6.5 (Royalty Term); Article 9 (Intellectual Property) (other than Sections 9.2.2 and 9.2.3, which shall terminate); and Exhibit 8.2 (Reverted
Licensed Products) (but only with respect to Reverted Licensed Products in existence as of the effective date of such termination) shall survive. 

(b) Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement, Millennium shall control prosecution of all Collaboration
Patents (including Sunesis Collaboration Patents, Biogen Idec Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents) at its own expense for such Patent Rights that are related to the PDK Target, PDK Compounds and PDK Products, as the
case may be, in addition to the prosecution rights that Millennium has pursuant to Section 9.2.2(a). Sunesis shall be given the opportunity to review Millennium’s activities and reasonably consult with Millennium with respect to such
Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents, and Millennium shall in good faith consider including in such patent applications such claims as Sunesis reasonably requests. Millennium shall keep Sunesis reasonably
informed as to the status of such patent matters, including by providing Sunesis with (i) copies of any documents relating to such Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents which Millennium receives from any
patent office within twenty (20) days of receipt thereof, including notice of all interferences, reissues, reexaminations, oppositions or requests for patent term extensions, and (ii) the opportunity to review and comment on any documents
relating to such Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents which will be filed in any patent office as soon practicable but in all cases at least twenty (20) days prior to such filing. All costs associated
with filing, prosecuting, issuing and maintaining such patent applications and patents within the Sunesis Core Technology shall be borne by Sunesis. In conducting the prosecution activities described in this Section 13.5.2(b), each Party shall
employ reasonable efforts not to substantially negatively impact the other Party’s rights under the surviving provisions of this Agreement. 

(c) Sunesis’s rights and obligations under Section 2.2.3 shall survive with respect to Co-Funded Products for which Sunesis has
exercised its Co-Funding Option prior to such termination, and Millennium shall pay royalties on any such Co-Funded Products in accordance with Section 6.3.2. Millennium shall no longer be obligated to provide the detailed plans required of a
Co-Development Plan and Budget to Sunesis, but shall provide Sunesis with annual budgets of post Phase I Development Costs for any such Co-Funded Products. Sunesis’s Co-Funding Option with respect to future Licensed Products shall terminate, as
will Article 3, as well as Sunesis’s right to participate in the JDC under Section 4.3 and any Licensed Product Teams under Section 2.3. 

  
 -42- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (d) The effects of an uncured failure to use Required Efforts under Section 16.4 shall
apply, and any inconsistent provisions under Section 13.5.2(a) shall be superseded by such provisions of Section 16.4. 
 13.5.3
Termination by Sunesis for Breach or Bankruptcy of Millennium. In the event of any termination by Sunesis pursuant to Section 13.2 due to Millennium’s breach (only with respect to the Licensed Compounds, Licensed Products and Raf
Target) or pursuant to Section 13.3 for Millennium’s bankruptcy, in addition to those provisions surviving under Section 13.8, the following provisions of this Section 13.5.3 shall apply: 

(a) Sections 2.5.1 (Research Records); 2.5.2 (Inspections) (but only with respect to Sunesis’s rights and Millennium’s obligations);
5.1.3 (License for Reverted Licensed Products); 6.1 (Research Milestones); 6.2 (Development Milestones); 6.3 (Royalties on Annual Net Sales of Licensed Products); 6.4 (Royalties on Net Sales of Reverted Licensed Products (except that any royalties
payable by Sunesis thereunder, commencing upon such termination and continuing thereafter, shall be reduced by [ * ]); 6.5 (Royalty Term); Article 8 (Diligence); Article 9 (Intellectual Property) (other than Sections 9.2.2 and 9.2.3, which shall
terminate); and Exhibit 8.2 (Reverted Licensed Products) shall survive, in addition to those provisions surviving under Section 13.8. 

(b) Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement, Millennium shall control prosecution of all the Biogen Idec
Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents at its own expense, only for such Patent Rights that are related to the Raf Target, Licensed Compounds and Licensed Products. Sunesis shall control prosecution of all Sunesis
Collaboration Patents at its own expense for such Sunesis Collaboration Patents that are related to the Raf Target, Licensed Compounds and Licensed Products, as the case may be, in addition to the prosecution rights that Sunesis has pursuant to
Section 9.2.2(b). Sunesis shall be given the opportunity to review Millennium’s activities and reasonably consult with Millennium with respect to such Joint Sunesis-Biogen Collaboration Patents, and Millennium shall in good faith consider
including in such patent applications such claims as Sunesis reasonably requests. Millennium shall keep Sunesis reasonably informed as to the status of such patent matters, including by providing Sunesis with (i) copies of any documents
relating to such Joint Sunesis-Biogen Collaboration Patents which Millennium receives from any patent office within twenty (20) days of receipt thereof, including notice of all interferences, reissues, reexaminations, oppositions or requests
for patent term extensions, and (ii) the opportunity to review and comment on any documents relating to such Joint Sunesis-Biogen Collaboration Patents which will be filed in any patent office as soon practicable but in all cases at least
twenty (20) days prior to such filing. All costs associated with filing, prosecuting, issuing and maintaining such patent applications and patents within the Sunesis Core Technology shall be borne by Sunesis. In conducting the prosecution
activities described in this Section 13.5.3(b), each Party shall employ reasonable efforts not to substantially negatively impact the other Party’s rights under the surviving provisions of this Agreement. 

  
 -43- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (c) Millennium’s rights with respect to Co-Funded Products and the Co-Funded Option shall
be as follows: 
 (i) With respect to any Co-Funded Product for which Sunesis has exercised its Co-Funding Option, and for which Millennium
has not obtained Regulatory Approval in any territory in the Co-Funded Territory for such Co-Funded Product, in each case as of the effective date of such termination, such Co-Funded Product shall become a Reverted Licensed Product in accordance
with Section 8.2 and Exhibit 8.2 and Sunesis shall thereafter pay royalties to Millennium on Net Sales of such Reverted Licensed Product in accordance with Section 6.4. 

(ii) With respect to any Co-Funded Product for which Sunesis has exercised its Co-Funding Option, and for which Millennium has obtained
Regulatory Approval in any territory in the Co-Funded Territory for such Co-Funded Product, in each case as of the effective date of such termination, Sunesis’s rights and obligations under Section 2.2.3 shall survive, and Millennium shall
pay royalties on any such Co-Funded Products in accordance with Section 6.3.2. Millennium shall no longer be obligated to provide the detailed plans required of a Co-Development Plan and Budget to Sunesis, but shall provide Sunesis with annual
budgets of post Phase I Development Costs for any such Co-Funded Products. Sunesis’s Co-Funding Option with respect to future Licensed Products shall terminate, as will Article 3, as well as Sunesis’s right to participate in the JDC under
Section 4.3 and any Licensed Product Teams under Section 2.3. 
 (iii) Sunesis’s Co-Funding Option under Section 2.2
with respect to future Licensed Products shall continue (i.e., with respect to Licensed Products that are not Co-Funded Products as of the effective date of such termination), provided that Millennium shall no longer be obligated to provide for each
Licensed Product the detailed plans and clinical data required of an Initial Development Plan and Phase II Notice pursuant to Section 2.2.1. Millennium shall, however, provide Sunesis with annual budgets of post Phase I Development Costs for
such Co-Funded Product in accordance with the timetable for a Phase II Notice set forth in Section 2.2.1, and shall provide reasonable cooperation to Sunesis in evaluating such Co-Funded Product and the post Phase I Development Costs related
thereto, including consulting with Sunesis in good faith regarding such annual budgets and the financial, scientific and regulatory assumptions reflected therein. 

13.6. Termination by Millennium for Convenience. In the event of termination of this Agreement by Millennium pursuant to
Section 13.4, in addition to those provisions surviving under Section 13.8, the following shall apply, only with respect to Licensed Compounds and Licensed Products (including terminated PDK Products): 

13.6.1 Sections 2.5.1 (Research Records); 2.5.2 (Inspections); Articles 2 (Product Development); 3 (Product Commercialization); 4 (Management);
5.1.3 (License for Reverted Licensed Products); 6.1 (Research Milestones); 6.2 (Development Milestones); 6.3 (Royalties on Annual Net Sales of Licensed Products); 6.4 (Royalties on Net Sales of Reverted Licensed Products) (except that any royalties
payable by Sunesis thereunder, commencing upon such termination and continuing thereafter, shall be reduced by [ * ]); Section 6.5 (Royalty Term); Article 8 (Diligence); Article 9 (Intellectual Property) (other than Sections 9.2.2 and 9.2.3,
which shall terminate); and Exhibit 8.2 (Reverted Licensed Products) shall survive, in addition to those provisions surviving under Section 13.8. 

  
 -44- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 13.6.2 Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement, Millennium
shall control prosecution of all the Biogen Idec Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents at its own expense, only for such Patent Rights that are related to the Raf Target, Licensed Compounds and Licensed Products.
Sunesis shall control prosecution of all Sunesis Collaboration Patents at its own expense, only for such Sunesis Collaboration Patents that are related to the Raf Target, Licensed Compounds and Licensed Products. Sunesis shall be given the
opportunity to review Millennium’s activities and provide input with respect to such Joint Sunesis-Biogen Collaboration Patents, and Millennium shall in good faith consider including in such patent applications such claims as Sunesis reasonably
requests. Millennium shall keep Sunesis reasonably informed as to the status of such patent matters, including by providing Sunesis with (i) copies of any documents relating to such Joint Sunesis-Biogen Collaboration Patents which Millennium
receives from any patent office within twenty (20) days of receipt thereof, including notice of all interferences, reissues, reexaminations, oppositions or requests for patent term extensions, and (ii) the opportunity to review and comment
on any documents relating to such Joint Sunesis-Biogen Collaboration Patents which will be filed in any patent office as soon practicable but in all cases at least twenty (20) days prior to such filing. All costs associated with filing,
prosecuting, issuing and maintaining the Sunesis Core Technology shall be borne by Sunesis. In conducting the prosecution activities described in this Section 13.6.2, each Party shall employ reasonable efforts not to substantially negatively
impact the other Party’s rights under the surviving provisions of this Agreement. 
 13.6.3 Millennium’s rights with respect to
Co-Funded Products and the Co-Funded Option shall be as follows: 
 (a) With respect to any Co-Funded Product for which Sunesis has
exercised its Co-Funding Option, and for which Millennium has not obtained Regulatory Approval in any territory in the Co-Funded Territory for such Co-Funded Product, in each case as of the effective date of such termination, such Co-Funded Product
shall become a Reverted Licensed Product in accordance with Section 8.2 and Exhibit 8.2 and Sunesis shall thereafter pay royalties to Millennium on Net Sales of such Reverted Licensed Product in accordance with Section 6.4. 

(b) With respect to any Co-Funded Product for which Sunesis has exercised its Co-Funding Option, and for which Millennium has obtained
Regulatory Approval in any territory in the Co-Funded Territory for such Co-Funded Product, in each case as of the effective date of such termination, Sunesis’s rights and obligations under Section 2.2.3 shall survive, and Millennium shall
pay royalties on any such Co-Funded Products in accordance with Section 6.3.2. Millennium shall no longer be obligated to provide the detailed plans required of a Co-Development Plan and Budget to Sunesis, but shall provide Sunesis with annual
budgets of post Phase I Development Costs for any such Co-Funded Products. Sunesis’s Co-Funding Option with respect to future Licensed Products shall terminate, as will Article 3, as well as Sunesis’s right to participate in the JDC under
Section 4.3 and any Licensed Product Teams under Section 2.3. 

  
 -45- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (c) Sunesis’s Co-Funding Option under Section 2.2 with respect to future Licensed
Products shall continue (i.e., with respect to Licensed Products that are not Co-Funded Products as of the effective date of such termination), provided that Millennium shall no longer be obligated to provide for each Licensed Product the detailed
plans and clinical data required of an Initial Development Plan and Phase II Notice pursuant to Section 2.2.1. Millennium shall, however, provide Sunesis with annual budgets of post Phase I Development Costs for such Co-Funded Product in
accordance with the timetable for a Phase II Notice set forth in Section 2.2.1, and shall provide reasonable cooperation to Sunesis in evaluating such Co-Funded Product and the post Phase I Development Costs related thereto, including
consulting with Sunesis in good faith regarding such annual budgets and the financial, scientific and regulatory assumptions reflected therein. 

13.7. Transition of Information and Materials. With respect to a Party’s obligation to transition Collaboration Technology,
information and material with respect to a particular Licensed Compound, each Party shall cooperate fully (and cause its Affiliates to cooperate fully) with the other Party to facilitate a smooth and prompt transition of Collaboration Technology,
information and materials that are necessary or useful for the receiving Party to exercise its licensed rights hereunder with respect to such Licensed Compound. 

13.8. Survival Sections. In addition to the provisions set forth in Sections 13.5.2, 13.5.3 and 13.6 above, as applicable, the following
provisions shall survive the expiration or termination of this Agreement for any reason: Articles 1 (Definitions), 7 (Payments, Books and Records), 10 (Confidentiality), 11 (Representations and Warranties), 12 (Indemnification), 13 (Term and
Termination), 14 (Dispute Resolution) and 15 (Miscellaneous); and Sections 5.1.1, 5.1.2 and 16.4(b) and (c). In the event of termination of this Agreement by Sunesis pursuant to Section 13.4, in addition to those provisions surviving under
Section 13.8, the effects of an uncured failure to use Required Efforts under Section 16.4 shall apply. 
 ARTICLE 14 

DISPUTE RESOLUTION 
 14.1.
Escalation to Senior Executives. In the event of a dispute or matter of significant concern arises between the Parties, then at the request of either Party, the matter shall be escalated to a senior executive from each Party. Such senior
executive shall be either the CEO or President of such Party, or another senior executive of such Party with the title of Vice President or higher and who has direct management responsibility for the matter in dispute. Upon such request, such senior
executives shall make themselves reasonably available to meet, and shall meet either by telephone or if, specifically requested, in person, to attempt to resolve such matter, and shall thereafter continue to use good faith efforts to attempt to
resolve such matter unless it becomes clear that the matter cannot be resolved by mutual agreement. Thereafter either Party may pursue such legal process as is otherwise available under applicable law. 

14.2. Injunctive Relief. This Article 14 shall not be construed to prohibit either Party from seeking preliminary or permanent
injunctive relief, restraining order or degree of specific performance in any court of competent jurisdiction to the extent not prohibited by this Agreement. For avoidance of doubt, any such equitable remedies provided under this Article 14 shall be
cumulative and not exclusive and are in addition to any other remedies, which either Party may have under this Agreement or applicable law. 

  
 -46- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 14.3. Matters to Proceed to Court. Notwithstanding the foregoing, any dispute relating to
the determination of validity of a Party’s patents or other issues relating solely to a Party’s intellectual property and any dispute asserting breach of this Agreement or of the representations and warranties made hereunder shall be
submitted exclusively to the federal court in Delaware, and the Parties hereby consent to the jurisdiction and venue of such court. 

ARTICLE 15 

MISCELLANEOUS 
 15.1.
Governing Laws. This Agreement and any dispute arising from the construction, performance or breach hereof shall be governed by and construed, and enforced in accordance with, the laws of the state of Delaware, without reference to conflicts
of laws principles. 
 15.2. Waiver. It is agreed that no waiver by either Party hereto of any breach or default of any of the
covenants or agreements herein set forth shall be deemed a waiver as to any subsequent or similar breach or default. 
 15.3.
Assignment. This Agreement shall not be assignable by either Party without the written consent of the other Party hereto, except either Party may assign this Agreement without such consent to its Affiliates, or to an entity that acquires all
or substantially all of the business or assets of such Party whether by merger, reorganization, acquisition, sale, or otherwise; provided, however, that the assignee shall agree in writing to be bound by the terms and conditions of this Agreement,
and that in the case of such an acquisition of all or substantially all of the business or assets of a Party, such assignment shall [ * ]. Notwithstanding any other provision in this Agreement, [ * ] involving Sunesis shall not be deemed to be a
breach of this Agreement or otherwise require [ * ], provided that such [ * ] shall not [ * ] to the Sunesis Licensed Patents and Sunesis Core Technology with respect to: the [ * ]; Biogen Idec Collaboration Patents; Joint Sunesis-Biogen
Collaboration Patents; Development Technology; Other Millennium Technology; and Confidential Information of Millennium. 
 15.4.
Independent Contractors. The relationship of the Parties hereto is that of independent contractors. The Parties hereto are not deemed to be agents, partners or joint venturers of the others for any purpose as a result of this Agreement or the
transactions contemplated thereby. 
 15.5. Compliance with Laws. In exercising their rights under this license, the Parties shall
fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this license including those applicable to the
development, manufacture, distribution, import and export and sale of Products pursuant to this Agreement. 
 15.6. Patent Marking.
Millennium agrees to mark and use reasonable efforts to make all its Sublicensees mark all Licensed Products sold pursuant to this Agreement in accordance with the applicable statute or regulations relating to patent marking in the country or
countries of 

  
 -47- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
manufacture and sale thereof. Sunesis agrees to mark and use reasonable efforts to make its Sublicensees mark all Reverted Licensed Products and PDK Products sold pursuant to this Agreement in
accordance with the applicable statute or regulations relating to patent marking in the country or countries of manufacture and sale thereof. 

15.7. Notices. All notices, requests and other communications hereunder shall be in writing and shall be personally delivered or by
registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the other Parties hereto and shall be deemed to have been given
upon receipt: 
  

			
	Sunesis:	  	 Sunesis Pharmaceuticals, Inc.
 395 Oyster Point
Boulevard, Suite 400
 South San Francisco, California 94080

Attn: Chief Executive Officer

		
	With a copy to:	  	 Cooley LLP
 3175 Hanover St.

Palo Alto, California 94304-1050
 Attn: Glen Sato

		
	Millennium	  	 Millennium Pharmaceuticals, Inc.
 40 Landsdowne
Street
 Cambridge, Massachusetts 02139
 Attn: General
Counsel

		
	With a copy to:	  	 Millennium Pharmaceuticals, Inc.
 40 Landsdowne
Street
 Cambridge, Massachusetts 02139
 Attn: Head Oncology
Therapeutic Area Unit

 15.8. Severability. In the event that any provision of this Agreement becomes or is declared by a court
of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the Parties shall amend the Agreement to the extent feasible to
lawfully include the substance of the excluded term to as fully as possible realize the intent of the Parties and their commercial bargain. If a Party seeks to avoid a provision of this Agreement by asserting that such provision is invalid, illegal
or otherwise unenforceable, the other Party shall have the right to terminate this Agreement upon sixty (60) days’ prior written notice to the asserting Party, unless such assertion is eliminated and cured within such sixty (60) day
period. If Millennium has sought to so avoid a provision of this Agreement, such termination shall be deemed a termination by Millennium under Section 13.4 above, and if Sunesis has sought such an avoidance, such termination shall be deemed a
termination by Millennium for breach by Sunesis under Section 13.2 above. 

  
 -48- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 15.9. Advice of Counsel. Sunesis and Millennium have each consulted counsel of their
choice regarding this Agreement, and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly. 

15.10. Performance by Affiliates; Warranty. Millennium may exercise any right or discharge any obligation hereunder through any of its
Affiliates. Each Party hereby warrants and guarantees the performance of any and all rights and obligations of this Agreement by its Affiliates and Sublicensees. 

15.11. Complete Agreement. This Agreement with its Exhibits, together with the Three Party Agreement, constitutes the entire agreement,
both written and oral, between the Parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are null and void and
of no effect. No amendment or change hereof or addition hereto shall be effective or binding on either of the Parties hereto unless reduced to writing and executed by the respective duly authorized representatives of Sunesis and Millennium. 

15.12. Headings. The captions to the several Sections and Articles hereof are not a part of this Agreement, but are included merely for
convenience of reference and shall not affect its meaning or interpretation. 
 15.13. Counterparts. This Agreement may be executed in
counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. 

ARTICLE 16 

DEVELOPMENT AND COMMERCIALIZATION OF PDK COMPOUNDS
AND PDK PRODUCTS 
 16.1 License to Sunesis. Subject to the terms and conditions of this Agreement,
Millennium hereby grants to Sunesis a worldwide, exclusive (even as to Millennium) license under the Millennium Licensed Technology, with the right to grant and authorize sublicenses as provided in Section 5.2 of the Agreement and, subject to
Section 16.5, to research, develop, perform regulatory activities for, make, have made, use, import, offer for sale, sell and otherwise exploit PDK Compounds and PDK Products in the Field. 

16.2 Transition. During the [ * ] following the Amendment Effective Date, Millennium shall cooperate fully with Sunesis and shall,
promptly after the Amendment Effective Date, provide Sunesis with copies of all data, documentation and information provided by Biogen Idec to Millennium relating to the PDK Compounds (to the extent not previously provided), and Sunesis shall have
the right to use and disclose such items. 
 16.3 Reporting. Sunesis shall provide Millennium with a Diligence Summary (describing
activities conducted in the previous [ * ] with respect to [ * ], notwithstanding language to the contrary regarding frequency in Section 1.15. [ * ], Sunesis shall include in the Diligence Summary [ * ] of such PDK Product. The Parties
acknowledge and agree that due to launch timing, this may require an additional Diligence Summary for such year. 

  
 -49- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 16.4 Diligence. (a) Sunesis shall use Required Efforts to research, develop, perform
regulatory activities and commercialize a PDK Product within the Field based upon the Millennium Licensed Technology. “Required Efforts” shall mean [ * ] for a compound or product of similar market potential and at a similar stage in its
development or product life, taking into account, without limitation, with respect to a product issues of safety and efficacy, product profile, the proprietary position of the product, the then current competitive environment for the product and the
likely timing of the product’s entry into the market, the regulatory environment of the product, and other relevant scientific, technical and commercial factors. Sunesis agrees to keep Millennium fully informed regarding the development,
regulatory and commercialization activities with respect to the PDK Product by providing reports to Millennium at least annually regarding ongoing activities being undertaken with respect to PDK Products. This Section 16.4 shall not limit other
provisions of this Agreement that address the provision of information regarding PDK Products or PDK Compounds. If Sunesis materially fails to use Required Efforts to develop and commercialize a PDK Product, and Sunesis shall continue to materially
fail to use Required Efforts to develop and commercialize a PDK Product for [ * ] after written notice thereof from Millennium, then Millennium shall have the right to terminate the license granted to Sunesis under Section 16.1 and to assume
the development and commercialization of such PDK Product using Required Efforts, upon written notice to Sunesis. 
 (b) Upon such
termination or for termination by Sunesis in accordance with Section 13.4: (i) all PDK Products shall no longer be deemed PDK Products but shall instead be deemed Licensed Products and shall be subject to Millennium’s licenses under
Section 5.1 of the Agreement, except that terminated PDK Products shall not become [ * ], (ii) all references in the Agreement to PDK Compounds and PDK Products shall be deemed references to Licensed Compounds and Licensed Products,
respectively, except that terminated PDK Products shall not become [ * ], (ii) all rights and obligations under the Agreement with respect to Licensed Compounds and Licensed Products shall apply to the terminated PDK Compounds and PDK Products,
except that terminated PDK Products shall not become [ * ], milestones payable by Millennium to Sunesis for such Licensed Products (that were previously PDK Products) shall be as set forth in Section 17.2 below (and not in Sections 6.1 and 6.2
of the Agreement) and royalties payable by Millennium to Sunesis on Net Sales of such Licensed Products (that were previously PDK Products) shall be as set forth in Section 17.3 below (and not in Section 6.3 of the Agreement), provided
that such royalties shall be payable by Millennium to Sunesis at rates that are [ * ] of the rates set forth in Section 17.3 below, (iv) the terms of Section 2 of Exhibit 8.2 of the Agreement shall apply (as applied to PDK Products in
place of Reverted Licensed Products), (v) Millennium shall have the right to control prosecution of the Patent Rights described in Section 9.2.2(b) of the Agreement in accordance with Section 9.2.2(a) of the Agreement (with costs
borne by Millennium) except that Millennium shall have no reporting or consulting obligations to Sunesis, and (vi) Millennium shall have the right to enforce and defend the Patent Rights described in Section 9.3.5 above in accordance with
Section 9.3.2 of the Agreement. 
 (c) In the event that there is a good faith dispute as to whether the activities of Sunesis
constitute Required Efforts under this Section 16.4, such dispute shall be referred to the Parties’ respective Chief Medical Officers (or a Vice President with responsibility for clinical research of such Party as the equivalent if there
is no such Chief Medical Officer of a Party) for 

  
 -50- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
resolution in accordance with Section 8.5 of the Agreement (as applied to a PDK Product in place of a Co-Funded Product or Reverted Licensed Product). The Parties by mutual agreement have
not formed the Joint Steering Committee as of the Amendment Effective Date. 
 16.5 [ * ]. (a) Sunesis shall not [ * ], except as
permitted by this Section 16.5. Sunesis hereby grants Millennium [ * ] as detailed in this Section 16.5. Prior to [ * ], other than in connection with [ * ], Sunesis shall notify Millennium in writing. Such written notice shall
include without limitation [ * ]. Millennium shall have [ * ] from such notice to notify Sunesis that it [ * ]. Millennium shall have a period of [ * ] following the date of such notice from Millennium to [ * ], including without limitation [ *
]. 
 (b) If the Parties do not [ * ], or if Millennium notifies Sunesis in writing [ * ] regarding such [ * ], then Sunesis
shall have no further obligations with respect to such [ * ] under this Section 16.5 during the [ * ]; provided that during the [ * ], if Millennium notified Sunesis of its [ * ], Sunesis shall not [ * ]. In the event that (i) the [ *
], or (ii) Sunesis does not [ * ], then Sunesis shall be obligated again to notify Millennium in writing pursuant to this Section 16.5 [ * ] in the case of (ii) of this subsection), and this Section 16.5 shall again apply to each
[ * ]. Sunesis shall provide Millennium’s legal counsel with a copy of [ * ] solely to enable Millennium to confirm compliance with the terms of this Section 16.5, which written [ * ] shall constitute Confidential Information of Sunesis.
For clarity, this Section 16.5 shall not apply to a [ * ] with a distributor for PDK Product(s). 
 ARTICLE 17

 PAYMENTS FOR PDK COMPOUNDS AND PDK PRODUCTS 

17.1 Upfront Payment. Sunesis shall pay Millennium [ * ] within [ * ] of the Amendment Effective Date. 

17.2 Milestones. Sunesis shall notify Millennium within ten (10) business days after the first achievement by a PDK Product
of each of the following milestone events, and shall pay to Millennium the following amounts within thirty (30) days following the first achievement of each such event by Sunesis or its Affiliates or Sublicensees: 

 

					
	 Milestone
	  	Payment Amount	 
	 [Start of GLP clinical toxicology testing of a PDK Product
	  	$	100,000	  
	 Filing of the first Investigational New Drug Application for a PDK Product with the FDA
	  	$	100,000	  
	 First Regulatory Approval of a PDK Product in the U.S.
	  	$	5,000,000	  
	 First Regulatory Approval of a PDK Product by the EMA
	  	$	4,000,000	] 

  
 -51- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 Milestone payments will be due only if achieved by a PDK Product that is [ * ]. Each milestone
payment will be payable one time only, regardless of the number of PDK Products to achieve the milestone event or the number of times the event is achieved by a PDK Product. Each milestone payment shall be non-refundable and non-creditable against
other amounts due Millennium under the Agreement. If a milestone for a PDK Product under Section 17.2 is achieved with respect to such PDK Product before a prior milestone for such PDK Product, then the earlier milestone payments shall then
also be due with respect to such PDK Product. 
 17.3 Royalties. 

(a) Generally. Subject to Sections 17.3(b) and (c), Sunesis shall pay to Millennium a royalty on Net Sales by Sunesis, its Affiliates
and Sublicensees of PDK Products on a PDK Product-by-PDK Product basis, equal to the percentage of such Net Sales set forth below: 
  

					
	 Annual Net Sales
	  	Royalty on Net Sales	 
	 Portion of Annual Net Sales of such PDK Product less than $[ * ]
	  	 	[ * ]	% 
	 Portion of Annual Net Sales of such PDK Product greater than or equal to $[ * ] and less than $[ * ]
	  	 	[ * ]	% 
	 Portion of Annual Net Sales of such PDK Product greater than or equal to $[ * ] and less than or equal to $[ * ]
	  	 	[ * ]	% 
	 Portion of Annual Net Sales of such PDK Product greater than $[ * ]
	  	 	[ * ]	% 

 For purposes of the foregoing, “Annual Net Sales” shall mean, for a particular PDK Product, the aggregate of the Net
Sales, in a particular calendar year, of such PDK Product in each country in which such PDK Product is covered by a Valid Claim of a Millennium Licensed Patent. 

(b) Third Party Patents. If: (i) a [ * ] of a Third Party should be in force in any country covering the practice of the Millennium
Licensed Technology with respect to the manufacture, use or sale of any PDK Product, (ii) it should prove in Sunesis’s reasonable judgment, after consultation with Millennium, [ * ] for Sunesis to commercialize such PDK Product without
obtaining a royalty bearing license from such Third Party [ * ] (with such agreement not to be unreasonably withheld or delayed), and (iii) the royalty paid to such Third Party is directed to the practice of rights granted to Sunesis under
Section 16.1 with respect to such PDK Product, then Sunesis shall be entitled to a credit against the royalty payments due under Section 17.3(a) with respect to the same PDK Product in such country of an amount equal to [ * ] of the
royalty paid to such Third Party for such PDK Product in such country, arising from the practice of such Millennium Licensed Technology with respect to the manufacture, use or sale of the PDK Product in said country, with such credit not to exceed [
* ] of the royalty otherwise due under this Agreement for such PDK Product in such country. 

  
 -52- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (c) Royalty Term. The royalties due pursuant to Section 17.3(a) shall be payable on a
country-by-country and PDK Product-by-PDK Product basis commencing on the first commercial sale in a country and continuing until the expiration of the last Valid Claim of the Millennium Licensed Patents Covering the sale or use of the relevant PDK
Product in such country. 
 17.4 Payment Terms. The payment terms of Article 7 of the Agreement will apply to payments made by
Sunesis under this Article 17. 
 * * * * * 

  
 -53- 

[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their
authorized representatives and delivered in duplicate originals as of the Amendment Effective Date. 
  

									
	MILLENNIUM PHARMACEUTICALS, INC.	 		 	SUNESIS PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Anna Protopapas
	 		 	By:	 	 /s/ Daniel N. Swisher, Jr.

	Name:	 	Anna Protopapas	 		 	Name:	 	 Daniel N. Swisher, Jr.

	Title:	 	President	 		 	Title:	 	 CEO and President

  

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT 1.4(a) 

RAF Portfolio 
  

																			
	 Country
	  	Case Type	 	Status	 	Title	 	Filing Date	 	Application
Number	 	Publication
Number	 	Publication
Date	 	Patent
Number	 	Grant
Date
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]	 	20-Dec-12]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

																			
	 Country
	  	Case Type	 	Status	 	Title	 	Filing Date	 	Application
Number	 	Publication
Number	 	Publication
Date	 	Patent
Number	 	Grant
Date
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 	[ * ]	 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 		 		 		 	

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 PDK Portfolio 
  

																			
	 Country
	  	 Case Type
	  	Status	  	Title	  	Filing Date	  	Application
Number	  	Publication
Number	  	Publication
Date	  	Patent
Number	  	Grant
Date
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

																			
	 Country
	  	 Case Type
	  	Status	  	Title	  	Filing Date	  	Application
Number	  	Publication
Number	  	Publication
Date	  	Patent
Number	  	Grant
Date
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  	[ * ]	  		  	
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  		  		  		  	

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT 1.41 

Sunesis Core Technology 
  

							
	 Sunesis No.
	  	 Serial No.
	  	 Title
	  	 Status

	 SU-100
	  	 US

09/105,372
	  	 Methods for Rapidly Identifying Small

Organic Molecule Ligands for Binding to

Biological Target Molecules
	  	Issued as U.S. Patent No. 6,335,155
	 SU-100

D1C1
	  	 US

10/043,833
	  	 Methods for Rapidly Identifying

Small Organic Molecule Ligands for Binding to

Biological Target Molecules
	  	allowed
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

							
	 Sunesis No.
	  	 Serial No.
	  	 Title
	  	 Status

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

							
	 Sunesis No.
	  	 Serial No.
	  	 Title
	  	 Status

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  		  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT 1.44 

[ * ] Target Selectivity 
 [ * ]

  

									
	 Name
	  	Units/Amount	 	Source	 	Catalog Number	 	Storage
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]oC
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]oC
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]oC
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]oC, [ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]oC
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]oC
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]oC
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]oC

 [ * ] 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 [ * ] Cellular Assay for [ * ] 

[ * ] 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 [ * ] Cellular Assay [ * ] 

[ * ] 
  

																																																	
	 	  	1	 	  	2	 	  	3
[ * ]	 	  	4
[ * ]	 	  	5
[ * ]	 	  	6
[ * ]	 	  	7
[ * ]	 	  	8
[ * ]	 	  	9
[ * ]	 	  	10
[ * ]	 	  	11	 	  	12	 
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 [ * ] Enzyme Assay [ * ] 

[ * ] 
  

																																																	
	 	  	1	 	  	2	 	  	3	 	  	4	 	  	5	 	  	6	 	  	7	 	  	8	 	  	9	 	  	10	 	  	11	 	  	12	 
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  
	 [ * ]
	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  	  	 	[ * ]	  

 [ * ]. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT 8.2 

Reverted Licensed Product 

Section 1. Reverted Licensed Product. 

1.1 Millennium shall cooperate fully with Sunesis and shall provide Sunesis with all data, documentation, information and materials generated
or used by Millennium in the development, production or other exploitation of such Reverted Licensed Product, and Sunesis shall have the right to use and disclose such items. 

1.2 To the extent not already terminated, the licenses granted to Millennium under Section 5.1 shall terminate with respect to such
Reverted Licensed Product. 
 1.3 All right, title and interest in and to (i) all regulatory filings related to the Reverted Licensed
Product, including all INDs, NDAs and all information and correspondence related thereto, and (ii) any trademarks specific to the Reverted Licensed Product shall be transferred and assigned to Sunesis. 

1.4 Millennium shall cooperate fully with Sunesis upon Sunesis’s request to assign to Sunesis, or otherwise secure for Sunesis the
benefits of, any arrangement between Millennium and a Third Party related to the development, production or exploitation of such Reverted Licensed Product, including clinical research agreements, manufacturing and supply agreements and distribution
agreements. In the event that such Reverted Licensed Product was manufactured by Millennium, then Millennium shall continue to provide Sunesis at fully loaded cost plus a 15% cost of capital charge with quantities of Reverted Licensed Products
reasonably ordered by Sunesis within twelve (12) months after the date of transition. 
 1.5 Without limiting the foregoing, Millennium
shall use reasonable efforts to implement the provisions of this Exhibit 8.2 and to ensure orderly transition and uninterrupted development of the Reverted Licensed Product. Sunesis shall promptly reimburse Millennium’s reasonable out-of-pocket
costs with respect to activities, services and materials provided by Millennium under Section 1 of this Exhibit 8.2. 

Section 2. Termination of a Reverted Licensed Product and Reversion to Millennium. 

2.1 Sunesis shall cooperate fully with Millennium and shall provide Millennium with all data, documentation, information and materials
generated or used by Sunesis in the development, production or other exploitation of such Reverted Licensed Product, and Millennium shall have the right to use and disclose such items. 

2.2 All right, title and interest in and to (i) all regulatory filings related to such Reverted Licensed Product, including all INDs, NDAs
and all information and correspondence related thereto, and (ii) any trademarks specific to the Reverted Licensed Product shall be transferred and assigned to Millennium. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 2.3 Sunesis shall cooperate fully with Millennium upon Millennium’s request to assign to
Millennium, or otherwise secure for Millennium the benefits of, any arrangement between Sunesis and a Third Party related to the development, production or exploitation of such Reverted Licensed Product, including clinical research agreements,
manufacturing and supply agreements and distribution agreements. In the event that such Reverted Licensed Product was manufactured by Sunesis, then Sunesis shall continue to provide Millennium at fully loaded cost plus a 15% cost of capital charge
with quantities of such Reverted Licensed Product reasonably ordered by Millennium within twelve (12) months after the date of transition. 

2.4 Without limiting the foregoing, Sunesis shall use reasonable efforts to implement the provisions of this Exhibit 8.2 and to ensure orderly
transition and uninterrupted development of such Reverted Licensed Product. Millennium shall promptly reimburse Sunesis’s reasonable out-of-pocket costs with respect to activities, services and materials provided by Sunesis under Section 2
of this Exhibit 8.2. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.EX-10.48

 Exhibit 10.48 

O Y S T E R     P O I N T     M A R I N A     P L A Z A 

Office Lease 
 of 

SUITE 400 

to 

SUNESIS PHARMACEUTICALS, INC., 

a Delaware corporation 
 395
Oyster Point Boulevard 
 South San Francisco, CA 94080 

  

  

					
		 		  	

 OYSTER POINT MARINA PLAZA 

Office Lease 
 THIS OFFICE
LEASE (the “Lease”) is entered into as of January 14, 2014, by and between KASHIWA FUDOSAN AMERICA, INC., a California corporation (“Landlord”) and SUNESIS PHARMACEUTICALS, INC., a Delaware corporation
(“Tenant”). 
 1         BASIC LEASE TERMS 

1.1 LEASE OF PREMISES. Landlord leases to Tenant, and Tenant rents and hires from Landlord,
the premises described in § 1.3 below, in the building known by the street address 395 Oyster Point Boulevard (the “Building”) in the City of South San Francisco, County of San Mateo, State of California, on the
property described in § 1.6 below, in the business park commonly known as Oyster Point Marina Plaza (the “Complex”), for the term stated in § 1.4 below, for the rents hereinafter reserved, and upon and subject to the
terms, conditions (including limitations, restrictions, and reservations), and covenants hereinafter provided. The Building and the Complex are more particularly described and depicted in Exhibit A which is attached hereto. Each party
hereby expressly covenants and agrees to observe and perform all of the conditions and covenants herein contained on its part to be observed and performed. 

1.1.1 Lease Contingency. This Lease is expressly contingent upon the ability of Tenant to obtain an extension of its sublease with
McKesson for the month of February, 2014. If Tenant fails after good-faith efforts to obtain such an extension of its sublease with McKesson, this Lease shall be void and shall be deemed to have terminated as
of the date on which Tenant gives Landlord written notice that it has not been able to obtain such an extension of its sublease with McKesson. Tenant’s ability to obtain such an extension of its sublease with McKesson is an express condition
precedent to the commencement of this Lease on the Commencement Date. 
 1.2 SUMMARY TABLE. The parties agree that the
following table (the “Table”) sets forth in summary form the basic terms of this Lease, including the specific space comprising the Premises and, with respect to such space, the Term of the Lease, the usable and rentable square footage,
the Base Rent, Base Year, and Tenant’s Share, as all of such terms are defined below: 
  

																													
	 PERIOD
	  	SUITE
NO.	 	  	RSF	 	  	USF	 	  	MONTHLY
BASE RENT	 	  	T’S SHARE
BLDG	 	 	T’S SHARE
COMPLEX	 	 	BASE
YEAR	 
	 March 1, 2014 through February 28, 2015
	  	 	400	  	  	 	15,378	  	  	 	13,372	  	  	$	28,449.30	  	  	 	6.608	% 	 	 	3.311	% 	 	 	2014	  
	 March 1, 2015 through April 30, 2015
	  	 	400	  	  	 	15,378	  	  	 	13,372	  	  	$	28,449.30	  	  	 	6.608	% 	 	 	3.311	% 	 	 	2014	  

 In the event of any conflict between the terms contained in the Table and the terms contained in subsequent sections of the
Lease, the terms of the Table shall control, except that any dates stated in the Table are subject to adjustment as appropriate to the extent any other provisions of the Lease provide for adjustments to the Commencement Date and/or the Expiration
Date. 
 1.3 PREMISES. The premises leased to Tenant (the “Premises”) are a portion of the fourth (4th) floor of the
Building and are commonly known as Suite 400, as shown on the floor plan annexed hereto as Exhibit B (the “Space Plan”). The Premises also include all fixtures and equipment which are attached thereto, except items
not deemed to be included therein and which are removable by Tenant as provided in Article 10 below. Landlord and Tenant agree that the usable and rentable area of the Premises, and the 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 1 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
respective rentable areas of the Property (as defined in § 1.6 below) and Complex, for all purposes under this Lease, are as follows and as specified in the Table: 

 

					
	 Property’s Rentable Area:
	  	 	232,733 rsf	  
	 Complex’s Rentable Area:
	  	 	464,502 rsf.	  

 Tenant acknowledges that it has caused its architect to verify the numbers stated in the Table and herein relating to the
measurements of such spaces prior to the Commencement Date of this Lease or has had an opportunity to do so. 
 1.4 TERM;
COMMENCEMENT DATE. The term (the “Term”) for which the Premises are hereby leased shall commence on the “Commencement Date,” which shall be March 1, 2014, and shall end at noon on the
“Expiration Date,” which shall be April 30, 2015, or any earlier date upon which the Term may expire or be cancelled or terminated pursuant to any of the conditions or covenants of this Lease or pursuant to law. Promptly following the
Commencement Date the parties hereto shall, if required by Landlord, enter into a supplementary agreement fixing the dates of the Commencement Date and the Expiration Date in the form which is attached hereto as Exhibit E and
incorporated herein by reference. 
 1.4.1 Option to Renew. Tenant is hereby granted one (1)option to extend (the “Extension
Option”) the Term of the Lease for one (1) additional period of six (6)months (the “Extension Period”). The Extension Period term shall begin the first day following the Expiration Date and shall take effect on the same terms and
conditions in effect under the Lease immediately prior to the Extension Period, except that (i) Tenant shall have no further right to extend and (ii) monthly Base Rent shall be Thirty Thousand Seven Hundred Fifty-Six Dollars per month. 
 (a) Exercise of Option. The Extension Option may be exercised only
by (i) delivering in person to Landlord’s Building Manager in the Building Office written notice of Tenant’s irrevocable election to exercise no earlier than ten (10) months and no later than six (6) months prior to the
commencement of the Extension Period, and (ii) collecting and retaining in exchange for such notice of exercise an original written receipt therefor signed and dated by Landlord’s Building Manager. Tenant’s exercise of its Extension
Option shall not be effective or valid if there is any deviation in the timing or manner of exercise prescribed herein. 
 (b) Failure to
Exercise. If Tenant shall fail validly and timely to exercise the Option herein granted, said Option shall terminate and shall be null and void and of no further force and effect. 

(c) Default. Tenant’s exercise of the Option shall, at Landlord’s election, be null and void if Tenant is in Default on the
date of Tenant’s notice of exercise or at any time thereafter and prior to commencement of the Extension Period. Tenant’s exercise of the Extension Option shall not operate to cure any Default by Tenant nor to extinguish or impair any
rights or remedies of Landlord arising by virtue of such Default. If the Lease or Tenant’s right to possession of the Premises shall terminate before Tenant shall have exercised the Extension Option, then immediately upon such termination the
Extension Option shall simultaneously terminate and become null and void. 
 (d) Time. Time is of the essence of the Extension Option
granted hereunder. 
 1.5 RENT. The “Rent” reserved under this Lease, for the Term thereof, shall consist of the following:

  

	 	(a)	“Base Rent” as set forth in the Table for the various spaces and periods described therein per month, which shall be payable in advance on the first day of each and every calendar month during the Term of this
Lease, except that Tenant shall pay the first month’s Base Rent due under the Lease upon the execution and delivery of this Lease by Tenant; and 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 2 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(b)	“Additional Rent” consisting of any and all other sums of money as shall become payable by Tenant to Landlord hereunder; and Landlord shall have the same remedies for default in the payment of Additional Rent
as for a default in payment of Base Rent). 

 1.5.1 Payment of Rent. Tenant shall pay the Base Rent and Additional Rent
promptly when due, without demand therefor and without any abatement, deduction, or setoff whatsoever, except as may be expressly provided in this Lease. Tenant shall pay the Rent to Landlord, in lawful money of the United States of America, at
Landlord’s office at the Complex or at such other place, or to such agent and at such place, as Landlord may designate by notice to Tenant. If the Commencement Date occurs on a day other than the first day of a calendar month, the Base Rent for
such calendar month shall be prorated based on a 30-day month, and the balance of the first month’s Base Rent theretofore paid shall be credited against the next monthly installment of Base Rent. 

1.5.2 Interest and Late Charges. If Tenant fails to pay any Rent when due, the unpaid amounts shall bear interest from the due date
until paid at a rate per annum equal to the Prime Rate plus five percent (5%) or, if less, at the highest rate of interest permitted by applicable law. As used herein, “Prime Rate” means the prime rate published in the Money Rates
section of the Wall Street Journal (Western edition) as the same may change from time to time or in a similar publication if the Wall Street Journal ceases publication or ceases publication of its Money Rates section during the Term.
Tenant acknowledges that the late payment of any monthly Rent will cause Landlord to lose the use of that money and incur costs and expenses not contemplated under this Lease, including administrative and collection costs and processing and account
expenses, the exact amount of which it is difficult to ascertain. Therefore, in addition to interest, if any such installment is not received by Landlord within five (5) days from the date it is due, Tenant shall pay Landlord a late charge
equal to ten percent (10%) of such installment. Landlord and Tenant agree that this late charge represents a reasonable estimate of such costs and expenses and is fair compensation to Landlord for the loss suffered from such nonpayment by
Tenant. In addition, any check returned by the bank for any reason will be considered late and will be subject to all late charges plus an additional returned check fee of Twenty Dollars ($20.00). After two such occasions upon which checks have been
returned in any twelve-month period, Landlord will have the right to require payment by a cashier’s check or money order. Acceptance of any interest or late charge shall not constitute a waiver of
Tenant’s default with respect to such nonpayment by Tenant nor prevent Landlord from exercising any other rights or remedies available to Landlord under this Lease or at law or in equity, unless the payment of such interest and late charges is
accompanied by all rentals then due and owning (notwithstanding anything to the contrary in § 20.2.1 below). 
 1.6
PROPERTY. For the purposes of this Lease, the “Property” shall mean the Building and any common or public areas or facilities, easements, corridors, lobbies, sidewalks, loading areas, driveways, landscaped areas,
skywalk, parking garages and lots, and any and all other structures or facilities operated or maintained in connection with or for the benefit of the Building, and all parcels or tracts of land on which all or any portion of the Building or any of
the other foregoing items are located, and any fixtures, machinery, equipment, apparatus, Systems and Equipment (as defined in § 1.6.5 below), furniture and other personal property located thereon or therein and used in connection
therewith, whether title is held by Landlord or its affiliates. The Property shall also be deemed to include such other of the Complex’s buildings or structures (and related facilities and parcels on which the same are located) as Landlord
shall have incorporated by reference to the total square footage of the Building stated in § 1.3 above. 
 1.6.1 Common
Areas. Tenant and its agents, employees, and invitees shall have the non-exclusive right with others designated by Landlord to the free use of the common areas in the Property and the Complex for the
common areas’ intended and normal purpose. The term common areas shall mean elevators, sidewalks, parking areas, driveways, hallways, stairways, public restrooms, common entrances, lobbies, and other similar public areas and access ways.

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 3 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 1.6.2 Athletic Facility. Notwithstanding the foregoing, the common areas do not
include the Building’s athletic facility (the “Athletic Facility”), which is an unsupervised and unattended weight and exercise room and shower facility. Tenant acknowledges that Landlord presently makes available (but is not
obligated under this Lease to make available) the Athletic Facility for the general use of all tenants and their officers and employees, subject to such rules and regulations as Landlord may impose from time to time in its sole and absolute
discretion regarding the use thereof. Tenant shall cause each of its officers and employees using the Athletic Facility to sign and deliver to Landlord an “Athletic Facility Use Agreement” in the form attached hereto as Exhibit D,
as such form may be revised by Landlord from time to time in its sole and absolute discretion. Tenant understands and agrees that no individual shall be permitted use of or access to the Athletic Facility unless and until such individual shall have
first signed and delivered the Athletic Facility Use Agreement to Landlord. Landlord shall have the right to limit the use of the Athletic Facility in any manner it may deem necessary, or to discontinue the Athletic Facility altogether, at any time,
in its sole and absolute discretion, and neither Tenant nor its officers or employees shall be entitled to any compensation, credit, allowance, or offset of expenses or Rent as a result of any such limitation or discontinuance. 

1.6.3 Reservation to Landlord. Notwithstanding anything to the contrary herein, possession of areas necessary for utilities, services,
safety, and operation of the Property, including the Systems and Equipment, telephone closets (whether located in the common areas or in the Premises), fire exits and stairways, perimeter walls, space between the finished ceiling of the Premises and
the slab of the floor or roof of the Property thereabove, and the use thereof, together with the right to install, maintain, operate, repair, and replace any part of the Systems and Equipment in, through, under, or above the Premises in locations
that will not materially interfere with Tenant’s use of the Premises, are hereby excepted from both the Premises and the common areas and are reserved by Landlord and not demised to Tenant. Tenant’s access to the telephone closets on each
floor and the Building’s main telephone room shall be subject to the Rules (as defined in § 13.1 below) and shall be permitted only with Landlord’s written consent and under the supervision of Landlord’s Building Engineer on
each occasion that such access is sought. 
 1.6.4 Changes and Alterations of the Property. Landlord reserves the right to make
repairs, alterations, additions, or improvements, structural or otherwise, in or to the Property or Complex as deemed necessary or desirable in Landlord’s sole and absolute discretion, so long as such repairs or alterations do not materially
and unreasonably interfere with Tenant’s access to or beneficial use of the Premises for their intended purposes. Landlord reserves the right hereunder to do the following: (i) install, use, maintain, repair, and replace pipes, ducts,
conduits, wires, and appurtenant meters and equipment for service to the various parts of the Property above the ceiling surfaces, below the floor surfaces, within the walls, and in the central core areas; (ii) to relocate any pipes, ducts,
conduits, wires, and appurtenant meters and equipment which are located in the Premises or located elsewhere outside the Premises; (iii) expand the Building or the Complex; (iv) make changes to the Property or the Complex, including
changes, expansions, and reductions in the location, size, shape, and number of driveways, entrances, loading and unloading areas, ingress, egress, direction of traffic, landscaped areas, walkways, parking spaces, and parking areas; (v) close
any of the common areas, so long as reasonable access to the Premises remains available; (vi) use the common areas while engaged in making additional improvements, repairs, or alterations to the Property, Complex, or any portion thereof; and
(vii) do and perform such other acts and make such other changes in, to, or with respect to the Property, Complex, common areas, and Building as Landlord may deem appropriate. The exercise of any of the foregoing rights shall not subject
Landlord to claims for constructive eviction, abatement of Rent, damages, or other claims of any kind, except as otherwise expressly provided in this Lease. If Landlord enters the Premises to exercise any of the foregoing rights, Landlord shall
provide reasonable advance written or oral notice to Tenant’s on-site manager. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 4 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 1.6.5 Systems and Equipment. As used in this Lease, “Systems and Equipment”
means collectively any existing plant, machinery, transformers, duct work, intrabuilding network cables and wires that transmit voice, data, and other telecommunications signals (“INC”), and other equipment, facilities, and systems
designed to supply water, heat, ventilation, air conditioning and humidity or any other services or utilities, or comprising or serving as any component or portion of the electrical, gas, steam, plumbing, sprinkler, communications, alarm, security,
or fire/life/safety systems or equipment, or any other mechanical, electrical, electronic, computer or other systems or equipment for the Property. 

2         USE 

2.1 USE AND ENJOYMENT OF PREMISES. Tenant shall use and occupy the Premises
for executive and general offices and for no other purpose. Notwithstanding anything contained herein to the contrary, Tenant may use portions of the Premises not to exceed one hundred fifty (150) usable square feet for the preparation and
reheating of food and beverages, including the use of refrigerators, ice makers, coffee machines, hot plates, microwave ovens, or similar heating devices (but not for the actual cooking of food) for service only to Tenant’s employees and
business invitees. 
 2.1.1 Suitability. Tenant acknowledges that neither Landlord nor any agent of Landlord has made any
representation or warranty with respect to the Premises, the Property, or the Complex, or with respect to the suitability of same for the conduct of Tenant’s business, except as expressly provided in this Lease. Tenant’s acceptance of
possession of the Premises shall conclusively establish that the foregoing were at such time in satisfactory condition. Landlord makes no representation to Tenant regarding the installation, ownership, location, or suitability for Tenant’s
purposes of the INC in the Building. 
 2.1.2 Insurance Rates. Tenant shall not do or suffer anything to be done in or about the
Premises, nor shall Tenant bring or allow anything to be brought into the Premises, which will in any way increase the rate of any fire insurance or other insurance upon the Property or its contents, cause a cancellation of said insurance, or
otherwise affect said insurance in any manner. 
 2.1.3 Use to Comply with Laws. Tenant shall use the Premises in conformity with all
applicable Laws, as specified in Article 6 below. 
 2.1.4 Floor Loading. Tenant shall not place or permit to be placed on any
floor a load exceeding eighty (80) pounds per square foot or such lower floor load as such floor was designed to carry. 
 2.2
NUISANCE AND WASTE. Tenant also shall not do or suffer anything to be done in or about the Premises which will in any way obstruct or interfere with the rights of other tenants or occupants of the
Property or injure or annoy said tenants or occupants, nor shall Tenant use or suffer the Premises to be used for any unlawful purposes. In no event shall Tenant cause or permit any nuisance in or about the Premises, and no loudspeakers or similar
devices shall be used without the prior written approval of Landlord, which approval may be withheld in Landlord’s sole and absolute discretion. Tenant shall not commit or suffer to be committed any waste in or upon the Premises. The provisions
of this section are for the benefit of Landlord only and shall not be construed to be for the benefit of any tenant or occupant of the Building. If any governmental license or permit, other than a Certificate of Occupancy, shall be required for the
proper and lawful conduct of Tenant’s business in the Premises, or any part thereof, and if failure to secure such license or permit would in any way affect Landlord, Tenant, at its sole expense, shall procure and thereafter maintain such
license or permit and submit the same for inspection by Landlord. Tenant shall at all times comply with the terms and conditions of each such license or permit. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 5 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 2.3 COMPLIANCE WITH CERTIFICATE OF
OCCUPANCY Tenant shall not at any time use or occupy the Premises, or suffer or permit anyone to use or occupy, the Premises, or do or permit anything to be done in the Premises, in violation of the Certificate of
Occupancy for the Premises or for the Building. 
 3         PREPARATION OF THE PREMISES 

3.1 CONDITION OF PREMISES. Tenant shall accept the Premises, any existing Improvements in the Premises (as
defined in § 10.1 below), and the Systems and Equipment serving the same in an “as is” condition on the date the Term commences, and Landlord shall have no obligation to improve, alter, remodel, or otherwise modify the
Premises prior to Tenant’s occupancy or thereafter under this Lease. 
 4         ADJUSTMENTS
OF RENT 
 4.1 TAXES, UTILITIES, AND OPERATING EXPENSES. In addition
to the Base Rent and all other payments due under this Lease, Tenant shall pay to Landlord, in the manner set forth in this Article 4, as Additional Rent, the following amounts: 

 

	 	(a)	Increased Operating Expenses. An amount equal to Tenant’s Pro Rata Share of that portion of Operating Expenses paid by Landlord during each Adjustment Period which exceeds the amount of Base Operating
Expenses (as all of such terms are defined in § 4.2 below). 

  

	 	(b)	Increased Utilities. An amount equal to Tenant’s Pro Rata Share of that portion of Utilities paid by Landlord during each Adjustment Period which exceeds the amount of Base Utilities (as all of such terms
are defined in § 4.2 below). 

  

	 	(c)	Increased Taxes. An amount equal to Tenant’s Pro Rata Share of that portion of Real Estate Taxes paid by Landlord during each Adjustment Period which exceeds the amount of Base Real Estate Taxes (as all of
such terms are defined in § 4.2 below). 

 Tenant’s Pro Rata Share of (i) such increase in Operating Expenses over the
Base Operating Expenses, (ii) such increase in Utilities over Base Utilities, and (iii) such increase in Real Estate Taxes over the Base Real Estate Taxes is sometimes referred to collectively herein as the “Rental Adjustment.”

 4.2 DEFINITIONS. For the purposes of this Lease, the following definitions shall apply: 

 

	 	(a)	Base Operating Expenses. “Base Operating Expenses” means the total of Operating Expenses paid by Landlord during calendar year 2014 (the “Base Expense Year”), as adjusted
under § 4.5 below. 

  

	 	(b)	Base Utilities. “Base Utilities” means the total of Utilities paid by Landlord during calendar year 2014 (the “Base Utilities Year”), as adjusted under § 4.5
below. 

  

	 	(c)	Base Real Estate Taxes. “Base Real Estate Taxes” means the total of Real Estate Taxes paid by Landlord during calendar year 2014 (the “Base Tax Year”). 

 

	 	(d)	Tenant’s Pro Rata Share. “Tenant’s Pro Rata Share” as to the Building is the percentage labeled as such in the Table in § 1.2 and is calculated by dividing the agreed
rentable area of the Premises (numerator) by the agreed rentable area of the Property (denominator) and expressing the resulting quotient as a percentage. “Tenant’s Pro Rata Share” as to the Complex is the percentage labeled as such
in the Table in § 1.2 as is calculated by dividing the agreed rentable area of the Premises (numerator) by the agreed rentable area of the Complex (denominator) and expressing the resulting quotient as a percentage. Tenant’s Pro Rata
Share shall be increased during the Term in proportion to any increase in the area of the Premises in accordance with the formula stated herein. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 6 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(e)	Adjustment Period. “Adjustment Period” as to Operating Expenses, Utilities, and Real Estate Taxes means each calendar year of which any portion occurs during the Term, excluding the Base
Year and beginning with the first calendar year immediately following the Base Year. 

  

	 	(f)	Real Estate Taxes. “Real Estate Taxes” means all of the following charges, whether or not now customary or in the contemplation of the parties hereto, and whether or not general, special,
ordinary, or extraordinary, which Landlord shall pay during any Adjustment Period because of or in connection with the ownership, leasing, or operation of the Property: 

 

	 	(1)	ad valorem real property taxes; 

  

	 	(2)	any form of assessment, license fee, license tax, business license fee, commercial rental tax, levy, charge, fee, tax, or other imposition imposed by any authority, including any city, county, state, or federal
governmental agency, or any school, agricultural, lighting, transportation, housing, drainage, or other improvement or special assessment district thereof; 

  

	 	(3)	any tax on Landlord’s ‘right’ to rent or ‘right’ to other income from the Building or as against Landlord’s business of leasing the Building; 

 

	 	(4)	any assessment, tax, fee, levy, or charge in substitution, partially or totally, of any assessment tax, fee, levy or charge previously included within the definition of Real Estate Taxes, it being acknowledged by Tenant
and Landlord that Proposition 13 was adopted by the voters of the State of California in the Election of June, 1978, and that assessments, taxes, fees, levies, and charges may be imposed by governmental agencies for such services as fire protection,
street, sidewalk, and road maintenance, refuse removal, and for other governmental services formerly provided without charge to property owners or occupants, and it being the intention of Tenant and Landlord that all such new and increased
assessments, taxes, fees, levies, and charges be included within the definition of Real Estate Taxes for the purposes of this Lease; 

  

	 	(5)	any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Building or Property or the Rent payable hereunder, including any gross income tax or excise tax levied by any city, county, state,
or federal governmental agency or any political subdivision thereof with respect to the receipt of such Rent, or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use, or occupancy by Tenant of
the Property or any portion thereof; 

  

	 	(6)	any assessment, tax, fee, levy, or charge upon this transaction or any document to which Tenant is a party, creating or transferring an interest or an estate in the Building or Property; 

 

	 	(7)	any assessment, tax, fee, levy, or charge by any governmental agency related to any transportation plan, fund, or system instituted within the geographic area of which the Building is a part; or 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 7 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	8)	reasonable legal and other professional fees, costs and disbursements incurred in connection with proceedings to contest, determine or reduce Real Estate Taxes. 

Exclusions. Notwithstanding the foregoing, Real Estate Taxes shall not include (A) federal, state, or local income taxes;
(B) franchise, gift, transfer, excise, capital stock, estate, succession, or inheritance taxes; or (C) penalties or interest for late payment of Real Estate Taxes. 
  

	 	(g)	Operating Expenses. “Operating Expenses” means all expenses, costs, and amounts (other than Real Estate Taxes and Utilities) of every kind and nature which Landlord shall pay during any
Adjustment Period of which any portion occurs during the Term, because of or in connection with the ownership, management, repair, maintenance, restoration, and/or operation of the Property, including costs of the following: 

 

	 	(1)	permits, licenses, and certificates necessary to operate, manage, and lease the Property; 

  

	 	(2)	supplies, tools, equipment, and materials used in the operation, repair, and maintenance of the Property; 

  

	 	(3)	all insurance premiums for any insurance policies deemed necessary or desirable by Landlord (including workers’ compensation, health, accident, group life, public liability, property damage, earthquake, and fire
and extended coverage insurance for the full replacement cost of the Property as required by Landlord or its lenders for the Property); 

  

	 	(4)	the deductible portion of any claim paid under any insurance policy maintained by Landlord in connection with its management and operation of the Property; 

 

	 	(5)	accounting, legal, inspection, consulting, concièrge, and other services; 

  

	 	(6)	services of independent contractors; 

  

	 	(7)	compensation (including employment taxes and fringe benefits) of all persons who perform duties in connection with the operation, maintenance, repair, or overhaul of the Building or Property, and equipment,
improvements, and facilities located within the Property, including engineers, janitors, painters, floor waxers, window washers, security, parking personnel, and gardeners; 

 

	 	(8)	operation and maintenance of a room for delivery and distribution of mail to tenants of the Building as required by the U.S. Postal Service (including an amount equal to the fair market rental value of the mail room
premises); 

  

	 	(9)	management of the Building or Property, whether managed by Landlord or an independent contractor (including an amount equal to the fair market value of any on-site manager’s office); 

 

	 	(10)	rental expenses for (or a reasonable depreciation allowance on) personal property used in maintenance, operation, or repair of the Property and installment equipment purchase or equipment financing agreements for such
personal property; 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 8 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(11)	costs, expenditures, or charges (whether capitalized or not) required by any governmental or quasi-governmental authority after the Commencement Date; 

 

	 	(12)	payments under any easement, operating agreement, declaration, restrictive covenant, or instrument pertaining to the sharing of costs in any planned development; 

 

	 	(13)	amortization of capital expenses (including financing costs) incurred by Landlord after the Commencement Date in order to (A) comply with Laws, (B) reduce Property Operating Expenses or Utilities, or
(C) upgrade the utility, efficiency, or capacity of any utility or telecommunication systems serving tenants of the Property; 

  

	 	(14)	operation, repair, and maintenance of all Systems and Equipment and components thereof (including replacement of components); janitorial service; alarm and security service; window cleaning; trash removal; elevator
maintenance; cleaning of walks, parking facilities, and building walls; removal of ice and snow; replacement of wall and floor coverings, ceiling tiles, and fixtures in lobbies, corridors, restrooms and other common or public areas or facilities;
maintenance and repair of the roof and exterior fabric of the Building, including replacement of glazing as needed; maintenance and replacement of shrubs, trees, grass, sod, and other landscaped items, irrigation systems, drainage facilities,
fences, curbs, and walkways; repaving and restriping parking facilities; and roof repairs; 

  

	 	(15)	the operation of any on-site maintenance shop(s) and the operation and maintenance of the Athletic Facility, any other fitness center, conference rooms, and all other common areas
and amenities in the Property; 

  

	 	(16)	provision of shuttle busses, shuttle services, and drivers between the Complex and BART and SFO airport, as required by the Bay Area Regional Transportation Act and deed covenants and restrictions applicable to the
Complex; and 

  

	 	(17)	any other costs or expenses incurred by Landlord which are reasonably necessary to operate, repair, manage, and maintain the Building and Property in a first-class manner and condition and which are not otherwise
reimbursed by tenants of the Building. 

 Exclusions. Notwithstanding the foregoing, Operating Expenses shall
not include (A) depreciation, interest, and amortization on Superior Mortgages (as defined in § 18.1 below), and other debt costs or ground lease payments, if any; (B) legal fees in connection with leasing, tenant disputes, or
enforcement of leases; (C) real estate brokers’ leasing commissions; (D) improvements or alterations to tenant spaces; (E) the cost of providing any service directly to, and reimbursed or paid directly by, any tenant;
(F) any costs expressly excluded from Operating Expenses elsewhere in this Lease; (G) costs of any items to the extent Landlord receives reimbursement from insurance proceeds or from a third party (such proceeds to be deducted from
Operating Expenses in the year in which received); (H) capital expenditures, except those expressly permitted above; provided, all such permitted capital expenditures (together with reasonable financing charges) shall be amortized for purposes
of this Lease over the shorter of (x) their useful lives, (y) the period during which the reasonably estimated savings in Operating Expenses equals the expenditures, or (z) three (3) years. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 9 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(h)	Utilities. “Utilities” means all expenses, costs, and amounts of every kind and nature which Landlord shall pay during any Adjustment Period of which any portion occurs during the Term,
because of or in connection with the electricity, power, gas, steam, oil or other fuel, water, sewer, lighting, heating, air conditioning, and ventilating delivered to or consumed or used in or on the Property. 

4.3 MANNER OF PAYMENT. To provide for current payments of the Rental Adjustment, Tenant shall pay as
Additional Rent during each Adjustment Period an amount equal to Landlord’s estimate of the Rental Adjustment which will be payable by Tenant for such Adjustment Period. Such payments shall be made in monthly installments, commencing on the
first day of the month following the month in which Landlord notifies Tenant of the amount it is to pay hereunder and continuing until the first day of the month following the month in which Landlord gives Tenant a new notice of the estimated Rental
Adjustment. It is the intention hereunder to estimate from time to time the amount of Tenant’s Rental Adjustment for each Adjustment Period and then to effect a reconciliation in the following year based on the actual expenses incurred for the
preceding Adjustment Period, as provided in 4.4 below. 
 4.4 RECONCILIATION. On or before the first day of April of each year after
the first Adjustment Period (or as soon thereafter as is practical), Landlord shall deliver to Tenant a statement (the “Statement”) setting forth the Rental Adjustment for the preceding year. If the actual Rental Adjustment for the
preceding Adjustment Period exceeds the total of the estimated monthly payments made by Tenant for such Adjustment Period, Tenant shall pay Landlord the amount of the deficiency within ten (10) days of the receipt of the Statement. If such
total of estimated payments made exceeds the actual Rental Adjustment for such Adjustment Period, then Tenant shall receive a credit for the difference against payments of Rent next due. If the credit is due from Landlord on the Expiration Date,
Landlord shall pay Tenant the amount of the credit, less any Rent then due. The obligations of Tenant and Landlord to make payments required under this § 4.4 shall survive the expiration or earlier termination of the Term of this Lease.

 4.4.1 Changes in Method. So long as Tenant’s obligations hereunder are not materially adversely affected thereby, Landlord
reserves the right reasonably to change from time to time the manner or timing of the foregoing payments. In lieu of providing one Statement covering Real Estate Taxes, Utilities, and Operating Expenses, Landlord may provide separate statements, at
the same or different times. No delay by Landlord in providing the Statement (or separate statements) shall be deemed a default by Landlord or a waiver of Landlord’s right to require payment of Tenant’s obligations for actual or estimated
Real Estate Taxes, Utilities, or Operating Expenses. In no event shall a decrease in Real Estate Taxes, Utilities, or Operating Expenses below the Base Operating Expenses, Base Utilities, or Base Real Estate Taxes ever decrease the monthly Base Rent
or give rise to a credit in favor of Tenant. 
 4.4.2 Proration of Rental Adjustment. If the Term does not commence on January 1
or does not end on December 31, Tenant’s obligations to pay estimated and actual amounts towards Real Estate Taxes, Utilities, and Operating Expenses for such first or final calendar year shall be prorated to reflect the portion of such
year(s) included in the Term. Such proration shall be made by multiplying the total estimated or actual (as the case may be) Real Estate Taxes, Utilities, and Operating Expenses for such calendar year(s), as well as the Base Real Estate Taxes, Base
Utilities, and Base Operating Expenses, by a fraction, the numerator of which shall be the number of days of the Term during such calendar year, and the denominator of which shall be three hundred
sixty-five (365). 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 10 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 4.5 GROSS-UP. If the Building is less than ninety-five
percent (95%) occupied during the Base Period or any Adjustment Period, then Operating Expenses, Utilities, and Real Estate Taxes for the Base Period and/or such Adjustment Period shall be “grossed up” to that amount of Operating
Expenses, Utilities, and Real Estate Taxes that, using reasonable projections, would normally have been incurred during the Base Period and/or such Adjustment Period if the Building had been ninety-five percent (95%) occupied during the Base
Period and/or such Adjustment Period, as determined in accordance with sound accounting and management practices, consistently applied. Only those component elements or items of expense of Operating Expenses, Utilities, and Real Estate Taxes that
are affected by variations in occupancy levels shall be grossed up. 
 4.6 ADJUSTMENT OF BASE
OPERATING EXPENSES. Notwithstanding anything to the contrary contained in the Lease, the parties agree that Base Operating Expenses and Operating Expenses for any subsequent Adjustment Period (herein called
“Subsequent Operating Expenses”) shall be subject to further adjustment by Landlord as follows: 
  

	 	(a)	Exclusion of Capital Expenditures. Landlord may exclude from Base Operating Expenses capital expenditures otherwise permitted, provided Landlord shall also exclude any amortization of such expenditures from
Subsequent Operating Expenses. 

  

	 	(b)	Elimination of Recurring Expenses. If Landlord eliminates from any Subsequent Operating Expenses a category of recurring expenses previously included in Base Operating Expenses, Landlord may subtract such
category from Base Operating Expenses commencing with such subsequent Adjustment Period. 

  

	 	(c)	New Recurring Expenses. If Landlord includes a new category of recurring Subsequent Operating Expenses not previously included in Base Operating Expenses, Landlord shall also include an amount (the “Assumed
Base Amount”) for such category in Base Operating Expenses commencing in such subsequent Adjustment Period. 

  

	 	(d)	Assumed Base Amount. The “Assumed Base Amount” under § 4.6(c) above shall be the annualized amount of expenses for such new category in the first Adjustment Period it is included, reduced by
an amount determined in Landlord’s sole good faith discretion (but in no event by an amount less than five percent (5%)) for each full or partial Adjustment Period that has elapsed during the Term of the Lease before such Adjustment
Period. 

 4.7 ADJUSTMENT OF REAL ESTATE TAXES. If Base Real
Estate Taxes are reduced as the result of protest, by means of agreement, as the result of legal proceedings, or otherwise, Landlord may adjust Tenant’s obligations for Real Estate Taxes in all years affected by any refund of taxes following
the Base Tax Year; and Tenant shall pay Landlord within thirty (30)days after notice any additional amount required by such adjustment for any Adjustment Periods that have theretofore occurred. Tenant shall be entitled to receive a share of any
refund or abatement of Real Estate Taxes received by Landlord to the extent of and in proportion to Tenant’s actual contribution to the amount of Real Estate Taxes paid by Landlord during the period to which such refund or abatement relates,
but in no event shall Tenant be entitled to any refund with respect to Real Estate Taxes paid by Landlord during Tenant’s Base Tax Year. If Real Estate Taxes for any Adjustment Period during the Term or any extension thereof shall be increased
after payment thereof by Landlord for any reason, including error or reassessment by applicable governmental authorities, Tenant shall pay Landlord upon demand Tenant’s Pro Rata Share of such increased Real Estate Taxes. Tenant shall pay
increased Real Estate Taxes whether Real Estate Taxes are increased as a result of increases in the assessment or valuation of the Property (whether based on a sale, change in ownership, refinancing of the Property, or otherwise), increases in the
tax rates, reduction or elimination 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 11 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
of any rollbacks or other deductions available under current law, scheduled reductions of any tax abatement, as a result of the elimination, invalidity, or withdrawal of any tax abatement, or for
any other cause whatsoever. Notwithstanding the foregoing, if any Real Estate Taxes shall be paid based on assessments or bills by a governmental authority using a fiscal year other than a calendar year, Landlord may elect to average the assessments
or bills for the subject calendar year, based on the number of months of such calendar year included in each such assessment or bill. 
 4.8
ALLOCATION WITHIN COMPLEX. So long as the Property shall be part of the Complex collectively owned or managed by Landlord or its affiliates or collectively managed by Landlord’s managing agent,
Landlord may allocate Real Estate Taxes, Utilities, and Operating Expenses within the Complex and between the buildings and structures comprising the Complex and the parcels on which they are located, in accordance with sound accounting and
management principles. In the alternative, Landlord shall have the right to determine, in accordance with sound accounting and management principles, Tenant’s Pro Rata Share of Real Estate Taxes, Utilities, and Operating Expenses based upon the
totals of each of the same for all such buildings and structures, the land constituting parcels on which the same are located, and all related facilities, including common areas and easements, corridors, lobbies, sidewalks, elevators, loading areas,
parking facilities, driveways, and other appurtenances and public areas, in which event Tenant’s Pro Rata Share shall be based on the ratio of the rentable area of the Premises to the rentable area of all buildings in the Complex. 

4.9 LANDLORD’S RECORDS. Landlord shall maintain records with respect to Real Estate Taxes, Utilities,
and Operating Expenses and determine the same in accordance with sound accounting and management practices, consistently applied. Although this Lease contemplates the computation of Real Estate Taxes, Utilities, and Operating Expenses on a cash
basis, Landlord shall make reasonable and appropriate accrual adjustments to ensure that each Adjustment Period includes substantially the same recurring items. Landlord reserves the right to change to a full accrual system of accounting so long as
the same is consistently applied and Tenant’s obligations are not materially adversely affected. Tenant or its representative shall have the right to examine such records, upon reasonable prior written notice specifying such records Tenant
desires to examine, during normal business hours at the place or places where such records are normally kept, by sending such notice no later than forty-five (45) days following the furnishing of the Statement. 

4.10 OTHER TAXES PAYABLE BY TENANT. In addition to the Base Rent and any
other charges to be paid by Tenant hereunder, Tenant shall, as an element of Rent, reimburse Landlord upon demand for any and all taxes payable by Landlord (other than net income taxes) which are not otherwise reimbursable under this Lease, whether
or not now customary or within the contemplation of the parties, where such taxes are upon, measured by, or reasonably attributable to (A) the cost or value of Tenant’s equipment, furniture, fixtures, and other personal property located at
the Premises, or the cost or value of any improvements made in or to the Premises by or for Tenant, regardless of whether title to such improvements is held by Tenant or Landlord; (B) the gross or net Rent payable under this Lease, including
any rental or gross receipts tax levied by any taxing authority with respect to the receipt of the Rent hereunder; (C) the possession, leasing, operation, management, maintenance, alteration, repair, use, or occupancy by Tenant of the Premises
or any portion thereof; or (D) this transaction or any document to which Tenant is a party creating or transferring an interest or an estate in the Premises. Tenant shall pay any rent tax, sales tax, service tax, transfer tax, value-added tax, or any other applicable tax on the Rent or services herein or otherwise respecting this Lease. 
 4.11
RENT CONTROL. If the amount of Rent or any other payment due under this Lease violates the terms of any governmental restrictions on such Rent or payment, then the Rent or payment due during the period of such
restrictions shall be the maximum amount allowable under those restrictions. Upon termination of the restrictions, Landlord shall, to the extent it is legally permitted, recover from Tenant the difference between the amounts received during the
period of the restrictions and the amounts Landlord would have received had there been no restrictions. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 12 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 5         SECURITY DEPOSIT 

5.1 DEPOSIT FOR SECURITY. Tenant shall deposit with Landlord the amount of Twenty-Eight Thousand Four
Hundred Forty-Nine Dollars and Thirty Cents ($28,449.30) (the “Security Deposit”) upon Tenant’s execution and submission of this Lease. The Security Deposit shall serve as security for the prompt, full, and faithful performance by
Tenant of the terms and provisions of this Lease, including the value of future rents as damages in accordance with California Civil Code § 1951.2, as set forth in § 20.3 below. Landlord shall not be required to keep the Security
Deposit separate from Landlord’s general funds or pay interest on the Security Deposit. 
 5.1.1 Application of Deposit. In the
event that Tenant is in Default hereunder and fails to cure within any applicable time permitted under this Lease, or in the event that Tenant owes any amounts to Landlord upon the expiration of this Lease, Landlord may use or apply the whole or any
part of the Security Deposit for the payment of Tenant’s obligations hereunder. The use or application of the Security Deposit or any portion thereof shall not prevent Landlord from exercising any other right or remedy provided hereunder or
under any Law and shall not be construed as liquidated damages. 
 5.1.2 Restoration of Full Deposit. In the event the Security
Deposit is reduced by such use or application, Tenant shall deposit with Landlord, within ten (10) days after written notice, an amount sufficient to restore the full amount of the Security Deposit. If the Premises shall be expanded at any
time, or if the Term shall be extended at any increased rate of Rent, the Security Deposit shall thereupon be proportionately increased. 

5.1.3 Disposition of Security Deposit. After the Expiration Date or any earlier termination of the Lease, any remaining portion of the
Security Deposit shall be returned to Tenant after deduction of all amounts due as Rent or otherwise. Tenant expressly waives the provisions of § 1950.7 of the California Civil Code. 

6         COMPLIANCE WITH LAWS 

6.1 TENANT’S COMPLIANCE WITH LAWS. Tenant shall use the Premises in
compliance with all applicable federal, state, county, and local governmental and municipal laws, statutes, ordinances, rules, regulations, codes, decrees, orders, and other such requirements, and decisions by courts in cases where such decisions
are considered binding precedents in the State of California (the “State”), and decisions of federal courts applying the laws of the State (collectively “Laws”). Tenant shall, at its sole cost and expense, promptly comply with
each and all of such Laws, and also with the requirements of any board of fire underwriters or other similar body now or hereafter constituted to deal with the condition, use, or occupancy of the Premises, except in the case of required structural
changes not triggered by Tenant’s change in use of the Premises or Tenant’s alterations, additions, or improvements therein. Tenant shall comply with all applicable Laws regarding the physical condition of the Premises, but only to the
extent that the applicable Laws pertain to the particular manner in which Tenant uses the Premises or the particular use to which Tenant puts the Premises, if different from that permitted under Article 2 of this Lease. Tenant shall also comply
with all applicable Laws which do not relate to the physical condition of the Premises and with which only the occupant can comply, such as laws governing maximum occupancy, workplace smoking, VDT regulations, and illegal business operations, such
as gambling. The judgement of any court of competent jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant has violated any of such Laws shall be conclusive of that fact as
between Landlord and Tenant. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 13 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 6.1.1 Code Costs. Notwithstanding anything to the contrary in this Article 6, if
the requirement of any public authority obligates either Landlord or Tenant to expend money in order to bring the Premises and/or any area of the Property into compliance with Laws as a result of (a) Tenant’s particular use or alteration
of the Premises; (b) Tenant’s change in the use of the Premises; (c) the manner of conduct of Tenant’s business or operation of its installations, equipment, or other property therein; (d) any cause or condition created by
or at the instance of Tenant, other than by Landlord’s performance of any work for or on behalf of Tenant; or (e) breach of any of Tenant’s obligations hereunder, then Tenant shall bear all costs (“Code Costs”) of bringing
the Premises and/or Property into compliance with Laws, whether such Code Costs are related to structural or nonstructural elements of the Premises or Property. 

6.2 LANDLORD’S COMPLIANCE WITH LAWS. Landlord represents that on the
Commencement Date Landlord has no actual knowledge of any violation of any applicable Laws respecting the Premises. During the Term Landlord shall comply with all applicable Laws regarding the Premises and Property, except to the extent Tenant must
comply under § 6.1 above. 
 7         HAZARDOUS MATERIALS 

7.1 REGULATION OF HAZARDOUS MATERIALS. Tenant shall not transport, use, store, maintain,
generate, manufacture, handle, dispose, release, or discharge any “Hazardous Material” (as defined below) upon or about the Property, nor permit Tenant’s employees, agents, contractors, and other occupants of the Premises to engage in
such activities upon or about the Property. However, the foregoing provisions shall not prohibit the transportation to and from, and use, storage, maintenance, and handling within, the Premises of substances customarily used in offices, provided all
of the following conditions are met: 
  

	 	(a)	such substances shall be used and maintained only in such quantities as are reasonably necessary for such permitted use of the Premises, strictly in accordance with applicable Laws and the manufacturers’
instructions therefor; 

  

	 	(b)	such substances shall not be disposed of, released, or discharged on the Property and shall be transported to and from the Premises in compliance with all applicable Laws, and as Landlord shall reasonably require;

  

	 	(c)	if any applicable Laws or Landlord’s trash removal contractor requires that any such substances be disposed of separately from ordinary trash, Tenant shall make arrangements at Tenant’s expense for such
disposal directly with a qualified and licensed disposal company at a lawful disposal site (subject to scheduling and approval by Landlord), and shall ensure that disposal occurs frequently enough to prevent unnecessary storage of such substances in
the Premises; and 

  

	 	(d)	any remaining such substances shall be completely, properly, and lawfully removed from the Property upon expiration or earlier termination of this Lease. 

7.1.1 DEFINITION OF HAZARDOUS MATERIAL. The term “Hazardous
Material” for purposes hereof shall mean any chemical, substance, material, or waste or component thereof which is now or hereafter listed, defined, or regulated as a hazardous or toxic chemical, substance, material, or waste or component
thereof by any federal, state, or local governing or regulatory body having jurisdiction, or which would trigger any employee or community “right-to-know” requirements adopted by any such body, or for which any such body has adopted any
requirements for the preparation or distribution of an MSDS. 
 7.2 NOTIFICATION OF LANDLORD. Tenant
shall promptly notify Landlord of (A) any enforcement, cleanup, or other regulatory action taken or threatened by any governmental or regulatory authority with respect to the presence of any Hazardous Material on the Premises or the migration
thereof from or to 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 14 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
other property; (B) any demands or claims made or threatened by any party against Tenant or the Premises relating to any loss or injury resulting from any Hazardous Material on or from the
Premises; and (C) any matters where Tenant is required by law to give a notice to any governmental or regulatory authority respecting any Hazardous Material on the Premises. Landlord shall have the right (but not the obligation) to join and
participate, as a party, in any legal proceedings or actions affecting the Premises initiated in connection with any environmental, health, or safety law. 

7.3 LIST OF HAZARDOUS MATERIALS. At such times as Landlord may reasonably request, Tenant
shall provide Landlord with a written list identifying any Hazardous Material then used, stored, or maintained upon the Premises, the use and approximate quantity of each such material, a copy of any material safety data sheet (“MSDS”)
issued by the manufacturer thereof, written information concerning the removal, transportation, and disposal of the same, and such other information as Landlord may reasonably require or as may be required by law. 

7.4 CLEANUP. If any Hazardous Material is released, discharged or disposed of by Tenant or any other occupant of the Premises, or their
employees, agents, or contractors, on or about the Property in violation of the foregoing provisions, Tenant shall immediately, properly, and in compliance with applicable Laws clean up and remove the Hazardous Material from the Property and any
other affected property and clean or replace any affected personal property (whether or not owned by Landlord), at Tenant’s expense. Such clean up and removal work shall be subject to Landlord’s prior written approval (except in
emergencies), and shall include any testing, investigation, and the preparation and implementation of any remedial action plan required by any governmental body having jurisdiction or reasonably required by Landlord. If Tenant shall fail to comply
with the provisions of this § 7.2 within five (5) days after written notice by Landlord, or such shorter time as may be required by Laws or in order to minimize any hazard to persons or property, Landlord may (but shall not be
obligated to) arrange for such compliance directly or as Tenant’s agent through contractors or other parties selected by Landlord, at Tenant’s expense (without limiting Landlord’s other remedies under this Lease or applicable Laws).

 7.5 CASUALTY DAMAGE. If any Hazardous Material is released, discharged, or disposed of on or about the Property and
such release, discharge, or disposal is not caused by Tenant or other occupants of the Premises, or their employees, agents, or contractors, such release, discharge, or disposal shall be deemed casualty damage under Article 15 to the extent
that the Premises or common areas serving the Premises are affected thereby; in such case, Landlord and Tenant shall have the obligations and rights respecting such casualty damage provided under Article 15 of this Lease. 

7.6 REFRIGERANT. Tenant shall not install any refrigerant-containing systems or equipment, including refrigerators, freezers,
supplemental HVAC systems or self-contained air conditioners, without Landlord’s prior approval, which Landlord may withhold in its sole discretion. Unless Tenant shall have obtained Landlord’s prior
written approval to install existing equipment after an inspection, at Tenant’s sole cost and expense, by Landlord’s engineer for defects and proper proposed installation in the Premises, all refrigerant-containing equipment and/or systems
which Tenant installs in the Premises shall be new. Whether Tenant’s refrigerant-containing equipment or systems are defective and are properly installed shall be determined at the sole discretion of Landlord’s engineer. If Tenant wishes
to install any refrigerant-containing equipment or systems, Tenant shall obtain and provide Landlord with copies of all required permits associated with such equipment or systems. 

7.6.1 Removal of Refrigerant. Notwithstanding anything to the contrary in this Lease, Tenant shall remove all refrigerant and
refrigerant-containing equipment and/or systems installed in the Premises by or on behalf of Tenant prior to the Expiration Date of this Lease. Prior to the removal of any such refrigerant or refrigerant-containing equipment and/or systems, Tenant
shall submit to Landlord for Landlord’s approval, the names of Tenant’s contractors and all plans and specifications for such removal. Tenant and Tenant’s contractors shall comply with all legal requirements,

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 15 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
industry practices and rules established by Landlord in performing such removal work. Tenant shall repair any damage to the Property or the Systems and Equipment associated with such removal, and
Tenant shall be responsible for the costs associated with restoring the Property to the condition which existed immediately prior to any modification undertaken by Landlord in order to accommodate Tenant’s refrigerant-containing equipment or
systems. 
 8         SERVICES AND UTILITIES 

8.1 LANDLORD’S SERVICES. Landlord agrees to provide, on the terms and conditions specified herein,
the following services and utilities for Tenant’s use and consumption in the Premises, the cost of which shall be included in Operating Expenses and/or Utilities and reimbursed to Landlord in accordance with § 4.1 above: 

 

	 	(a)	Electricity. Electricity for standard office lighting fixtures and for equipment and accessories customary for offices, provided (i) the connected electrical load of all the same does not exceed an average
of four (4) watts per usable square foot of the Premises (or such lesser amount as may be available, based on the safe and lawful capacity of the existing electrical circuit(s) and facilities serving the Premises); (ii) the electricity
will be at nominal 120 volts, single phase (or 110 volts, depending on available service in the Building); and (iii) the safe and lawful capacity of the existing electrical circuit(s) serving the Premises is not exceeded. Landlord will permit
its electric feeders, risers, and wiring servicing the Premises to be used by Tenant to the extent available and safely capable of being used for such purpose. 

  

	 	(b)	Telecommunications Interface. Interface with the telephone network at the demarcation point or minimum point of entry (“MPOE”) supplied by the local regulated public utility by means of Landlord’s
INC consisting of cable pairs with a capacity consistent with the engineering standards to which the Building was designed. 

  

	 	(c)	HVAC. Heat, ventilation, and air-conditioning (“HVAC”) to provide a temperature required, in Landlord’s reasonable opinion and in accordance with applicable Laws, for the comfortable occupancy of
the Premises during business hours (as defined in § 8.1.1 below). Landlord shall not be responsible for inadequate air-conditioning or ventilation to the extent the same occurs because Tenant uses
any item of equipment consuming more than 500 watts at rated capacity without providing adequate air-conditioning and ventilation therefor. 

 

	 	(d)	Water. Water for drinking, lavatory and toilet purposes at those points of supply provided for nonexclusive general use of other tenants at the Property. 

 

	 	(e)	Janitorial Services. Customary office cleaning and trash removal service Monday through Friday or Sunday through Thursday in and about the Premises. 

 

	 	(f)	Elevator Services. Operatorless passenger elevator service and freight elevator service (if the Property has such equipment serving the Premises, and subject to scheduling by Landlord) in common with Landlord and
other tenants and their contractors, agents, and visitors. 

 8.1.1 Business Hours. The term business hours in this Lease shall
mean the hours from 8:00 a.m. until 6:00 p.m. on Monday through Friday and from 9:00 a.m. until 1:00 p.m. on Saturday throughout the year, except for New Year’s Day, Presidents’ Day, Memorial Day, Independence Day, Labor Day,
Thanksgiving Day, Christmas Day, and any other federally-observed holiday which may be created during the Term (“Holidays”). 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 16 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 8.2 ADDITIONAL ELECTRICAL CAPACITY. Any additional
risers, feeders, or other equipment or service proper or necessary to supply Tenant’s electrical requirements will be installed by Landlord, upon written request of Tenant, at the sole cost and expense of Tenant, if, in Landlord’s sole
judgement, the same are necessary and will not cause permanent damage or injury to the Property, the Premises, or the Systems and Equipment or cause or create a dangerous or hazardous condition or entail excessive or unreasonable alterations,
repairs, or expense or interfere with or disturb other tenants or occupants. Rigid conduit only will be allowed. 
 8.2.1 Approved
Electrical Load. Tenant agrees not to connect any additional electrical equipment of any type to the building electric distribution system, beyond that on Tenant’s approved plans for initial occupancy, other than lamps, typewriters, and
other office machines which consume comparable amounts of electricity or other electrical equipment which in the aggregate consumes the same amount of electricity as those approved for initial occupancy and will not result in any overload of
electrical circuits, lines, or wiring, without Landlord’s prior written consent. In no event shall Tenant use or install any fixtures, equipment, or machines the use of which in conjunction with other fixtures, equipment, and machines in the
Premises would result in an overload or the electrical circuits servicing the Premises. Tenant covenants and agrees that at all times its use of electric current shall never exceed the capacity of the feeders to the Building or the risers or wiring
installation existing at the time in question. 
 8.3 ADDITIONAL TELECOMMUNICATIONS CAPACITY. If Tenant
desires any telecommunications capacity in excess of that available as of the Commencement Date in the form of the INC between the MPOE and the telephone closet nearest the Premises and provided pursuant to § 8.1 above, Tenant shall bear
the cost of installing additional risers or INC or replacing existing INC serving the Premises pursuant to Article 9 below. 
 8.4
REPLACEMENT BULBS AND TUBES. Tenant shall furnish, install, and replace, as required, all
non-Building-standard lighting tubes, lamps, bulbs, and ballasts required in the Premises, at Tenant’s sole cost and expense. All lighting tubes, lamps, bulbs, and
ballasts so installed become Landlord’s property upon the expiration or sooner termination of this Lease. 
 8.5
TWENTY-FOUR HOURS ACCESS. Subject to the provisions of § 8.8, Tenant, its employees, agents, and invitees shall have access to the Premises
twenty-four (24) hours a day, seven (7) days a week. Landlord may restrict access outside of business hours by requiring persons to show a badge or identification card issued by Landlord. Landlord
shall not be liable for denying entry to any person unable to show the proper identification. Landlord may without liability temporarily close the Building if required because of a life-threatening or Building-threatening situation. 

8.6 EXTRA SERVICES. Landlord shall, subject to all applicable Laws, seek to provide such utilities or
services in excess of those Landlord is required to provide under § 8.1 above as Tenant may from time to time request, if the same are reasonable and feasible for Landlord to provide and do not involve modifications or additions to the
Property or the Systems and Equipment and if Landlord shall receive Tenant’s request within a reasonable period prior to the time such extra utilities or services are required. Landlord may comply with written or oral requests by any officer or
employee of Tenant, unless Tenant shall notify Landlord of, or Landlord shall request, the names of authorized individuals (up to three (3) for each floor on which the Premises are located) and procedures for written requests. Tenant shall, for
such extra utilities or services, pay such charges as Landlord shall from time to time establish. 
 8.6.1 Extraordinary Service
Usage. If Tenant shall utilize Building services for the Premises at any time other than during business hours, Landlord shall furnish such extraordinary services (excluding air-conditioning, except as provided below) at Landlord’s then-current prevailing rate for such services. In addition to the foregoing services, if Tenant shall require air-conditioning service for the Premises at any time other than during business hours, Landlord shall,
upon reasonable 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 17 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
advance notice from Tenant, furnish such after-hours air-conditioning service at Landlord’s then-current
prevailing rate for such services as a separate charge; provided, however, in the event Tenant requests such after-hours air-conditioning service at a time not immediately preceding or immediately succeeding
times when “regular hours” service is being furnished hereunder, then Tenant must request not less than five (5) hours of after-hours air-conditioning
service. Notwithstanding anything contained herein to the contrary, Landlord’s prevailing rate for the extraordinary services described herein shall be subject to increase from time to time as Landlord may reasonably determine. 

8.6.2 Payment for Excess Usage. All charges for extra utilities or services or those requested outside business hours shall be due at
the same time as the installment of Base Rent with which the same are billed, or if billed separately, shall be due within twenty (20) days after such billing. 

8.6.3 Changes in HVAC System. Use of the Premises, or any part thereof, in a manner exceeding the design conditions (including occupancy
and connected electrical load) for the heating or cooling units in the Premises, or rearrangement of partitioning which interferes with normal operation of the HVAC system in the Premises, may require changes in the HVAC system servicing the
Premises. Such changes shall be made by Tenant, at its expense, as Tenant’s Changes pursuant to Article 9. Tenant shall not change or adjust any closed or sealed thermostat or other element of the HVAC system without Landlord’s
express prior written consent. 
 8.6.4 Separate Metering. Landlord may install and operate meters or any other reasonable system for
monitoring or estimating any services or utilities used by Tenant in excess of those required to be provided by Landlord under this Article 8 (including a system for Landlord’s engineer reasonably to estimate any such excess usage). If
such system indicates such excess services or utilities, Tenant shall pay Landlord’s reasonable charges for installing and operating such system and any supplementary air-conditioning, ventilation, heat,
electrical, or other systems or equipment (or adjustments or modifications to the existing Systems and Equipment), and Landlord’s reasonable charges for such amount of excess services or utilities used by Tenant. If Tenant’s use of extra
utilities or services causes Landlord’s regulated baseline quantities of water, gas, electricity, or any other utility or service to be exceeded, Tenant shall pay for such excess quantities of such utilities or services at the rate which is
imposed upon Landlord for quantities in excess of the regulated baseline. In addition, Tenant shall pay prior to delinquency any fine or penalty which may be imposed upon or assessed against Landlord or the Building or the Property by virtue of
Tenant’s excess usage of any services or utilities, including water, gas, and electricity. 
 8.7 INTERRUPTION OF
SERVICES. Landlord does not warrant that any services or utilities provided hereunder for Tenant’s use in the Premises will be free from shortages, failures, variations, or interruptions caused by repairs, maintenance,
replacements, improvements, alterations, changes of service, strikes, lockouts, labor controversies, accidents, inability to obtain services, fuel, steam, water or supplies, governmental requirements or requests, or other causes beyond
Landlord’s reasonable control, including interference with light or other incorporeal hereditaments and any interruption in services or any failure to provide services to Landlord by a designated utility company at the demarcation point at
which Landlord accepts responsibility for such service or at any point prior thereto, which interference impedes Landlord in furnishing plumbing, HVAC, electrical, sanitary, life safety, elevator, telecommunications, or other Building services,
utilities, or the Systems and Equipment. None of the same shall be deemed an eviction or disturbance of Tenant’s use and possession of the Premises or any part thereof, shall render Landlord liable to Tenant for abatement of Rent, or shall
relieve Tenant from performance of Tenant’s obligations under this Lease. Landlord in no event shall be liable for damages by reason of loss of profits, business interruption, or other compensatory or consequential damages. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 18 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 8.8 SAFETY AND SECURITY DEVICES,
SERVICES, AND PROGRAMS. The parties acknowledge that safety and security devices, services, and programs provided by Landlord, if any, while intended to deter crime and ensure
safety, may not in given instances prevent theft or other criminal acts or ensure safety of persons or property, and such devices, services and programs shall not under any circumstances be deemed to be a guaranty, representation, or warranty by
Landlord to Tenant or any third parties as to the safety or protection of person or property. The risk that any safety or security device, service, or program may not be effective, or may malfunction, or be circumvented by a criminal, is
assumed by Tenant with respect to Tenant’s property and interests; and Tenant shall obtain insurance coverage to the extent Tenant desires protection against such criminal acts and other losses, as further described in Article 14. Tenant
agrees to coöperate in any reasonable safety or security program developed by Landlord or required by Law. 

9         TENANT’S CHANGES 

9.1 TENANT’S REQUESTED CHANGES. Tenant may, subject to § 9.2 below, from
time to time during the Term of this Lease, at its expense, make such alterations, additions, installations, substitutions, improvements, and decorations (collectively “Tenant’s Changes”) in and to the Premises as Tenant may
reasonably consider necessary for the conduct of its business in the Premises (except for changes which would require modification of the Property outside the Premises), on the following conditions: 

 

	 	(a)	the outside appearance or the strength of the Building or of any of its structural parts shall not be affected, and Tenant shall cause no penetration of the roof or the exterior fabric of the Building;

  

	 	(b)	no part of the Building outside of the Premises shall be physically affected; 

  

	 	(c)	the proper functioning of any of the Systems and Equipment shall not be adversely affected, and the usage of such systems by Tenant shall not be increased; 

 

	 	(d)	no such change shall require the addition of new INC riser cable or expand the number of telephone pairs dedicated to the Premises by the Buildings’ telecommunications engineering design; 

 

	 	(e)	in performing the work involved in making such changes, Tenant shall be bound by and observe all of the conditions and covenants contained in the following sections of this Article 9; and 

 

	 	(f)	with respect to Tenant’s Changes, Tenant shall make all arrangements for, and pay all expenses incurred in connection with, use of the freight elevators servicing the Premises. 

9.2 PLANS AND APPROVAL. Before proceeding with any Tenant’s Changes, Tenant shall advise Landlord
thereof and arrange a meeting with the Building Manager, the Building Architect, and/or the Building Contractor, as required by Landlord in relation to the scope of the proposed Changes. Except in extraordinary circumstances which would reasonably
require an exception, all work to be performed in the Building shall be performed by the Building Contractor on the basis of plans and drawings prepared by the Building Architect. If Landlord grants permission for Tenant to utilize another
contractor and/or architect for its Changes, before proceeding with any Tenant’s Changes, Tenant shall submit to Landlord plans and specifications and all changes and revisions thereto for the work to be done for Landlord’s reasonable
approval; and Tenant shall, upon demand of Landlord, pay to Landlord the reasonable costs incurred and paid to third parties by Landlord for the review of such plans and specifications and all changes and revisions thereto by its architect,
engineer, and other consultants. Landlord may as a condition of its approval require Tenant to make reasonable revisions in and to the plans and specifications. Landlord may require Tenant to post a bond or other security reasonably satisfactory to

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 19 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
Landlord to insure the completion of such change. If Landlord consents to any Tenant’s Changes or supervises the work of constructing any Tenant’s Changes, such consent or supervision
shall not be deemed a warranty as to the adequacy of the design, workmanship, or quality of materials, and Landlord hereby expressly disclaims any responsibility or liability for the same. Landlord shall under no circumstances have any obligation to
repair, maintain, or replace any portion of such work. 
 9.2.1 As-Built Plans. Within
thirty (30) days after completion of Tenant’s Changes requiring the submission of plans to Landlord, Tenant shall furnish to Landlord a complete set of “as-built” plans and specifications. 

9.3 PERMITS AND PERFORMANCE. Tenant, at its expense, shall obtain all necessary governmental permits and
certificates for the commencement and prosecution of Tenant’s Changes and for final approval thereof upon completion and shall furnish copies thereof to Landlord. Tenant shall cause Tenant’s Changes to be performed in compliance therewith
and with all applicable Laws and requirements of public authorities and with all applicable requirements of insurance bodies, and in good and workmanlike manner, using new materials and equipment at least equal in quality and class to the original
installations in the Property. Tenant’s Changes shall be performed in such manner as not unreasonably to interfere with, delay, or impose any additional expense upon Landlord in the renovation, maintenance, or operation of the Property or any
portion thereof, unless Tenant shall indemnify Landlord therefor to the latter’s reasonable satisfaction. 
 9.4 CONTRACTORS. All
electrical, mechanical, and plumbing work in connection with Tenant’s Changes shall be performed by Landlord’s contractors at Tenant’s expense. If Tenant shall request any electrical, mechanical, or plumbing work in connection with
Tenant’s Changes, Landlord shall request Landlord’s contractors to furnish Tenant with prices to perform the same prior to prosecuting same. In addition to the foregoing, and notwithstanding anything to the contrary in this Article 9,
Landlord may, at Landlord’s option, require that the work of constructing any Tenant’s Changes be performed by Landlord’s contractor, in which case the cost of such work shall be paid for before commencement of the work. 

9.5 SUPERVISION AND FEE. Landlord may require that all work of constructing Tenant’s Changes be
performed under Landlord’s supervision. If Landlord does not elect to require that Tenant use Landlord’s contractor, and if Tenant chooses to use its own contractor for the work of constructing Tenant’s Changes, Tenant shall pay to
Landlord upon completion of any such work by Tenant’s contractor an administrative fee of fifteen percent (15%) of the cost of the work, to cover Landlord’s overhead in reviewing Tenant’s plans and specifications and performing
any supervision of the work of Tenant’s Changes. If Tenant chooses to use Landlord’s contractor for such work, Tenant shall pay to Landlord upon completion an administrative fee equal to five percent (5%) of the cost of the work. 

9.6 RESTORATION OF FIXTURES. If any of Tenant’s Changes shall involve the removal of any fixtures,
equipment, or other property in the Premises which are not Tenant’s Property (as defined in Article 10), such fixtures, equipment, or other property shall be promptly replaced, at Tenant’s expense, with new fixtures, equipment, or
other property (as the case may be) of like utility and at least equal value, unless Landlord shall otherwise expressly consent in writing; and Tenant shall, upon Landlord’s request, store and preserve, at Tenant’s sole cost and expense,
any such fixtures, equipment or property so removed and shall return same to Landlord upon the expiration or sooner termination of this Lease. 
 9.7
MECHANIC’S LIENS. Tenant shall keep the Property and Premises free from any mechanic’s, materialman’s, or similar liens or other such encumbrances, including the liens of any security
interest in, conditional sales of, or chattel mortgages upon, any materials, fixtures, or articles so installed in and constituting part of the Premises, in connection with any Tenant’s Changes on or respecting the Premises not performed by or
at the request of Landlord and shall indemnify, defend, protect, and hold Landlord harmless from and against any claims, liabilities, judgements, or costs (including attorneys’ fees) arising 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 20 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
out of the same or in connection with any such lien, security interest, conditional sale or chattel mortgage or any action or proceeding brought thereon. Tenant shall give Landlord written notice
at least twenty (20) days prior to the commencement of work on any Tenant’s Change in the Premises (or such additional time as may be necessary under applicable Laws), in order to afford Landlord the opportunity of posting and recording
appropriate notices of nonresponsibility. Tenant shall remove any such lien or encumbrance by bond or otherwise within thirty (30) days after written notice by Landlord; and if Tenant shall fail to do so, Landlord may pay the amount necessary
to remove such lien or encumbrance, without being responsible for investigating the validity thereof. The amount so paid shall be deemed Additional Rent under this Lease payable upon demand, without limitation as to other remedies available to
Landlord under this Lease. Nothing contained in this Lease shall authorize Tenant to do any act which shall subject Landlord’s title to the Property or Premises to any liens or encumbrances, whether claimed by operation of law or express or
implied contract. Any claim to a lien or encumbrance upon the Property or Premises arising in connection with any Work on or respecting the Premises not performed by or at the request of Landlord shall be null and void, or, at Landlord’s
option, shall attach only against Tenant’s interest in the Premises and shall in all respects be subordinate to Landlord’s title to the Property and Premises. 

9.8 NOTICES OF VIOLATION. Tenant, at its expense, and with diligence and dispatch, shall procure the
cancellation or discharge of all notices of violation arising from or otherwise connected with Tenant’s Changes which shall be issued by any governmental, public, or quasi-public authority having or asserting jurisdiction. However, nothing
herein contained shall prevent Tenant from contesting, in good faith and at its own expense, any such notice of violation, provided that Landlord’s rights hereunder are in no way compromised or diminished thereby. 

9.9 INDUSTRIAL RELATIONS. Tenant agrees that the exercise of its rights pursuant to the provisions of this Article 9
or any other provision of this Lease shall not be done in a manner which would create any work stoppage, picketing, labor disruption, or dispute or violate Landlord’s union contracts affecting the Property and/or Complex or interfere with the
business of Landlord or any Tenant or occupant of the Building. Tenant shall, immediately upon notice from Landlord, cease any activity, whether or not permitted by this Lease, giving rise to such condition. If Tenant fails to do so, Landlord, in
addition to any rights available to it under this Lease and pursuant to Law, shall have the right to an ex parte injunction without notice. 

10         TENANT’S PROPERTY 

10.1 FIXTURES AND IMPROVEMENTS. All fixtures, equipment, improvements, alterations, and appurtenances
attached to or built into the Premises at the commencement of or during the Term of this Lease, including cabinets, sinks, faucets, appliances, hot water heaters, etc. (collectively “Improvements”), whether or not by or at the expense of
Tenant, shall be and remain a part of the Premises, shall be deemed the property of Landlord, and shall not be removed by Tenant, except as expressly provided in Article 11 below. 

10.2 TENANT’S PROPERTY AND TRADE FIXTURES. All movable
partitions, trade fixtures, office machinery and equipment, communications equipment, and computer equipment (whether or not attached to or built into the Premises) which are installed in the Premises by or for the account of Tenant, without expense
to Landlord and which can be removed without structural damage to the Property, and all furniture, furnishings, and other articles of movable personal property owned by Tenant and located in the Premises (collectively “Tenant’s
Property”) shall be and shall remain the property of Tenant and may be removed by it at any time during the Term of this Lease; provided that if any of Tenant’s Property is removed, Tenant or any party or person entitled to remove same
shall repair or pay the cost of repairing any damage to the Premises or to the Property resulting from such removal. Any equipment or other property for which Landlord shall have granted any allowance or credit to Tenant or which has replaced such
items originally provided by Landlord at Landlord’s expense shall not be deemed to have been installed by or for the account of Tenant, without expense to Landlord, and shall not be considered Tenant’s Property. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 21 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 11         CONDITION UPON SURRENDER 

11.1 CONDITION AND RESTORATION. At or before the Expiration Date or the date of any earlier termination of
this Lease, or as promptly as practicable using Tenant’s best efforts after such an earlier termination date, Tenant, at its expense, shall do all of the following: 
  

	 	(a)	surrender possession of the Premises in the condition required under § 12.1 below, ordinary wear and tear excepted; 

 

	 	(b)	surrender all keys, any key cards, and any parking stickers or cards to Landlord and give Landlord in writing the combinations of any locks or vaults then remaining in the Premises; 

 

	 	(c)	remove from the Premises all of Tenant’s Property, including any data wiring and cabling that Tenant has installed, except such items thereof as Tenant shall have expressly agreed in writing with Landlord
were to remain and to become the property of Landlord; and 

  

	 	(d)	fully repair any damage to the Premises or the Property resulting from such removal. 

 Tenant’s
obligations herein shall survive the expiration or earlier termination of the Lease, unless expressly provided to the contrary herein. All Improvements and other items in or upon the Premises (except Tenant’s Property), whether installed by
Tenant or Landlord, shall be Landlord’s property and shall remain upon the Premises, all without compensation, setoff, allowance, or credit to Tenant; provided, however, that if prior to such expiration or earlier termination Landlord so
directs by notice, Tenant shall promptly remove such of the Improvements in the Premises as are designated in such notice and shall restore the Premises to their condition prior to the installation of such Improvements. Notwithstanding the
foregoing, Landlord shall not require removal of customary office improvements installed pursuant to the Work Letter Agreement, if any (except as expressly provided to the contrary therein), or installed by Tenant with Landlord’s written
approval (except as expressly required by Landlord in connection with granting such approval). 
 11.2 TENANT’S
FAILURE TO REMOVE OR RESTORE. If Tenant shall fail to perform any repairs or restoration or fail to remove any items from the Premises as required under this
Article 11, Landlord may do so, and Tenant shall pay Landlord the cost thereof upon demand. All property removed from the Premises by Landlord pursuant to any provisions of this Lease or any Law may be handled or stored by Landlord at
Tenant’s expense, and Landlord shall in no event be responsible for the value, preservation, or safekeeping thereof. All property not removed from the Premises or retaken from storage by Tenant within thirty (30) days after expiration or
earlier termination of this Lease or Tenant’s right to possession shall at Landlord’s option be conclusively deemed to have been conveyed by Tenant to Landlord as if by bill of sale without payment by Landlord. Unless prohibited by
applicable Laws, Landlord shall have a lien against such property for the costs incurred in removing and storing the same. 

12         REPAIRS AND MAINTENANCE 

12.1 TENANT’S CARE OF PREMISES. Except for customary cleaning and trash
removal provided by Landlord under § 8.1 above and damage covered under Article 15, Tenant shall keep the Premises in good and sanitary condition, working order, and repair, including carpet, wall-covering, doors pertinent to and
within the Premises, plumbing, all telecommunications cables and wiring within Tenant’s 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 22 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
Premises (“IW”) from the interface of such IW with the INC, and other fixtures, equipment, alterations, and improvements, whether installed by Landlord or Tenant. In addition, Tenant,
at its expense, shall promptly make all repairs, ordinary or extraordinary, interior or exterior, structural or otherwise, in and about the Premises and the Property, as shall be required by reason of (a) the performance or existence of
Tenant’s Work or Tenant’s Changes; (b) the installation, use, or operation of Tenant’s Property in the Premises; (c) the moving of Tenant’s Property in or out of the Building; or (d) the misuse or neglect of Tenant
or any of its employees, agents, or contractors. Tenant, at its expense, shall replace all scratched, damaged, or broken doors or other glass in or about the Premises and shall be responsible for all repairs, maintenance, and replacement of wall and
floor coverings in the Premises and for the repair and maintenance of all lighting fixtures therein. All repairs except for emergency repairs made by Tenant as provided herein shall be performed by contractors or subcontractors approved in writing
by Landlord prior to commencement of such repairs, which approval shall not be unreasonably withheld or delayed. If Tenant does not promptly make such arrangements, Landlord may, but need not, make such repairs, maintenance, and replacements, and
the costs paid or incurred by Landlord therefor shall be reimbursed by Tenant promptly after request by Landlord. 
 12.2
LANDLORD’S CARE OF PROPERTY. Landlord, at its expense, shall keep and maintain the common areas of the Property and the Systems and Equipment serving the Premises in
good working order, condition, and repair and shall make all repairs, structural and otherwise, interior and exterior, as and when needed in or about the Premises, except for those repairs for which Tenant is responsible pursuant to § 12.1
above or any other provisions of this Lease. Landlord shall maintain and repair all INC in the Building, and Tenant shall have no right to make repairs to INC. The cost of Landlord’s maintenance and repairs pursuant to this Article 12
shall be reimbursed to Landlord to the extent provided in Article 4 above. 
 12.3 WAIVER BY
TENANT. Tenant waives the benefits of any statute now or hereafter in effect which would otherwise afford Tenant the right to make repairs at Landlord’s expense or to terminate this Lease because of Landlord’s failure to
keep the Premises in good order, condition, and repair. 
 13         RULES AND REGULATIONS

 13.1 OBSERVANCE AND MODIFICATION. Tenant and its employees and agents shall faithfully observe
and comply with the Rules and Regulations attached hereto as Exhibit C (the “Rules”) and such reasonable changes therein (whether by modification, elimination, or addition) as Landlord at any time or times hereafter may make and
communicate in writing to Tenant, so long as such changes do not unreasonably affect the conduct of Tenant’s business in the Premises, except as required by any applicable Law; provided, however, that in case of any conflict or inconsistency
between the provisions of this Lease and any of the Rules as originally promulgated or as changed, the provisions of this Lease shall control. 
 13.2
APPLICATION TO TENANT. Nothing in this Lease shall be construed to impose upon Landlord any obligation to Tenant to enforce the Rules or the terms, covenants, or conditions in any other lease, as
against any other tenant, and Landlord shall not be liable to Tenant for violation of the same by any other tenant or its employees, agents, or visitors. 

14         INSURANCE AND INDEMNIFICATION 

14.1 TENANT’S INSURANCE. Tenant shall obtain and maintain in effect at all times during Tenant’s
possession of the Premises the following insurance coverages and policies: 
 14.1.1 Liability Insurance. Tenant shall maintain a
policy of commercial general liability insurance, which shall include coverages for (a) personal injury; (b) broad-form contractual liability; (c) owner’s (i.e.,
Tenant’s) & contractor’s protective; (d) automobile liability; and (e) broad-form property damage liability. The minimum limits of liability shall be a combined single limit with

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 23 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
respect to each occurrence of not less than Two Million Dollars ($2,000,000) and an aggregate limit of not less than Three Million Dollars ($3,000,000). The policy shall contain a cross-liability endorsement and a severability of interest clause. Tenant shall increase the insurance coverage as required by Landlord’s lender or if Landlord’s insurance consultant believes that the
coverage is not adequate. 
 14.1.2 Tenant’s Business Personal Property Insurance. Tenant shall maintain on all of its business
personal property, including valuable business papers and accounts receivable; operating supplies; inventory; and furniture, fixtures, and equipment (whether owned, leased, or rented) (collectively “Business Personal Property”) an
“all risk” property damage insurance policy including coverages for earthquake damage and sprinkler leakage and containing an agreed amount endorsement (or, if applicable, a business owner’s policy with a no-coinsurance provision) in an amount not less than one hundred percent (100%) of the full replacement cost valuation of such Business Personal Property. The proceeds from any such policy shall be used by
Tenant for the replacement of such Business Personal property. 
 14.1.3 Workers’ Compensation Insurance. Tenant shall maintain
workers’ compensation insurance as required by law and employer’s liability insurance in an amount not less than Five Hundred Thousand Dollars ($500,000). 

14.1.4 Business Interruption/Extra Expense Insurance. Tenant shall maintain business interruption or (if applicable) contingent business
interruption and extra expense insurance in such amounts as will reimburse Tenant for direct or indirect loss of earnings and incurred costs attributable to the perils commonly covered by Tenant’s property insurance described in
§ 14.1.2 above but in no event less than the average total of Tenant’s annual gross receipts during the three-year period immediately preceding such interruption or loss. Such insurance will be
carried with the same insurer that issues the insurance for Tenant’s Business Personal Property pursuant to § 14.1.2 above. 

14.1.5 Other Coverage. Tenant, at its cost, shall maintain such other insurance as Landlord may reasonably require from time to time,
but in no event may Landlord require any other insurance which is not then available at commercially reasonable rates. 
 14.2
TENANT’S INSURANCE CRITERIA. All insurance required to be maintained by Tenant under this Lease shall conform to the following criteria: 

(i) Tenant’s insurance shall be issued by insurance companies authorized to do business in the State of California with a financial
rating of at least A:XIII for any property insurance and at least A-:IX for any liability insurance, as rated in the most recent edition of Best’s Insurance Reports; 

(ii) Tenant’s insurance shall be issued as primary and noncontributory; 

(iii) Tenant’s liability and property insurance policies shall name Tenant as the insured and Landlord, Landlord’s agents, and
any Lessors and Holders (as such terms are defined in § 18.1 below) whose names shall have been furnished to Tenant as additional insureds; 

(iv) Tenant’s insurance shall contain an endorsement requiring at least thirty (30) days’ written notice from the
insurance company to each insured and additional insured before cancellation or any material change in the coverage, scope, or amount of any policy; and 

(v) with respect to damage to or loss of Tenant’s Business Personal Property, a waiver of subrogation must be obtained, as required
under § 14.4 below. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 24 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 14.2.1 Blanket Coverage. All of the insurance requirements set forth herein on the
part of Tenant to be observed shall be deemed satisfied if the Premises are covered by a blanket insurance policy complying with the limits, requirements, and criteria contained in this Article 14 insuring all or most of Tenant’s
facilities in California. 
 14.2.2 Evidence of Coverage. A duplicate original policy or a certificate of insurance shall be deposited
with Landlord at the commencement of the Term or, if earlier, upon Tenant’s taking possession of the Premises; and on renewal of the policy a certificate of insurance listing the insurance coverages required hereunder and naming the appropriate
additional insureds shall be deposited with Landlord not less than seven (7) days before expiration of the policy. 
 14.3
LANDLORD’S INSURANCE. Landlord shall maintain “all risk” property damage insurance containing an agreed amount endorsement covering not less than one hundred percent (100%) of the
full insurable replacement cost valuation of (y) the Building and the tenant improvements, betterments, and the alterations thereto; and (z) Landlord’s personal property, business papers, furniture, fixtures, and equipment
(collectively “Landlord’s Property”), exclusive of the costs of excavation, foundations and footings, and risks required to be covered by Tenant’s insurance, and subject to commercially reasonable deductibles. Landlord shall also
obtain and keep in full force the following policies of insurance: (a) commercial general liability insurance; (b) loss of rent insurance (also known as rent continuation insurance); (c) workers’ compensation insurance, if
required by applicable Law; and (d) such other insurance as Landlord deems appropriate or as may be required by any Holder or Lessor. 
 14.4
RELEASES AND WAIVERS OF SUBROGATION. The purpose of this provision is to allow Landlord and Tenant to allocate and assume certain risks to coincide with insurance
coverages required to be maintained pursuant to the terms to this Lease. Landlord and Tenant recognize the benefit that each will receive from the waivers of subrogation each is required to obtain pursuant to this § 14.4 and that there are
significant advantages to each in connection with minimizing duplication of insurance coverages. Accordingly, Landlord and Tenant agree to accept and place the limitations which follow on each other’s respective liabilities and responsibility
for damages in order to coincide with required insurance coverages. 
 14.4.1 Tenant’s Property Agreement. In light of
Tenant’s agreement to insure Tenant’s Business Personal Property in accordance with § 14.1.2 above, Tenant agrees that Landlord will have no liability to Tenant in the event Landlord damages or destroys, negligently or otherwise,
all or any part of Tenant’s Business Personal Property. Tenant will cause to be placed in its insurance policies covering Tenant’s Business Personal Property a waiver of subrogation so that its insurance company will not become subrogated
to Tenant’s rights and will not be able to proceed against Landlord in connection with any such damage or destruction. 
 14.4.2
Landlord’s Property Agreement. In light of Landlord’s agreement to insure Landlord’s Property in accordance with § 14.3 above, Landlord agrees that Tenant will have no liability to Landlord in the event that Tenant
damages or destroys, negligently or otherwise, all or any part of Landlord’s Property. Landlord will cause to be placed in its insurance policies covering Landlord’s Property a waiver of subrogation so that its insurance company will not
become subrogated to Landlord’s rights and will not be able to proceed against Tenant in connection with any such damage or destruction. 

14.4.3 Tenant’s Release. Landlord shall not be responsible or liable to Tenant for any damages or destruction to Tenant’s
Business Personal Property caused by Landlord’s employees, agents, visitors, invitees, guests, or independent contractors (collectively “Landlord’s Associates”), and Tenant hereby releases Landlord from any claims, liabilities,
demands, losses, damages, consequential damages, and the like, including reasonable attorneys’ fees and court costs (collectively “Claims”) resulting from damage or destruction to Tenant’s Business Personal Property caused
directly or indirectly by Landlord and/or Landlord’s Associates; provided, however, that nothing herein shall be deemed to release Landlord’s independent contractors from any such Claims Tenant may have against Landlord’s independent
contractors. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 25 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 14.4.4 Landlord’s Release. Tenant shall not be responsible or liable to Landlord
for any damages or destruction to Landlord’s Property caused by Tenant’s employees, agents, visitors, invitees, guests, or independent contractors (collectively “Tenant’s Associates”), and Landlord hereby releases Tenant
from any Claims resulting from damage or destruction to Landlord’s Property caused directly or indirectly by Tenant and/or Tenant’s Associates; provided, however, that nothing herein shall be deemed to release Tenant’s independent
contractors from any such Claims Landlord may have against Tenant’s independent contractors. 
 14.4.5 Damage to Business and Loss of
Rents. In light of Landlord’s agreement to carry continuation of rent insurance pursuant to § 14.3 above and Tenant’s agreement to carry business interruption insurance (extra expense insurance) in accordance with
§ 14.1.4 above, in the event that Landlord’s Property is damaged or destroyed because of any act or conduct, negligent or otherwise, by Tenant and/or by Tenant’s Associates, Landlord shall have no rights against Tenant by virtue
of such damage or destruction, and Landlord hereby releases Tenant from all Claims, including claims for loss of rent, by Landlord directly or indirectly resulting from the damage or destruction of Landlord’s Property by conduct by Tenant
and/or by Tenant’s Associates. Likewise, in the event that Tenant’s Business Personal Property is damaged or destroyed because of any act or conduct, negligent or otherwise, by Landlord and/or by Landlord’s Associates, Tenant shall
have no rights against Landlord by virtue of such damage or destruction, and Tenant hereby releases Landlord from all Claims by Tenant directly or indirectly resulting from the damage or destruction to Tenant’s Business Personal Property by the
conduct of Landlord and/or Landlord’s Associates, including Claims for loss of business or loss of profits. Notwithstanding the foregoing, nothing herein shall be deemed to release Tenant’s or Landlord’s independent contractors from
any liability to Tenant and/or Landlord. 
 14.4.6 Injury and Death to Individuals. Landlord and Tenant understand that waivers of
subrogation do not apply to injury to and death of individuals. Landlord and Tenant shall each carry insurance, as provided by this Article 14, in connection with injury and death to individuals. Landlord hereby agrees to indemnify and hold
Tenant harmless from any Claims which Tenant may otherwise have with respect to injury or death to individuals occurring within the Property but outside the Premises, except to the extent that such injury or death is caused by Tenant and/or
Tenant’s Associates, through negligence or otherwise, and is not covered by the insurance Landlord is required to carry under this Lease. Likewise, Tenant agrees to indemnify, defend, protect, and hold Landlord harmless from any Claims for
injury or death to persons occurring within the Premises or caused, directly or indirectly, by Tenant or Tenant’s Associates outside the Premises, except to the extent such injuries or death are caused by Landlord and/or Landlord’s
Associates, through negligence or otherwise, and are not covered by the insurance Tenant is required to carry under this Lease. 
 14.4.7
Abatement of Rent. Except as may be expressly provided elsewhere in this Lease, Tenant shall not be entitled to Rent abatement and shall not otherwise have, and hereby releases Landlord from, any Claims resulting from Tenant’s inability to
utilize all or any part of the Premises, except to the extent that Tenant is unable to use all or any part of the Premises and does not use all or any part of the Premises as a result of Landlord’s intentional decision to refuse to provide
access to the Building and/or the Premises and/or to provide services and/or utilities to Tenant as required to be provided by Landlord to Tenant pursuant to this Lease, where such refusal is not caused by a Force Majeure occurrence. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 26 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 14.4.8 Availability of Waiver of Subrogation. If an insurance policy cannot be
obtained with a waiver of subrogation or is obtainable only by the payment of an additional premium charge above that charged by insurance companies issuing policies without waiver of subrogation, the party undertaking to obtain the insurance shall
notify the other party of this fact. The other party shall have a period of ten (10) days after receiving the notice either to place the insurance with a company that is reasonably satisfactory to the other party and that will carry the
insurance with a waiver of subrogation at no additional cost or to agree to pay the additional premium if such a policy is obtainable at additional cost. If the insurance cannot be obtained or the party in whose favor a waiver of subrogation is
desired refuses to pay the additional premium charged, the other party is relieved of the obligation to obtain a waiver of subrogation with respect to the particular insurance involved. 

14.5 OTHER CASES OF DAMAGE OR INJURY. In all cases not
covered by the foregoing provisions of this Article 14, Tenant hereby assumes all risk of damage to property or injury to persons in, upon, or about the Premises from any cause other than the active negligence or intentional misconduct of
Landlord and its agent or employees. Without limiting the generality of the foregoing, Landlord shall not be liable for injury or damage which may be sustained by the person, goods, wares, merchandise, or property of Tenant or Tenant’s
Associates or any other person in or about the Premises caused by or resulting from fire, steam, electricity, gas, water or rain, which may leak or flow from or into any part of the Premises, or from the breakage, leakage, obstruction, or other
defects of the Systems and Equipment, pipes, sprinklers, wires, INC, appliances, plumbing, heating, air-conditioning, or lighting fixtures of the same, whether the damage or injury results from conditions
arising upon the Premises or upon other portions of the Property, the Complex, or from other sources. Landlord shall not be liable for any damages arising from any act or omission of any other tenant or occupant of the Property or Complex. In all
cases not covered by the foregoing provisions of this Article 14, Tenant shall indemnify, defend, protect, and hold Landlord harmless against (a) any and all Claims arising from any death or injury to any person or damage to any property
whatsoever occurring in, on, or about the Premises or any part thereof, and (b) any and all Claims occurring in, on or about any of the Common Areas, the Property, or the Complex, when such injury or damage is caused in whole or in part by the
act, negligence, fault, or omission of any duty with respect to the same by Tenant or Tenant’s Associates. In all cases not covered by the foregoing provisions of this Article 14, Tenant shall further indemnify, defend, protect, and hold
Landlord harmless from and against any and all Claims arising from any breach or default in the performance of any obligation on Tenant’s part to be performed under this Lease, or arising from any act or negligence of Tenant or Tenant’s
Associates, and from and against all costs, attorneys’ fees, expenses, and liabilities incurred in connection with any such Claim or any action or proceeding brought thereon. In case any action or proceeding be brought against Landlord by
reason of any such Claim, Tenant, upon notice from Landlord, shall defend the same at Tenant’s expense by counsel reasonably satisfactory to Landlord; provided, however, that Tenant shall not be liable in any case for damage to property or
death or injury to person(s) occasioned by the active negligence or intentional misconduct of Landlord or Landlord’s Associates, unless covered by insurance Tenant is required to provide. 

15         DAMAGE OR DESTRUCTION 

15.1 LOSS COVERED BY INSURANCE. If at any time prior to the expiration or termination of
this Lease the Premises or the Property is wholly or partially damaged or destroyed by any casualty which results in a loss to Landlord that is fully covered by insurance maintained by Landlord or for Landlord’s benefit (or required to be
maintained by Landlord pursuant to § 14.3 above), which casualty renders the Premises totally or partially inaccessible or unusable by Tenant in the ordinary conduct of Tenant’s business, the parties agree that the following
provisions shall modify their obligations under this Lease after such damage or destruction. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 27 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 15.1.1 Repairs Which Can Be Completed Within Six (6) Months. Within
thirty (30) days after Tenant’s written notice to Landlord of such damage or destruction, Landlord shall provide Tenant with notice of its determination of whether the damage or destruction can be repaired within six (6) months after
the commencement of the work of repairing such damage or destruction without the payment of overtime or other premiums. If all repairs to Premises or Property can, in Landlord’s judgement, be completed within six (6) months following the
date of the commencement of the work of repairing such damage or destruction without the payment of overtime or other premiums, Landlord shall, at Landlord’s expense, repair the same; and this Lease shall remain in full force and effect, except
that a proportionate reduction of the Base Rent shall be allowed Tenant to the extent that the Premises shall be rendered inaccessible or unusable by Tenant and are not used by Tenant during the period of time that such portion is unusable or
inaccessible and not used by Tenant. 
 15.1.2 Repairs Which Cannot Be Completed Within Six (6) Months. If all such
repairs to the Property and Premises cannot, in Landlord’s judgement, be completed within six (6) months following the commencement of the work of repairing such damage or destruction without the payment of overtime or other premiums,
Landlord shall notify Tenant of such determination; and in such an event, either Landlord or Tenant may, at its option, upon written notice to the other party given within sixty (60) days after the occurrence of such damage or destruction,
elect to terminate this Lease as of the date of the occurrence of such damage or destruction. In the event that neither Landlord nor Tenant elects to terminate the Lease in accordance with the foregoing provisions, then Landlord shall, at
Landlord’s expense, repair such damage or destruction; and in such event, this Lease shall continue in full force and effect, except that the Base Rent shall be proportionately reduced as provided in § 15.1.1 above; provided, however,
that if any such repair is not commenced by Landlord within ninety (90) days after the occurrence of such damage or destruction or is not substantially completed by Landlord within nine (9) months after the occurrence of such damage or
destruction, then in either such event Tenant may, at its option, upon written notice to Landlord, elect to terminate this Lease as of the date of Landlord’s receipt of such notice. Notwithstanding the foregoing, Tenant shall have no right to
terminate this Lease in the situation just described if all of the following conditions are met: (x) Landlord shall have informed Tenant in its notice of determination that the repair of such damage or destruction could not be substantially
completed by Landlord within nine (9) months after the occurrence of such damage or destruction; (y) Tenant shall not have elected to terminate the Lease by written notice delivered to Landlord within sixty (60) days after the
occurrence of such damage or destruction; and (z) Landlord shall have commenced the work of repairing such damage or destruction. 
 15.2
LOSS NOT COVERED BY INSURANCE. If at any time prior to the expiration or earlier termination of this Lease the Premises or the Property is totally or partially damaged
or destroyed in connection with a casualty, which loss to Landlord is not fully covered by insurance maintained by Landlord or for Landlord’s benefit (or required to be maintained by Landlord pursuant to § 14.3 above); and if such
damage renders the Premises inaccessible or unusable to Tenant for their intended purpose in the ordinary course of its business, Landlord may, at its option, upon written notice given to Tenant within sixty (60) days after Tenant’s
written notice to Landlord of the occurrence of such damage or destruction, either (a) elect to repair or to restore such damage or destruction or (b) elect to terminate this Lease. If Landlord elects to repair or restore such damage or
destruction, this Lease shall continue in full force and effect, except that the Base Rent shall be proportionately reduced as provided in § 15.1.1 above. If Landlord does not elect by notice to Tenant to repair such damage, the Lease
shall terminate as of the date of Tenant’s receipt of Landlord’s notice of election to terminate. Notwithstanding the foregoing, if all repairs to the Premises or the Building cannot, in Landlord’s reasonable judgement, be completed
within six (6) months following the date of the commencement of the work of repairing such damage or destruction without the payment of overtime or other premiums, then either Landlord or Tenant may at the option of either, upon written notice
to the other party given within sixty (60) days after the occurrence of such damage or destruction, elect to terminate this Lease as of the date of such notice. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 28 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 15.3 DESTRUCTION DURING FINAL YEAR.
Notwithstanding anything to the contrary contained in §§ 15.1 and 15.2, if the Premises or the Building are wholly or partially damaged or destroyed within the final twelve (12) months of the Term of this Lease or, if an
applicable renewal option has been exercised, during the last year of any renewal term, in such a way that Tenant shall be prevented from using the Premises for at least thirty (30) consecutive days as a result of such damage or destruction,
then either Landlord or Tenant may, at the option of either, by written notice to the other party delivered within sixty (60) days after the occurrence of such damage or destruction, elect to terminate the Lease as of the date of such notice.

 15.4 DESTRUCTION OF TENANT’S PROPERTY. Under no
circumstances shall Landlord be required to repair any injury or damage to, or make any repairs to or replacements of, Tenant’s Property. However, as part of Operating Expenses, Landlord shall cause to be insured the Improvements in the
Premises which do not consist of Tenant’s Property and shall cause such Improvements to be repaired and restored at Landlord’s sole expense, except that Tenant shall pay any applicable deductible. Landlord shall have no responsibility for
any contents placed or kept in or on the Premises or the Property by Tenant or Tenant’s employees or invitees or any other person claiming through Tenant. 

15.5 EXCLUSIVE REMEDY. Landlord and Tenant agree that their respective rights and obligations in the event of any damage
or destruction of the Premises, Property, or Complex shall be governed exclusively by this Lease. Tenant, as a material inducement to Landlord entering into this Lease, irrevocably waives and releases Tenant’s rights under California Civil Code
§§ 1932(2), 1933(4), and 1942, as the same may be modified or replaced hereafter. No damages, compensation, setoff, allowance, or claim shall be payable by Landlord for any inconvenience, interruption, or cessation of Tenant’s
business or any annoyance arising from any damage to or destruction of all or any portion of the Premises, Property, or Complex. 

16         EMINENT DOMAIN 

16.1 CONDEMNATION. If the whole or any material part of the Premises or Property shall be taken by power of eminent domain or condemned
by any competent authority for any public or quasi-public use or purpose; or if any adjacent property or street shall be so taken, condemned, reconfigured, or vacated by such authority in such manner as to require the use, reconstruction, or
remodeling of any part of the Premises or Property; or if Landlord shall grant a deed or other instrument in lieu of such taking by eminent domain or condemnation (collectively “Takings”), Landlord shall have the option to terminate this
Lease upon ninety (90) days’ notice, provided such notice is given no later than one hundred and eighty (180) days after the date of such Taking. Tenant shall have reciprocal termination rights, on the same terms and conditions and to
be exercised in the same manner as the foregoing sentence provides, if the whole or any material part of the Premises is permanently taken, or if access to the Premises is permanently materially impaired. 

16.2 RENTAL APPORTIONMENT. All Rent shall be apportioned as of the date of such termination or the date of
such Taking, whichever shall first occur. If any part of the Premises shall be taken, and this Lease shall not be so terminated, the Rent shall be proportionately abated. 

16.3 AWARDS AND DAMAGES. Landlord shall be entitled to receive the entire award or payment in connection
with any Taking, except that Tenant shall have the right to file any separate claim available to Tenant for any taking of Tenant’s personal property and fixtures belonging to Tenant and removable by Tenant upon expiration of the Term, and for
moving expenses, so long as such claim does not diminish the award available to Landlord and such claim is payable separately to Tenant. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 29 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 16.4 TEMPORARY CONDEMNATION. If part or all of the Premises are
condemned for a limited period of time (“Temporary Condemnation”), this Lease shall remain in effect. The Rent and Tenant’s obligations for the part of the Premises taken shall abate during the Temporary Condemnation in proportion to
the part of the Premises that Tenant is unable to use in its business operations as a result of the Temporary Condemnation. Landlord shall receive the entire award for any Temporary Condemnation. 

17         ASSIGNMENT AND SUBLETTING 

17.1 CONSENT REQUIRED FOR TRANSFER. Tenant agrees that it shall not assign, sublet,
mortgage, hypothecate, or encumber this Lease, nor permit or allow the Premises or any part thereof to be used or occupied by others, without the prior written consent of Landlord in each instance. The actions described in the foregoing sentence are
referred to collectively herein as “Transfers” and individually as a “Transfer.” If the Premises or any part thereof be sublet or occupied by anybody other than Tenant, Landlord may, after default by Tenant, collect rent from the
subtenant or occupant and apply the net amount collected to the Rent herein reserved; but no Transfer, occupancy, or collection shall be deemed a waiver of the provisions hereof, the acceptance of the subtenant or occupant as tenant, or a release of
Tenant from the further performance hereunder by Tenant. The consent by Landlord to a Transfer shall not relieve Tenant from obtaining the Landlord’s express written consent to any further Transfer. In no event shall any permitted sublessee
assign or encumber its sublease or further sublet all or any portion of its sublet space, or otherwise suffer or permit the sublet space or any part thereof to be used or occupied by others, without Landlord’s prior written consent in each
instance. 
 17.1.1 Corporate Transferor. If Tenant is a corporation, the provisions of § 17.1 shall apply to a transfer (by
one or more transfers) of a majority of the stock of Tenant as if such transfer of a majority of the stock of Tenant were an assignment of this Lease. 

17.2 NOTICE OF INTENT TO TRANSFER. If Tenant shall at any time or times
during the Term of this Lease desire to assign this Lease or sublet all or part of the Premises, Tenant shall give notice thereof (the “Transfer Notice”) to Landlord, which notice shall set forth all of the following: 

 

	 	(a)	the proposed terms of the assignment or subletting, including (i) the effective or commencement date thereof, which shall be not less than thirty (30) nor more than one hundred eighty (180) days after the
giving of such notice; (ii) in the case of a proposed assignment, the consideration therefor; and (iii) in the case of a proposed subletting, the rental rate to be paid by the proposed subtenant (including any escalation or Additional Rent
payable), the term of the proposed sublease (including any renewal options), any work to be performed or paid for by Tenant, the amount of any security deposit, the cost and extent of any so-called “take-over” obligations to be assumed by
Tenant on behalf of such subtenant, the amount of any rent concessions to be granted by Tenant, and any other additional monetary or so-called “business” terms or conditions; 

 

	 	(b)	a statement setting forth in reasonable detail the identity of the proposed assignee or subtenant, the nature of its business, and its proposed use of the Premises; and 

 

	 	(c)	current financial information with respect to the proposed assignee or subtenant, including its most recent financial report, and any other information which may reasonably be required by Landlord. 

17.3 LANDLORD’S RECAPTURE RIGHT. The Transfer Notice shall be deemed an offer from
Tenant to Landlord whereby Landlord (or Landlord’s designee) may, at its option, terminate this Lease as to all or the affected portion of the Premises (as the case may be) as of the effective date of the proposed Transfer. Landlord may
exercise its recapture right by notice to Tenant at any time within thirty (30) days after Landlord’s receipt of Tenant’s Transfer Notice; and during such thirty-day period Tenant shall not
assign this Lease nor sublet such space to any person. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 30 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 17.3.1 Date of Termination. If Landlord exercises its option to terminate this Lease
as provided in § 17.3 above, this Lease shall end and expire on the date that such Transfer was to be effective or commence, as the case may be, and the Base Rent and Additional Rent shall be paid and apportioned to such date. 

17.4 CONDITIONS OF CONSENT. If Landlord does not exercise its recapture right pursuant to § 17.3
above, and providing that Tenant is not in default of any of Tenant’s obligations under this Lease after notice and the expiration of any applicable grace period, Landlord’s consent (which must be in writing and in form reasonably
satisfactory to Landlord) to the proposed assignment or sublease shall not be unreasonably withheld or delayed, provided the following conditions are met: 
  

	 	(a)	Tenant shall have complied with the provisions of § 17.2 above, and Landlord shall not have exercised its recapture right pursuant to § 17.3 above within the time permitted therefor;

  

	 	(b)	In Landlord’s reasonable judgement the proposed assignee or subtenant is engaged in a business which would use the Premises, or the relevant part thereof, in a manner which is in keeping with the then-current standards of the Building, is limited to the use expressly permitted under this Lease, and will not violate any negative covenant or other restriction or agreement as to use contained in any other lease
of space in the Complex; 

  

	 	(c)	The proposed assignee or subtenant is a reputable entity or person of good character and with reasonably sufficient financial worth considering the responsibility involved (and in no event of less financial standing
than Tenant), is not subject to any toxic or hazardous materials cleanup order with respect to any other property, and Landlord has been furnished with reasonable proof thereof; 

 

	 	(d)	Neither the proposed assignee or sublessee nor any person which, directly or indirectly, controls, is controlled by, or is under common control with, the proposed assignee or sublessee or any person who controls the
proposed assignee or sublessee, is then an occupant of any part of the Complex, provided Landlord then has suitable space in the Complex available for leasing. For purposes of this Lease control shall be deemed to mean ownership of more than
fifty percent (50%) of all the voting stock of a corporation or more than fifty percent (50%) of all the legal and equitable interest in any other business entity; 

 

	 	(e)	The proposed assignee or sublessee is not a person or entity with whom Landlord is then negotiating to lease space in the Building; 

  

	 	(f)	The form of the proposed lease shall be in form reasonably satisfactory to Landlord and shall comply with the applicable provisions of this Article 17; 

 

	 	(g)	There shall not be more than two (2) subtenants (not including the Permitted Occupant (as defined in § 17.14 below) of the Premises); 

 

	 	(h)	The amount of the aggregate rent to be paid by the proposed subtenant is not less than the then-current market rent per rentable square foot for comparable space in the Complex,
as though the Premises were vacant, and the rental and other terms and conditions of the sublease are the same as those contained in the proposed sublease furnished to Landlord in the Transfer Notice pursuant to § 17.2 above;

  

	 	(i)	Tenant shall reimburse Landlord on demand for any reasonable costs that may be incurred or paid by Landlord to third persons in connection with said assignment or sublease, including costs of making investigations as to
the acceptability of the proposed assignee or subtenant and legal costs incurred in connection with the granting of any requested consent; and 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 31 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(j)	Tenant shall not have advertised or publicized in any way the availability of the Premises without prior notice to and approval by Landlord, nor shall any advertisement state the name (as distinguished from the address)
of the Complex or the rental rate; 

  

	 	(k)	Tenant shall not have listed the Premises for subletting or assignment at a rental rate less than the greater of (i) the Base Rent and Additional Rent then payable hereunder for such space or (ii) the Base
Rent and Additional Rent at which Landlord is then offering to lease other comparable space in the Building; and 

  

	 	(l)	The sublease shall not allow the use of the Premises or any part thereof for (i) the sale of food for on or off-premises consumption or (ii) use by a foreign or domestic
governmental agency. 

 Whether or not Landlord shall grant consent, Tenant shall pay $500.00 towards Landlord’s review and processing
expenses in connection with any Transfer request, as well as any reasonable legal fees incurred by Landlord, within thirty (30) days after written request by Landlord. In addition, Tenant agrees to reimburse Landlord for its reasonable
attorneys’ fees incurred in the review of (i) any transaction with respect to which Tenant is required to give notice under § 17.13 below and/or (ii) any other change of name, registration, corporate status or merger,
acquisition, consolidation, transfer, or other matter related to Tenant’s legal or corporate status requiring Landlord’s attention and legal advice. 

17.5 CONTINUATION OF LEASE TERMS. Each subletting pursuant to this Article 17 shall be
subject to all of the covenants, agreements, terms, provisions, and conditions contained in this Lease. Notwithstanding any such subletting to any other subtenant and/or acceptance of Rent by Landlord from any subtenant, Tenant shall remain liable
for the payment of the Base Rent and Additional Rent due and to become due hereunder and for the performance of all the covenants, agreements, terms, provisions, and conditions contained in this Lease on the part of Tenant to be performed and all
acts and omissions of any licensee or subtenant or anyone claiming under or through any subtenant which shall be in violation of any of the obligations of this Lease; and any such violation shall be deemed to be a violation by Tenant. Tenant further
agrees that notwithstanding any such subletting, no other and further subletting of the Premises by Tenant or any person or entity claiming through or under Tenant shall or will be made except upon compliance with and subject to the provisions of
this Article 17. If Landlord shall decline to give its consent to any proposed assignment or sublease, or if Landlord shall exercise its recapture right under § 17.3 above, Tenant shall indemnify, defend, protect, and hold Landlord
harmless against and from any and all Claims resulting from any Claims that may be made against Landlord by the proposed assignee or sublessee or by any brokers or other persons claiming a commission or similar compensation in connection with the
proposed assignment or sublease. 
 17.6 LAPSE OF CONSENT. In the event that Landlord consents to a
proposed Transfer described in the Transfer Notice and Tenant fails to execute and deliver the assignment or sublease described in the Transfer Notice to which Landlord consented within one hundred twenty (120) days after the giving of such
consent, then Tenant shall again comply with all of the provisions and conditions of § 17.2 above before assigning this Lease or subletting all or part of the Premises. 

17.7 TRANSFER DOCUMENTATION. With respect to each and every Transfer authorized by Landlord under the provisions of this
Lease, it is further agreed as follows: 
  

	 	(a)	no subletting shall be for a term ending later than one day prior to the Expiration Date of this Lease; 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 32 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(b)	no sublease shall be valid, and no subtenant shall take possession of the Premises or any part thereof, until an executed counterpart of such sublease has been delivered to Landlord; 

 

	 	(c)	each sublease shall provide that it is subject and subordinate to this Lease and to the matters to which this Lease is or shall be subordinate, and that in the event of termination (whether by voluntary surrender or
otherwise), re-entry, or dispossession by Landlord under this Lease, Landlord may, at its option, take over all of the right, title, and interest of Tenant, as sublessor, under such sublease, and such subtenant shall, at Landlord’s option,
attorn to Landlord pursuant to the then-executory provisions of such sublease, except that Landlord shall not be (i) liable for any previous act or omission of Tenant under such sublease;
(ii) subject to any offset, credit, or allowance not expressly provided in such sublease which theretofore accrued to such subtenant against Tenant or (iii) bound by any previous modification of such sublease or by any previous prepayment
of more than one month’s rentals; and 

  

	 	(d)	each assignment or sublease document must provide that the assignee or subtenant expressly assumes all obligations of the Tenant under the Lease as joint and several obligations without any release of Tenant.

 17.8 TRANSFER PREMIUM. If Landlord shall give its consent to any assignment of this Lease or to any
sublease, Tenant shall in consideration therefor pay to Landlord, as Additional Rent, the following amounts (collectively the “Transfer Premium”): 
  

	 	(a)	in the case of an assignment, an amount equal to seventy-five percent (75%) of all sums and other considerations paid to Tenant by the assignee for or by reason of such assignment, including sums paid for the sale
of Tenant’s Property, but excluding the following: (i) in the case of a sale of Tenant’s Property, the then-current net unamortized or undepreciated cost thereof determined on the basis of
Tenant’s federal income tax returns; (ii) then-customary brokerage commissions being paid by Landlord for leasing of space in the Building or, if less, the brokerage commission paid by Tenant in
connection with the assignment; (iii) reasonable legal fees and disbursements; and (iv) reasonable amounts paid by Tenant for tenant improvements constructed for the assignee; and 

 

	 	(b)	in the case of a sublease, seventy-five percent (75%) of any rents, additional charge, or other consideration payable under the sublease to Tenant by the subtenant which is in excess of the Base Rent and Additional
Rent accruing during the term of the sublease in respect of the subleased space (at the rate per square foot payable by Tenant hereunder) pursuant to the terms hereof, including sums paid for the sale or rental of Tenant’s Property, but
excluding the following: (i) in the case of the sale or lease of Tenant’s Property, the then-current net unamortized or undepreciated cost thereof determined on the basis of Tenant’s federal
income tax returns; (ii) then-customary brokerage commissions being paid by Landlord for leasing of space in the Building or, if less, the brokerage commission paid by Tenant in connection with the
sublease; (iii) reasonable legal fees and disbursements; and (iv) reasonable amounts paid by Tenant for tenant improvements constructed for the subtenant. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 33 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 The sums payable as the Transfer Premium under this § 17.8 shall be paid to Landlord as and when
payable by the subtenant or assignee to Tenant. 
 17.9 ASSUMPTION BY TRANSFEREE Any
Transfer, whether made with Landlord’s consent pursuant to § 17.1 or without Landlord’s consent pursuant to § 17.1.1, shall be made only if, and shall not be effective until, the assignee or subtenant shall execute,
acknowledge, and deliver to Landlord an agreement in form and substance satisfactory to Landlord under which the assignee or transferee shall assume the obligations of this Lease on the part of Tenant to be performed or observed, from and after the
date of Transfer, and whereby the assignee or transferee shall agree that the provisions in § 17.1 shall, notwithstanding such Transfer, continue to be binding upon it in respect of all future Transfers. The original named Tenant covenants
that, notwithstanding any Transfer, whether or not in violation of the provisions of this Lease, and notwithstanding the acceptance of Base Rent and/or Additional Rent by Landlord from an assignee, transferee, or any other party, the original named
Tenant shall remain fully liable for the payment of the Base Rent and Additional Rent and for the other obligations of this Lease on the part of Tenant to be performed or observed. 

17.10 NO WAIVER OR DISCHARGE. The joint and several liability of Tenant and any immediate
or remote successor in interest of Tenant and the due performance of the obligations of this Lease on Tenant’s part to be performed or observed shall not be discharged, released, or impaired in any respect by any agreement or stipulation made
by Landlord extending the time of, or modifying any of the obligations of, this Lease, or by any waiver or failure of Landlord to enforce any of the obligations of this Lease. 

17.11 LISTING OF NAME. The listing of any name other than that of Tenant, whether on the doors of the
Premises or the Building directory, or otherwise, shall not operate to vest any right or interest in this Lease or in the Premises, nor shall it be deemed to be the consent of Landlord to any Transfer of this Lease or to any sublease of the Premises
or to the use or occupancy of the Premises by others. 
 17.12 NET PROFITS AGREEMENT. Anything contained
in the foregoing provisions of this Article 17 to the contrary notwithstanding, neither Tenant nor any other person or entity having an interest in the possession, use, occupancy, or utilization of the Premises shall enter into any lease,
sublease, license, concession, or other agreement for use, occupancy, or utilization of space in the Premises which provides for rental or other payment for such use, occupancy, or utilization based, in whole or in part, on the net income or profits
derived by any person from the premises leased, used, occupied, or utilized (other than an amount based on a fixed percentage or percentages of receipts or sales); and any such purported lease, sublease, license, concession, or other agreement shall
be absolutely void and ineffective as a conveyance of any right or interest in the possession, use, occupancy, or utilization of any part of the Premises. 

17.13 AFFILIATES. Notwithstanding anything to the contrary in this Article 17, Landlord’s consent shall not be required in the
event Tenant desires to assign this Lease or sublet the Premises or any portion thereof to any corporation or entity which controls, is controlled by, or is under common control with Tenant, provided and subject to the following conditions: 

 

	 	(a)	Tenant shall not be in default of any of the terms, covenants, or conditions on Tenant’s part to observe or perform hereunder; 

  

	 	(b)	such sublet or assignment shall be subject to all of the terms, covenants, and conditions of this Lease; 

  

	 	(c)	Tenant shall notify Landlord of such sublet or assignment in accordance with § 17.2 hereof and furnish Landlord with reasonably satisfactory evidence that such sublessee or assignee controls, is controlled by,
or is under common control with Tenant; and 

  

	 	(d)	 in the event of such merger, consolidation, or transfer of substantially all of Tenant’s assets, the successor to Tenant has a net worth,
computed in accordance with generally-accepted accounting principles, at least equal to the greater of (i) the 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 34 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	
net worth of Tenant immediately prior to such merger, consolidation, or transfer or (ii) the net worth of Tenant herein named on the date of this Lease; and proof satisfactory to Landlord of
such net worth shall have been delivered to Landlord at least ten (10) days prior to the effective date of any such transaction. 

 As
used herein, the terms control and common control shall be deemed to mean that the ownership of fifty percent (50%) or more of all of the issued and outstanding voting shares of such corporation, or fifty percent (50%) or
more of all the legal and equitable interest in any such business entities. 
 17.14 PERMITTED OCCUPANTS. Landlord
hereby agrees that the provisions of this Article 17 shall not apply to the shared occupancy of individual offices in the Premises with Tenant by individuals renting not more than one (1) such office (the “Permitted Occupant”),
provided that the space occupied by the Permitted Occupant shall not be separately demised or contain separate entrances, demarcations, or reception areas and the occupancy by the Permitted Occupant shall be upon and subject to all of the terms and
conditions of this Lease. 
 18         SUBORDINATION AND ATTORNMENT 

18.1 SUBORDINATION OF LEASE. This Lease and all rights of Tenant hereunder are and shall be subject and
subordinate in all respects to (a) all ground leases, overriding leases, and underlying leases of the Building, Property, and/or the Complex now or hereafter existing; (b) all mortgages which may now or hereafter affect the Building,
Property, or Complex and any of such leases, whether or not such mortgages shall also cover other lands and/or buildings; (c) each and every advance made or hereafter to be made under such mortgages; and (d) to all renewals, modifications,
replacements, and extensions of such leases and such mortgages and spreaders and consolidations of such mortgages. This § 18.1 shall be self-operative, and no further instrument of subordination
shall be required. In confirmation of such subordination, Tenant shall promptly execute and deliver any instrument that Landlord, the lessor of any such lease or the holder (“Holder”) of any such mortgage or any of their respective
successors in interest may reasonably request to evidence such subordination. The leases to which this Lease is, at the time referred to, subject and subordinate pursuant to this Article 18 are hereinafter sometimes referred to as
“Superior Leases”; the mortgages to which this Lease is, at the time referred to, subject and subordinate are hereinafter sometimes referred to as “Superior Mortgages”; and the lessor of a superior lease or its successor in
interest at the time referred to is sometimes hereinafter referred to as a “Lessor.” Notwithstanding the foregoing, Tenant agrees, upon written request from Landlord or any Holder or Lessor, to reorder the relative priority of the Lease
with respect to any particular Superior Mortgage or Superior Lease so as to subordinate the lien of any such Superior Mortgage or Superior Lease to the Lease. Tenant agrees to execute any instrument which Landlord or any Holder or Lessor may present
in order to effect such prioritization of the Lease, provided that such instrument does not modify any material term of the Lease or increase Tenant’s obligations thereunder. 

18.2 NOTICE AND CURE RIGHT. In the event of any action or omission of Landlord which would
give Tenant the right, immediately or after lapse of a period of time, to cancel or terminate this Lease, or to claim a partial or total eviction, Tenant shall not exercise such right unless and until (i) Tenant shall have given written notice
of such act or omission to the Holder of each Superior Mortgage and the Lessor of each Superior Lease whose name and address shall previously have been furnished to Tenant in writing; and (ii) unless such act or omission shall be one which is
not capable of being remedied by Landlord or such mortgage Holder or Lessor within a reasonable period of time, a reasonable period for remedying such act or omission shall have elapsed following the giving of such notice and following the time when
such Holder or Lessor shall have become entitled under such Superior Mortgage or Superior Lease, as the case may be, to remedy the same (which reasonable period shall in no event be less than the period to which Landlord would be entitled under this
Lease or otherwise, after similar notice, to effect such remedy), provided such Holder or Lessor shall with due diligence give Tenant written notice of intention to remedy such act or omission and shall thereafter diligently and continuously
prosecute such cure to completion. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 35 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 18.3 ATTORNMENT. If the Lessor of a Superior Lease or the Holder of a Superior
Mortgage shall succeed to the rights of Landlord under this Lease, whether through possession or foreclosure action or delivery of a new lease or deed, then at the request of such party so succeeding to Landlord’s rights or other person having
or acquiring title by virtue of such foreclosure or termination (herein sometimes referred to as “Successor Landlord”) and upon such Successor Landlord’s written agreement to accept Tenant’s attornment, Tenant shall attorn to and
recognize such Successor Landlord as Tenant’s landlord under this Lease and shall promptly execute and deliver any instrument that such Successor Landlord may reasonably request to evidence such attornment. Upon such attornment this Lease shall
continue in full force and effect as a direct lease between the Successor Landlord and Tenant upon all of the terms, conditions, and covenants in this Lease, except as follows: 

 

	 	(a)	the Successor Landlord shall not be liable for any previous act or omission of Landlord under this Lease; 

  

	 	(b)	the Successor Landlord shall not be subject to any offset (unless expressly provided for in this Lease) which shall have theretofore accrued to Tenant against Landlord; 

 

	 	(c)	the Successor Landlord shall not be bound by any previous modification of this Lease, unless expressly provided for in this Lease, or by any previous prepayment of more than one month’s Base Rent, unless such
modification or prepayment shall have been expressly approved in writing by the Lessor of the Superior Lease or the Holder of the Superior Mortgage through or by reason of which the Successor Landlord shall have succeeded to the rights of Landlord
under this Lease. 

 19         FINANCING REQUIREMENTS 

19.1 LENDER-REQUESTED MODIFICATIONS. If, in connection with obtaining financing or refinancing for the
Property or Complex a prospective lender shall request reasonable modifications to this Lease as a condition to such financing or refinancing, Tenant shall not withhold, delay, or unreasonably condition its consent thereto. It is agreed that, among
the modifications which shall be deemed reasonable, are modifications to the subordination and attornment provisions of this Lease, modifications to the notice provisions of this Lease, modifications to the provisions of this Lease which permit the
lender to cure any defaults by Landlord, and modifications to the provisions which grant additional time to cure as may be reasonably required by the lender. 

19.2 FAILURE TO COMPLY. If Tenant fails or refuses to execute and deliver to Landlord, within
fifteen (15) days after written notice to do so, the amendment(s) to this Lease accomplishing such reasonable modification(s), Landlord, at its sole option, shall have the right either (a) to terminate this Lease or (b) to execute the
amendment for and on behalf of Tenant as its attorney-in-fact. Tenant hereby irrevocably appoints Landlord as its attorney-in-fact solely to execute any documents required to carry out the intent of § 19.1 above on behalf of Tenant. 

20         DEFAULT 

20.1 TENANT’S DEFAULT. Tenant’s failure to perform any of its obligations under this Lease when
due and in the manner required shall constitute a material breach and default (“Event of Default”) of this Lease by Tenant, subject to any cure period(s) permitted or available under applicable laws or statutes. In addition, the following
shall also be deemed Events of Default hereunder: 
  

	 	(a)	Tenant’s failure to take possession of the Premises for a period of sixty (60) days or longer after the Commencement Date; 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 36 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(b)	Tenant’s abandonment or vacation of the Premises; 

  

	 	(c)	any material misrepresentation or omission herein or in any financial statements or other materials provided by Tenant or any Guarantor in connection with negotiating or entering this Lease or in connection with any
Transfer under Article 17; 

  

	 	(d)	cancellation of any guaranty of this Lease by any Guarantor; 

  

	 	(e)	failure by Tenant to cure within any applicable times permitted thereunder any default under any other lease for space in the Complex or any other buildings owned or managed by Landlord or its affiliates now or
hereafter entered by Tenant; and any Default hereunder not cured within the times permitted for cure herein shall, at Landlord’s election, constitute a default under any other such lease or leases; 

 

	 	(f)	The levy of a writ of attachment or execution on this Lease or on any of Tenant’s property; 

  

	 	(g)	Tenant’s or any Guarantor’s general assignment for the benefit of creditors or arrangement, composition, extension, or adjustment with its creditors; 

 

	 	(h)	Tenant’s or any Guarantor’s filing of a voluntary petition for relief, or the filing of a petition against Tenant or any Guarantor in a proceeding under the Federal Bankruptcy laws or other insolvency laws
which is not withdrawn or dismissed within forty-five (45) days thereafter; or, under the provisions of any law providing for reorganization or winding up of corporations, the assumption by any court of competent jurisdiction of jurisdiction,
custody, or control of Tenant or any substantial part of its property, or of any Guarantor, where such jurisdiction, custody, or control remains in force unrelinquished, unstayed, or unterminated for a period of forty five (45) days;

  

	 	(i)	In any proceeding or action in which Tenant is a party, the appointment of a trustee, receiver, agent, or custodian to take charge of the Premises or Tenant’s Property for the purpose of enforcing a lien against
the Premises or Tenant’s Property; or 

  

	 	(j)	If Tenant or any Guarantor is a partnership or consists of more than one (1) person or entity, the involvement of any partner of the partnership or other person or entity in any of the acts or events described in
subsections (i) through (l) above. 

 20.2 LANDLORD’S REMEDIES. Upon the
occurrence of an Event of Default hereunder, Landlord shall have the right, in addition to any other rights or remedies Landlord may have under Laws, at Landlord’s option, without further notice or demand of any kind, to elect to do one of the
following alternatives: 
  

	 	(i)	Terminate this Lease and Tenant’s right to possession of the Premises, re-enter the Premises, and take possession thereof; and Tenant shall have no further claim to the Premises or under this Lease; or

  

	 	(ii)	Continue this Lease in effect and collect any unpaid Rent or other charges which have theretofore accrued or which thereafter become due and payable. It is intended hereunder that Landlord have the remedy described in
California Civil Code § 1951.4, which provides that a landlord may continue a lease in effect after a tenant’s breach and abandonment and recover rent as it becomes due, if tenant has the right to sublease or assign, subject only to
reasonable limitations. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 37 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 In the event of any re-entry or retaking of possession by Landlord, Landlord shall have the right, but not
the obligation, to remove all or any part of Tenant’s Property from the Premises and to place such property in storage at a public warehouse at the expense and risk of Tenant. 

20.2.1 No Waiver of Default. The waiver by Landlord of any Event of Default or of any other breach of any term, covenant, or condition
of this Lease shall not be deemed a waiver of such term, covenant, or condition or of any subsequent breach of the same or any other term, covenant, or condition. Acceptance of Rent by Landlord subsequent to any Event of Default or breach hereof
shall not be deemed a waiver of any preceding Event of Default or breach other than the failure to pay the particular Rent so accepted, regardless of Landlord’s knowledge of any breach at the time of such acceptance of Rent. Landlord shall not
be deemed to have waived any term, covenant, or condition of this Lease, unless Landlord gives Tenant written notice of such waiver. Tenant should not rely upon Landlord’s failure or delay in enforcing any right or remedy hereunder. 

20.2.2 Landlord’s Right to Cure. If Tenant defaults in the performance of any of its obligations under this Lease, Landlord may
(but shall not be obligated to), without waiving such default, perform the same for the account and at the expense of Tenant. Tenant shall pay Landlord all costs of such performance promptly upon receipt of a bill therefor. 

20.3 DAMAGES. Should Landlord elect to terminate this Lease under the provisions of § 20.2 (i) above, Landlord may
recover as damages from Tenant the following: 
  

	 	(a)	Past Rent: The worth at the time of the award of any unpaid Rent which had been earned at the time of termination; plus 

 

	 	(b)	Rent Prior to Award: The worth at the time of the award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such
rental loss that Tenant proves could have been reasonably avoided; plus 

  

	 	(c)	Rent After Award: The worth at the time of the award of the amount by which the unpaid Rent for the balance of the Term after the time of award exceeds the amount of the rental loss that Tenant
proves could have been reasonably avoided; plus 

  

	 	(d)	Proximately Caused Damages: Any other amount necessary to compensate Landlord for all detriment proximately caused by Tenant’s failure to perform its obligations under this Lease or which in
the ordinary course of things would be likely to result therefrom, including, but not limited to, any costs or expenses (including attorneys’ fees), incurred by Landlord in (i) retaking possession of the Premises; (ii) maintaining the
Premises after Tenant’s default; (iii) preparing the Premises for reletting to a new tenant, including any repairs or alterations; and (iv) reletting the Premises, including brokers’ commissions. 

“The worth at the time of the award” as used in subsections (a) and (b) above is to be computed by allowing interest at the rate of ten
percent (10%) per annum or, if different, the legal rate then applicable in California. “The worth at the time of the award” as used in subsection (c) above is to be computed by discounting the amount at the discount rate of the
Federal Reserve Bank situated nearest to the Premises at the time of the award plus one percent (1%). 
 20.4
LANDLORD’S DEFAULT. If Landlord fails to perform any covenant, condition, or agreement contained in this Lease within thirty (30) days after receipt of written notice from Tenant specifying
a default and the relevant Lease provision, or if Landlord fails within that thirty-day period after notice to commence to cure any such default which cannot reasonably be cured within thirty (30) days, then, subject to § 21.1 below,
Landlord shall be liable to Tenant for any damages sustained by Tenant as a result 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 38 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 
of Landlord’s breach. Tenant shall not have the right to terminate this Lease or to withhold, reduce, or offset any amount against any payments of Rent or any other charges due and payable
under this Lease, except to the extent that a specific Lease provision permits such termination or withholding, reduction, or offset of Rent. 
 20.5
HOLDER’S RIGHT TO CURE. Tenant shall give any Holder a copy, by registered mail, of any notice of default served upon Landlord, provided that Tenant previously has
been notified in writing of the address of such Holder. If Landlord fails to cure such default within the time provided in this Lease, any such Holder shall have an additional forty-five (45) days within which to cure such default by Landlord
or, if such default cannot reasonably be cured within that time, such additional time as may be necessary, provided that within such forty-five (45) day period the Holder has commenced and is pursuing the remedies necessary to cure such default
(including commencement of foreclosure proceedings, if necessary to effect such cure), in which event this Lease shall not be terminated while such remedies are being so pursued. 

20.6 SURVIVAL OF REMEDIES. The remedies permitted under this Article 20, the parties’
indemnities under §§ 14.4.3, 14.4.4, and14.4.5, and § 29.5 below shall survive the termination of this Lease. 

21         LIMITATIONS ON LANDLORD’S LIABILITY 

21.1 PERSONAL LIABILITY. The liability of Landlord to Tenant for any default by Landlord under this Lease or arising in
connection herewith or with Landlord’s operation, management, leasing, repair, renovation, alteration, or any other matter relating to the Property or the Premises shall be limited to the interest of Landlord in the Property (and the rental
proceeds thereof). Under no circumstances shall Landlord ever be liable for consequential or punitive damages, including damages for lost profits or for business interruption. Tenant agrees to look solely to Landlord’s interest in the Property
(and the rental proceeds thereof) for the recovery of any judgement against Landlord, and Landlord shall not be personally liable for any such judgement or deficiency after execution thereon. The limitations of liability contained in this
Article 21 shall apply equally and inure to the benefit of Landlord’s present and future partners, beneficiaries, officers, directors, trustees, shareholders, agents, and employees, and their respective partners, heirs, successors, and
assigns. Under no circumstances shall any present or future general or limited partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner of Landlord is a trust) or corporate officer, director, or
shareholder (if Landlord or any partner of Landlord is a corporation or company) or member (if Landlord is a limited liability company) have any liability for the performance of Landlord’s obligations under this Lease. 

21.2 LIABILITY UPON TRANSFER. The term Landlord as used in this Lease, so far as covenants or
obligations on the part of the Landlord are concerned, shall be limited to mean and include only the owner or owners, at the time in question, of the fee title to, or a lessee’s interest in a ground lease or master lease of the Property. In the
event of any transfer, assignment, or other conveyance or transfer of any such title or interest, Landlord herein named (and in case of subsequent transfers or conveyances, the current grantor) shall be automatically freed and relieved from and
after the date of such transfer, assignment, or conveyance of all liability with respect to the performance of any covenants or obligations on the part of Landlord contained in this Lease thereafter to be performed; and, without further agreement,
the transferee of such title or interest shall be deemed to have assumed and agreed to observe and perform any and all obligations of Landlord hereunder, during its ownership of the Premises. Landlord may transfer its interest in the Premises
without the consent of Tenant, and such transfer or subsequent transfer shall not be deemed a violation on Landlord’s part of any of the terms and conditions of this Lease. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 39 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 22         ESTOPPEL CERTIFICATES 

22.1 REQUEST AND DELIVERY. Within ten (10) days following any written request Landlord may make from
time to time, Tenant without any charge therefor, shall execute, acknowledge, and deliver a statement certifying the following: (a) the Commencement Date of this Lease; (b) the fact that this Lease is unmodified and in full force and
effect or, if there have been modifications hereto, that this Lease is in full force and effect, as modified, and stating the date and nature of such modifications; (c) the date to which the Rent and other sums payable under this Lease have
been paid; (d) the fact that there are no current defaults under this Lease by either Landlord or Tenant except as specified in the statement; and (e) such other matters as may be reasonably requested by Landlord. Landlord and Tenant
intend that any statement delivered pursuant to this Article 22 may be relied upon by any Holder, Lessor, beneficiary, purchaser, or prospective purchaser of the Building, the Complex, or any interest therein. Tenant’s failure to deliver
any such statement within the specified ten-day period shall constitute a material default hereunder, and Tenant shall indemnify, defend, protect, and hold Landlord harmless from and against any and all Claims
which Landlord may sustain or incur as a result of or in connection with Tenant’s failure or delay in delivering such statement. 
 22.2
ELECTION TO SELL BUILDING. If Landlord elects to sell the Building or to obtain loans secured by a lien on the Building, Tenant, promptly after demand, shall include with the estoppel
certificate(s) provided to any prospective purchaser or lender as required under this Article 22 any financial statements of Tenant reasonably required by the purchaser or lender. The financial statements so provided shall be kept confidential
as to any parties other than the purchaser or lender. 
 23         NOTICES 

23.1 MANNER OF DELIVERY. Any notice required or permitted under this Lease shall be in writing and shall
be delivered in at least one of the following ways: (a) personally or by private hand-delivery messenger service; (b) by depositing the same in the United States mail, postage prepaid, registered or
certified, return receipt requested; (c) by depositing such notice, postage prepaid, with Federal Express or another nationally-recognized private overnight delivery service; or (d)by any other means
permitted or required by applicable California law or statutes relevant in the context in which such notice is given. Each such notice shall be addressed to the intended recipient at such party’s address set forth as follows, or at such other
address as such party has theretofore specified by written notice delivered in accordance with this § 23.1: 
 if to Landlord:

 KASHIWA FUDOSAN AMERICA, INC. 

c/o Cushman & Wakefield of California, Inc. 

Attn: Property Manager 
 400 Oyster
Point Boulevard, Suite 117 
 South San Francisco, CA 94080 

copy to: 
 Colliers
International, Agent 
 Attn: Oyster Point Asset Manager 

3 Park Plaza, Suite 1200 
 Irvine,
CA 92614 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 40 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 if to Tenant: 

SUNESIS PHARMACEUTICALS, INC. 

Attn: General Manager 

395 Oyster Point Boulevard, Suite 400 

South San Francisco, CA 94080 
 23.2
REQUIRED CONTENTS. Every notice (other than the giving or withholding of consent or approval under the provisions of the Lease) given to a party shall state the section of the Lease pursuant to which the notice is
given; the period of time within which the recipient of the notice must respond (or, if no response is required, a statement to that effect); and if applicable, that the failure to object to the notice within the stated time period will be deemed to
be the equivalent of the recipient’s approval, consent to, or satisfaction with the subject matter of the notice. 
 23.3 PRESUMPTION
OF RECEIPT. Any notice delivered personally or by private messenger service shall be deemed delivered on the next day following the deposit of such notice at the recipient’s address. Any notice delivered by
Federal Express or another nationally-recognized private overnight delivery service shall be deemed delivered on the earlier of (y) the second day following deposit thereof with the carrier or
(z) the delivery date shown on the carrier’s record of delivery. Any notice delivered by mail in the manner specified in § 23.1 shall be deemed delivered on the earlier of (a) the third day following deposit thereof in the
United States Mail or (b) the delivery date shown on the return receipt prepared in connection therewith. Refusal by Tenant or Landlord to accept either certified or registered mail shall constitute a waiver of such notice by the respective
party. 
 24         BROKERS 

24.1 TENANT’S REPRESENTATION. Tenant represents and warrants to Landlord that Tenant has dealt with
no broker in connection with this Lease other than Cresa Partners and Cushman & Wakefield of California, Inc. Tenant shall be responsible for all foreseeable consequences of damages (including attorneys’ fees and costs)
resulting from any claims that may be asserted against Landlord by any other broker, finder, or other person with whom Tenant has or purportedly has dealt in connection with this Lease, and Tenant agrees to indemnify, defend, protect, and hold
Landlord harmless in connection with any such Claims which may be asserted. 
 25         RIGHTS
RESERVED TO LANDLORD 
 25.1 ACCESS TO PROPERTY. All of the Property except the inside surfaces of
all walls, windows, and doors bounding the Premises (including exterior Building walls, core corridor walls and doors, and any core corridor entrance) and any space in or adjacent to the Premises used for shafts, stacks, pipes, conduits, fan rooms,
ducts, electric, or other utilities, sinks or other Building facilities, and the use thereof, as well as access thereto through the Premises for the purpose of operation, maintenance, decoration, and repair, are reserved to Landlord. Tenant shall
permit Landlord to install, use, replace, and maintain pipes, ducts, and conduits within the demising walls, bearing columns, and ceilings of the Premises. 

25.2 CONTROL OF PROPERTY. Except to the extent expressly limited herein, Landlord reserves full rights to
control the Property (which rights may be exercised without subjecting Landlord to claims for constructive eviction, abatement of Rent, damages, or other claims of any kind), including more particularly the following rights: 

 

	 	(a)	Name, Address, Access. To change the name or street address of the Property; install and maintain signs on the exterior and interior of the Property; retain at all times, and use in appropriate instances, keys to
all doors within and into the Premises; grant to any Person the right to conduct any business or render any service at the Property, whether or not it is the same or similar to the use permitted Tenant by this Lease; and have access for Landlord and
other tenants of the Property to any mail chutes located on the Premises according to the rules of the United States Postal Service. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 41 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(b)	Entry into Premises. To enter the Premises at reasonable hours for reasonable purposes, including inspection and supplying cleaning service or other services to be provided Tenant hereunder, to show the Premises
to current and prospective lenders, ground lessors, insurers, and prospective purchasers, tenants and brokers, at reasonable hours; and if Tenant shall abandon the Premises at any time, or shall vacate the same during the last three (3) months
of the Term, to decorate, remodel, repair, or alter the Premises. 

  

	 	(c)	Safety Measures. To limit or prevent access to the Property, shut down elevator service, activate elevator emergency controls, or otherwise take such action or preventative measures deemed necessary by Landlord
for the safety of tenants or other occupants of the Property or the protection of the Property and other property located thereon or therein, in case of fire, invasion, insurrection, riot, civil disorder, public excitement or other dangerous
condition, or threat thereof. 

  

	 	(d)	Improvements. To decorate and to make alterations, additions and improvements, structural or otherwise, in or to the Property or any part thereof, and any adjacent building, structure, parking facility, land,
street or alley (including changes and reductions in corridors, lobbies, parking facilities and other public areas and the installation of kiosks, planters, sculptures, displays, escalators, mezzanines, and other structures, facilities, amenities
and features therein, and changes for the purpose of connection with or entrance into or use of the Property in conjunction with any adjoining or adjacent building or buildings, now existing or hereafter constructed). In connection with such
matters, or with any other repairs, maintenance, improvements or alterations, in or about the Property, Landlord may erect scaffolding and other structures reasonably required, and during such operations may enter upon the Premises and take into and
upon or through the Premises, all materials required to make such repairs, maintenance, alterations or improvements, and may close public entry ways, other public areas, restrooms, stairways or corridors. 

25.3 LANDLORD’S RIGHT TO MAINTAIN. Except as expressly otherwise
provided in this Lease, Landlord shall have no liability to Tenant by reason of any inconvenience, annoyance, interruption, or injury to business arising from Landlord’s making any repairs or changes which Landlord is required or permitted to
make by this Lease, by any other lease or agreement affecting the Property, or by Law, in or to any portion of the Property, Complex, or the Premises, including the Systems and Equipment and appurtenances of the Property or the Premises, provided
that Landlord shall use due diligence with respect thereto and shall perform such work, except in case of emergency, at times reasonably convenient to Tenant and otherwise in such manner as will not materially diminish Tenant’s beneficial
enjoyment of the Premises for their intended use. 
 25.4 REASONABLE NOTICE. In connection with entering the Premises
to exercise any of the foregoing rights, Landlord shall: (a) provide reasonable advance written or oral notice to Tenant’s on-site manager or other appropriate person (except in emergencies, or for
routine cleaning or other routine matters), and (b) take reasonable steps to avoid any unreasonable interference with Tenant’s business. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 42 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 26         BUILDING PLANNING 

26.1 RELOCATION RIGHT. In the event Landlord requires the Premises for use in conjunction with another suite or for other
reasons connected with Landlord’s planning program for the Building, upon notifying Tenant in writing, Landlord shall have the right to move Tenant to other space in the Building or in the Complex, provided such space is not more than ten
percent (10%) larger than the Premises. If Landlord elects to move Tenant to such other space, Landlord shall pay for (a) all direct, out-of-pocket, reasonable
expenses of Tenant in moving from the Premises to the new space and (b) the cost of improving the new space so that the level of improvements in the new space is comparable to the level of improvements in the Premises. All the terms and
conditions of the original Lease shall remain in full force and effect, except that (i) a revised Exhibit B shall become a part of this Lease and shall reflect the location of the new space; and (ii) Tenant agrees to execute promptly
upon notice from Landlord an amendment to this Lease amending the Table and corresponding sections of the Lease in order to reflect all correct data for the new space. 

27         HOLDING OVER 

27.1 HOLDOVER. Unless Landlord expressly agrees otherwise in writing, Tenant shall pay Landlord two hundred percent (200%) of the
amount of Rent then applicable prorated on per diem basis for each day Tenant shall retain possession of the Premises or any part thereof after expiration of the Term or earlier termination of this Lease, together with all damages sustained by
Landlord on account thereof. In the case of any such holdover, the Lease shall be converted to a month-to-month tenancy which either party may terminate upon written
notice of not less than thirty (30) days to the other. Tenant shall remain bound to comply with all provisions of this Lease until Tenant vacates the Premises and shall be subject to the provisions of § 11.1 above. 

27.2 PERMISSIVE MONTH-TO-MONTH
TENANCY. Notwithstanding the foregoing to the contrary, at any time before or after expiration or earlier termination of the Term of the Lease, Landlord may serve notice advising Tenant of the amount of Rent and other terms
required, should Tenant desire to enter a month-to-month tenancy. If Tenant shall hold over more than one full calendar month after such notice, Tenant shall thereafter be deemed a
month-to-month tenant, on the terms and provisions of this Lease then in effect, as modified by Landlord’s notice, except that Tenant shall not be entitled to any
renewal or expansion rights contained in this Lease or any amendments hereto. 
 28        
PARKING 
 28.1 AVAILABLE PARKING. Subject to the terms and conditions contained in the balance of this
Article 28, Landlord agrees to make available to Tenant during the Term of this Lease and any renewal term up to a maximum of fifty-four (54) parking spaces on a non-exclusive basis in the area(s) designated by Landlord for parking in the
Building’s parking lots and/or facility (the “Parking Facility”). Said parking spaces shall be in locations designated by Landlord, and parking shall be on a first-come-first-served, unassigned, nonreserved basis. Landlord reserves the right to designate different locations or different parking areas for Tenant’s use without any liability to Tenant and
Tenant agrees that any change shall not give rise to any claims or offset against Landlord hereunder. Tenant shall abide by any and all parking regulations and rules established from time to time by Landlord or Landlord’s parking operator.
Landlord reserves the right in its sole and absolute discretion to restrict or prohibit the use of the Parking Facility for any vehicles other than passenger automobiles, such as full-sized vans or trucks.
Tenant shall not permit any vehicles belonging to Tenant or Tenant’s employees, agents, customers, contractors, or invitees to be loaded, unloaded, or parked in areas other than those designated by Landlord for such activities. A failure to
comply with the foregoing provisions shall afford Landlord the right without notice to remove any vehicles involved and to charge the cost to Tenant, which cost shall be immediately due and payable upon demand by Landlord. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 43 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 28.2 USE AT TENANT’S OWN
RISK. Landlord shall have no obligation to monitor the use of the Parking Facility. Tenant’s and its employees’ use of the Parking Facility shall be at the sole risk of Tenant and its employees. Unless caused by the
willful harmful act of Landlord, Landlord shall have no responsibility or liability for any injury or damage to any person or property by or as a result of the use of the Parking Facility (or substitute parking) by Tenant and its employees, whether
by theft, collision, criminal activity, or otherwise, and Tenant hereby assumes, for itself and its employees, all risks associated with any such occurrences in or about the Parking Facility. 

29         MISCELLANEOUS PROVISIONS. 

29.1 GENERAL DEFINITIONS. The definitions which follow shall apply generally to the provisions of this Lease. 

 

	 	(a)	The term business days means Monday through Friday inclusive, excluding Holidays as defined in § 8.1.1 above. Throughout this Lease, wherever days is used the term shall refer to calendar
days. Wherever the term business days is used the term shall refer to business days as defined hereunder. 

  

	 	(b)	The term mortgage shall include any mortgage or deed of trust, and the term mortgagee shall include a trustee. 

 

	 	(c)	The terms include, including, and such as shall each be construed as if followed by the phrase “without limitation.” The rule of eiusdem generis shall not be
applicable to limit a general statement following or referrable to an enumeration of specific matters to matters similar to the matters specifically mentioned. 

  

	 	(d)	The term obligations under this Lease and words of like import shall mean the covenants to pay Rent and Additional Rent under this Lease and all of the other covenants and conditions contained in this
Lease. Any provision in this Lease that one party or the other or both shall do or not do or shall cause or permit or not cause or permit a particular act, condition, or circumstance shall be deemed to mean that such party so covenants or both
parties so covenant, as the case may be. 

  

	 	(e)	The term Tenant’s obligations hereunder and words of like import and the term Landlord’s obligations hereunder and words of like import shall mean the obligations under this Lease
which are to be performed or observed by Tenant, or by Landlord, as the case may be. Reference to performance of either party’s obligations under this Lease shall be construed as “performance and observance.”

  

	 	(f)	Reference to Tenant being or not being in default hereunder or words like import shall mean that Tenant is in default in the performance of one or more of Tenant’s obligations hereunder, or that
Tenant is not in default in the performance of any of Tenant’s obligations hereunder, or that a condition of the character described in § 20.1 above has occurred and continues or has not occurred or does not continue, as the case may
be. 

  

	 	(g)	References to Landlord as having no liability to Tenant or being without liability to Tenant shall mean that Tenant is not entitled to terminate this Lease or to claim actual or constructive
eviction, partial or total, or to receive any credit, allowance, setoff, abatement, or diminution of Rent, or to be relieved in any manner of any of its other obligations hereunder, or to be compensated for loss or injury suffered or to enforce any
other kind of liability whatsoever against Landlord under or with respect to this Lease or with respect to Tenant’s use or occupancy of the Premises. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 44 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

	 	(h)	The term requirements of insurance bodies and words of like import shall mean rules, regulations, orders, and other requirements of the California Board of Fire Underwriters and/or the California Fire
Insurance Rating Organization and/or any other similar body performing the same or similar functions and having jurisdiction or cognizance of the Property and/or the Premises. 

 

	 	(i)	The term repair shall be deemed to include restoration and replacement as may be necessary to achieve and/or maintain good working order and condition. 

 

	 	(j)	Reference to termination of this Lease includes expiration or earlier termination of the Term of this Lease or cancellation of this Lease pursuant to any of the provisions of this Lease or to Law. Upon a
termination of this Lease, the Term and estate granted by this Lease shall end at noon of the date of termination as if such date were the date of expiration of the Term of this Lease, and neither party shall have any further obligation or liability
to the other after such termination, except as shall be expressly provided for in this Lease and except for any such obligation as by its nature or under the circumstances can only be, or by the provisions of this Lease may be, performed after such
termination; and in any event, unless expressly provided to the contrary in this Lease, any liability for a payment or obligation which shall have accrued to or with respect to any period ending at the time of termination shall survive the
termination of this Lease. 

  

	 	(k)	The term in full force and effect when herein used in reference to this Lease as a condition to the existence or exercise of a right on the part of Tenant shall be construed in each instance as including
the further condition that at the time in question no default on the part of Tenant exists, and no event has occurred which has continued to exist for such period of time (after the notice, if any, required by this Lease), as would entitle Landlord
to terminate this Lease or to dispossess Tenant. 

  

	 	(l)	The term Tenant shall mean Tenant herein named or any assignee, heir, distributee, executor, administrator, legal representative, or other successor in interest (immediate or remote) of Tenant herein
named, while such Tenant or such assignee or other successor in interest, as the case may be, is in possession of the Premises as owner of the Tenant’s estate and interest granted by this Lease and also, if Tenant is not a single individual or
a corporation, all of the persons, firms, and corporations then comprising Tenant; and their liability hereunder shall be joint and several. 

29.2 LIGHT AND AIR. No diminution of light, air or view by any structure which may hereafter be erected
(whether or not by Landlord) shall entitle Tenant to any reduction of Rent under this Lease, result in any liability of Landlord to Tenant, or in any other way affect this Lease. 

29.3 WAIVER OF TERMS. If either Landlord or Tenant waives the performance of any term, covenant, or
condition contained in this Lease, such waiver shall not be deemed to be a waiver of the term, covenant, or condition itself or a waiver of any subsequent breach of the same or any other term, covenant, or condition contained herein. Furthermore,
the acceptance of Rent by Landlord shall not constitute a waiver of any preceding breach by Tenant of any term, covenant, or condition of this Lease, regardless of Landlord’s knowledge of such preceding breach at the time Landlord accepts such
Rent. Failure by Landlord to enforce any of the terms, covenants, or conditions of this Lease for any length of time shall not be deemed to waive or to decrease the right of Landlord to insist thereafter upon strict performance by Tenant. Waiver by
Landlord of any term, covenant, or condition contained in this Lease may only be made by a written document signed by Landlord. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 45 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 29.4 FAILURE TO DELIVER STATEMENTS.
Landlord’s failure during the Term of this Lease to prepare and deliver any of the Statements, estimates, notices, or bills contemplated or required under this Lease, or Landlord’s failure to make a demand, shall not in any way cause
Landlord to forfeit or surrender its rights to collect any of the foregoing items of Rent which may have become due during the Term of this Lease. 

29.5 ATTORNEY’S FEES. In the event that any action or proceeding (including arbitration) is brought
to enforce or interpret any term, covenant, or condition of this Lease on the part of Landlord or Tenant, the prevailing party in such action or proceeding (whether after trial or upon appeal) shall be entitled to recover from the party not
prevailing its expenses therein, including reasonable attorneys’ fees and all allowable costs as fixed by the court. 
 29.6 JURY
TRIAL. Tenant and Landlord each hereby waive their respective rights to a trial by jury under applicable Laws in the event of any litigation or dispute between Landlord and Tenant arising out of or in connection with this Lease
and the parties’ performance thereunder. 
 29.7 MERGER. Notwithstanding the acquisition (if same should occur) by the same party
of the title and interests of both Landlord and Tenant under this Lease, there shall never be a merger of the estates of Landlord and Tenant under this Lease, but instead the separate estates, rights, duties, and obligations of Landlord and Tenant,
as existing hereunder, shall remain unextinguished and continue, separately, in full force and effect until this Lease expires or otherwise terminates in accordance with the express provisions herein contained. 

29.8 NO MERGER ON VOLUNTARY SURRENDER. A voluntary or other surrender of
this Lease by Tenant or the mutual cancellation of this Lease shall not work a merger and shall, at the option of Landlord, terminate all or any existing subleases or subtenancies, or may, at the option of Landlord, operate as an assignment to it of
any or all such subleases or subtenancies. 
 29.9 CONSENT. Notwithstanding anything contained in this Lease to the contrary, Tenant
shall have no claim and hereby waives the right to any claim against Landlord for money damages by reason of any refusal, withholding, or delaying by Landlord of any consent, approval, statement, or satisfaction; and in such event, Tenant’s
only remedies therefor shall be an action for specific performance, injunction, or declaratory judgement to enforce any right to such consent, approval, statement, or satisfaction. 

29.10 COUNTERPARTS. This Lease may be executed in multiple counterparts, each of which shall be deemed an original and all of which
together shall constitute one and the same instrument. 
 29.11 FINANCIAL STATEMENTS. In order to induce Landlord to
enter into this Lease, Tenant agrees that it shall promptly furnish Landlord, from time to time, upon Landlord’s written request, with financial statements reflecting Tenant’s current financial condition. Tenant represents and warrants
that all financial statements, records, and information furnished by Tenant to Landlord in connection with this Lease are and shall be true, correct, and complete in all respects. 

29.12 GENDER AND NUMBER. Words used in neuter gender include the feminine and masculine, where applicable,
and words used in the singular or plural shall include the opposite number if appropriate. 
 29.13 JOINT AND
SEVERAL OBLIGATION. If more than one person executes this Lease as Tenant, each of them is jointly and severally liable for the keeping, observing, and performing of all of the terms, covenants, conditions,
provisions, and agreements of this Lease to be kept, observed, and performed by Tenant. The term Tenant as used in this Lease shall mean and include each of such signatories jointly and severally. The act of or notice from, or notice or
refund to, or the signature of, any one or more of such signatories with respect to the tenancy or this Lease, including any renewal, extension, expiration, termination, or modification of this Lease, shall be binding upon each and all of the
persons executing this Lease as Tenant with the same force and effect as if each and all of them had so acted or so given or received such notice or refund or so signed. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 46 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 29.14 HEADINGS AND SECTION NUMBERS. The
headings and titles of the articles and sections of this Lease are used for convenience only and shall have no effect upon the construction or interpretation of this Lease. Wherever a reference is made in this Lease to a particular article or
section, such reference shall be deemed to include all subsections following such section reference, unless the contrary is expressly provided in connection with such reference. All references in this Lease to numbered articles, numbered sections,
and lettered exhibits are references to articles and sections of this Lease and exhibits annexed to (and thereby made part of) this Lease, as the case may be, unless expressly otherwise designated in the context. 

29.15 TIME. Time is of the essence of this Lease and all of its provisions. 

29.16 APPLICABLE LAW. This Lease shall in all respects be governed by and interpreted in accordance with the laws of the
State of California without reference to its conflicts of law principles. If suit is brought by a party to this Lease, the parties agree that jurisdiction of such action shall be vested exclusively in the state courts of the State of California,
County of San Mateo, or in the United States District Court for the Northern District of California, and with its execution an delivery of this Lease Tenant waives any defense it might otherwise have against the jurisdiction of such courts. 

29.17 SEVERABILITY. If any provision of this Lease or the application thereof to any person or circumstance shall be invalid or
unenforceable to any extent, the remainder of this Lease and the application of such provision to other persons or circumstances shall not be affected thereby and shall be enforced to the greatest extent permitted by law. 

29.18 SIGNS. Tenant shall not place or permit to be placed in or upon the Premises where visible from outside the Premises or any part
of the Building, any signs, notices, drapes, shutters, blinds or window coatings, or displays of any type without the prior written consent of Landlord. Landlord shall consent to the location at the cost of Tenant of a building standard sign on or
near the entrance of the Premises and shall include Tenant in the Building and Complex directories located in the Building. Landlord reserves the right in Landlord’s sole discretion to place and locate on the roof and exterior of the Building
and Complex and in any area of the Building and the Complex not leased to Tenant, such signs, notices, displays and similar items as Landlord deems appropriate in the proper operation of the Building and the Complex. 

29.19 EXECUTION BY LANDLORD. The submission of this document for examination and negotiation does not
constitute an offer to lease, or a reservation of, or option for, the Premises. This document becomes effective and binding only upon execution and delivery hereof by Tenant and by Landlord. No act or omission of any employee or agent of Landlord or
of Landlord’s broker shall alter, change or modify any of the provisions hereof. 
 29.20 USE OF
NAME. Tenant shall not use the name of the Building or Complex for any purpose other than the address of the business to be conducted by Tenant in the Premises. Tenant shall not use any picture of the Building or Complex in its
advertising, stationery or in any other manner so as to imply that the entire Building or Complex is leased by Tenant. Landlord expressly reserves the right at any time to change the name or street address of the Building and/or Complex without in
any manner being liable to Tenant therefor. 
 29.21 NONRECORDABILITY OF LEASE. Tenant agrees that in no
event shall this Lease or a memorandum hereof be recorded without Landlord’s express prior written consent, which consent Landlord may withhold in its sole discretion. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 47 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 29.22 CONSTRUCTION. All provisions hereof, whether covenants or conditions, shall be
deemed to be both covenants and conditions. The definitions contained in this Lease, shall be used to interpret the Lease. All rights and remedies of Landlord and Tenant shall, except as otherwise expressly provided, be cumulative and non-exclusive
of any other remedy at law or in equity. 
 29.23 FORCE MAJEURE DELAYS. This Lease and the obligations
of Tenant hereunder shall not be affected or impaired because Landlord is unable to fulfill any of its obligations hereunder or is delayed in doing so, if such inability or delay is caused by reason of force majeure, strike, labor troubles, acts of
God, acts of government, unavailability of materials or labor, or any other cause beyond the reasonable control of Landlord (collectively “Force Majeure Delays”). 

29.24 AUTHORITY. If Tenant is a corporation, each individual executing this Lease on behalf of Tenant represents and warrants that
Tenant is qualified to do business in California and that he is duly authorized to execute and deliver this Lease on behalf of Tenant and shall deliver appropriate certification to that effect if requested. If Tenant is a limited liability company,
partnership, joint venture, or other unincorporated association, each individual executing this Lease on behalf of Tenant represents and warrants that he is duly authorized to execute and deliver this Lease on behalf of Tenant and that this Lease is
binding on Tenant. Furthermore, Tenant agrees that the execution of any written consent hereunder, or any written modification or termination of this Lease, by any general partner or member of Tenant or any other authorized agent of Tenant, shall be
binding on Tenant. 
 29.25 NONDISCLOSURE. Tenant agrees that it shall not disclose any of the matters set forth in this Lease or
disseminate or distribute any information concerning the terms, covenants, or conditions thereof to any person, firm, or entity, other than a prospective assignee or subtenant of the Premises, without first obtaining the express written approval of
Landlord; provided, however, that Tenant may disclose the contents of this Lease to any director, officer, or employee of Tenant, to Tenant’s lawyers, accountants, or other third party consultants or professionals, to any lenders, investors, or
others to whom Tenant provides financial statements, or in response to any legally effective demand for disclosure pursuant to court order or from any other properly constituted legal authority. 

29.26 QUIET ENJOYMENT. So long as Tenant is not in default under this Lease, Tenant shall have quiet enjoyment of the
Premises for the Term, subject to all the terms and conditions of this Lease and all liens and encumbrances prior to this Lease. 
 29.27
ACCESS INSPECTION DISCLOSURE. Pursuant to California Civil Code § 1938, Landlord hereby notifies Tenant that, as of the date of this Lease, the Premises have not undergone inspection by a
“Certified Access Specialist” to determine whether the Premises meet all applicable construction-related accessibility standards under California Civil Code § 55.53, and the Premises have
not been determined to meet all applicable construction-related accessibility standards pursuant to Civil Code § 55.53. 
 29.28
EXHIBITS AND ATTACHMENTS. All exhibits and attachments referred to in the body of this Lease are deemed attached hereto and incorporated herein by reference. The parties have attached the following
exhibits to the Lease prior to execution: 
  

			
	Exhibit A	  	Site Plan
	Exhibit B	  	Floor Plan of Premises
	Exhibit C	  	Rules and Regulations
	Exhibit D	  	Athletic Facility Use Agreement
	Exhibit E	  	Commencement Date Agreement

 29.29 LANDLORD’S REPRESENTATIVE. Tenant acknowledges and agrees
that, in executing this Lease, TAK Development, Inc., a California corporation, is acting solely in its capacity as Landlord’s authorized attorney-in-fact. TAK Development, Inc. is not acquiring or assuming any legal liability or obligation to
any other party executing this Lease, and any claim or demand of any such other party arising under or with respect to this Lease shall be made and enforced solely against Landlord. 

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 48 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 29.30 ENTIRE AGREEMENT. This Lease, together with its exhibits,
contains all the agreements of the parties hereto and supersedes any previous negotiations. There have been no representations made by the Landlord or understandings made between the parties other than those set forth in this Lease and its exhibits.
This Lease may not be modified except by a written instrument duly executed by the parties hereto. 
 In witness whereof, the parties have
executed this Lease as of the date first above written. 
  

											
	Landlord:	  		  	Tenant:
			
	KASHIWA FUDOSAN AMERICA, INC., a California corporation	  		  	SUNESIS PHARMACEUTICALS, INC., a Delaware corporation
					
	    By:	 	TAK Development, Inc., a California corporation	  		  	        By:	 	 /s/ Eric Bjerkholt

Eric Bjerkholt

	    Its:	 	Attorney-in-Fact	  		  		 	 [name typed]

						
		 	By:	 	 /s/ Yujin Yumaai
	  		  	        Its:	 	EVP Corp Dev and Finance, CFO
		 		 	Yujin Yumaai, Vice President	  		  		 	

  

  

					
		 	 Oyster Point Marina Plaza Office Lease

Kashiwa Fudosan America, Inc. :: Sunesis Pharmaceuticals, Inc.

page 49 of 49
  
	  	[Suite 400 (395 OPB); 15,378 rsf]

 TABLE OF CONTENTS 

 

							
	1	  	BASIC LEASE TERMS	  	 	1	  
			
	2	  	USE	  	 	5	  
			
	3	  	PREPARATION OF THE PREMISES	  	 	6	  
			
	4	  	ADJUSTMENTS OF RENT	  	 	6	  
			
	5	  	SECURITY DEPOSIT	  	 	13	  
			
	6	  	COMPLIANCE WITH LAWS	  	 	13	  
			
	7	  	HAZARDOUS MATERIALS	  	 	14	  
			
	8	  	SERVICES AND UTILITIES	  	 	16	  
			
	9	  	TENANT’S CHANGES	  	 	19	  
			
	10	  	TENANT’S PROPERTY	  	 	21	  
			
	11	  	CONDITION UPON SURRENDER	  	 	22	  
			
	12	  	REPAIRS AND MAINTENANCE	  	 	22	  
			
	13	  	RULES AND REGULATIONS	  	 	23	  
			
	14	  	INSURANCE AND INDEMNIFICATION	  	 	23	  
			
	15	  	DAMAGE OR DESTRUCTION	  	 	27	  
			
	16	  	EMINENT DOMAIN	  	 	29	  
			
	17	  	ASSIGNMENT AND SUBLETTING	  	 	30	  
			
	18	  	SUBORDINATION AND ATTORNMENT	  	 	35	  
			
	19	  	FINANCING REQUIREMENTS	  	 	36	  
			
	20	  	DEFAULT	  	 	36	  
			
	21	  	LIMITATIONS ON LANDLORD’S LIABILITY	  	 	39	  
			
	22	  	ESTOPPEL CERTIFICATES	  	 	40	  
			
	23	  	NOTICES	  	 	40	  
			
	24	  	BROKERS	  	 	41	  
			
	25	  	RIGHTS RESERVED TO LANDLORD	  	 	41	  
			
	26	  	BUILDING PLANNING	  	 	43	  
			
	27	  	HOLDING OVER	  	 	43	  
			
	28	  	PARKING	  	 	43	  
			
	29	  	MISCELLANEOUS PROVISIONS	  	 	44	  

  

  
 Oyster Point Marina
Plaza Lease Table of Contents 
 page T-1 of 1 

 INDEX OF DEFINED TERMS 

 

			
	A	  	
		
	Additional Rent	  	4, 8, 12, 23, 33, 34, 35, 36, 46
	Adjustment Period	  	8, 9, 10, 12, 13, 14, 15
	Assumed Base Amount	  	14
	Athletic Facility	  	5, 12, 51
		
	B	  	
		
	Base Expense Year	  	9
	Base Operating Expenses	  	8, 9, 13, 14
	Base Real Estate Taxes	  	9, 13, 14
	Base Rent	  	1, 4, 8, 13, 15, 20, 30, 31, 33, 34, 35, 36, 38
	Base Tax Year	  	9, 14
	Base Utilities	  	9, 13
	Building	  	1, 4, 5, 6, 7, 9, 10, 11, 12, 13, 18, 19, 20, 21, 22, 24, 25, 27, 29, 31, 33, 34, 36, 37, 42, 44, 45, 46, 49, 50
	Business Hours	  	19
	Business Personal Property	  	26, 27, 28
		
	C	  	
		
	Claims	  	28, 29, 30, 35, 42, 44
	Code Costs	  	16
	Commencement Date	  	1, 2, 4, 8, 11, 16, 19, 39, 42, 51
	Complex	  	1, 2, 4, 5, 6, 9, 12, 14, 24, 29, 31, 33, 34, 37, 39, 42, 45, 49, 50
		
	E	  	
		
	Event of Default	  	39, 40
	Expiration Date	  	1, 2, 13, 16, 18, 24, 35
		
	F	  	
		
	Force Majeure Delays	  	50
		
	H	  	
		
	Hazardous Material	  	16, 17, 18
	Holder	  	27, 38, 39, 41, 42
	Holidays	  	19, 46
	HVAC	  	18, 19, 20, 21
		
	I	  	
		
	Improvements	  	7, 24, 25, 31, 44
	INC	  	1, 6, 19, 22, 25, 29
	IW	  	25
		
	L	  	
		
	Landlord	  	1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
	Laws	  	6, 11, 16, 17, 19, 20, 22, 23, 25
	Lease	  	i, 1, 2, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
	Lessor	  	27, 38, 42

  

  
 Oyster Point Marina
Plaza Lease Table of Defined Terms 
 Page I-ii of 1 

			
		
	M	  	
	 MPOE
	  	19
	 MSDS
	  	17
		
	O	  	
		
	Occupancy Conditions	  	7, 8
	 Operating Expenses
	  	8, 9, 10, 11, 12, 13, 14, 18, 31
		
	P	  	
		
	Parking Facility	  	46
	 Permitted Occupant
	  	34, 37
	 Premises
	  	1, 2, 5, 6, 7, 8, 9, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 44, 45, 47, 49, 50, 51
	 Prime Rate
	  	4
	 Property
	  	2, 4, 5, 6, 9, 10, 11, 12, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 36, 37, 39, 40, 41, 42, 43, 44, 45, 47
		
	R	  	
		
	Real Estate Taxes	  	9, 10, 13, 14
	 Rent
	  	1, 4, 5, 6, 8, 10, 12, 13, 15, 16, 20, 21, 23, 29, 30, 31, 32, 33, 34, 35, 36, 38, 40, 41, 42, 44, 45, 46, 47, 48
	 Rental Adjustment
	  	9, 12, 13
	 Rules
	  	5, 26, 51
		
	S	  	
		
	Security Deposit	  	15, 16
	 State
	  	1, 10, 16, 27, 49
	 Statement
	  	12, 13, 15
	 Subsequent Operating Expenses
	  	13, 14
	 Successor Landlord
	  	38
	 Superior Leases
	  	38
	 Superior Mortgages
	  	12, 38
	 Systems and Equipment
	  	4, 5, 6, 7, 11, 18, 19, 20, 21, 22, 25, 29, 45
		
	T	  	
		
	Table	  	1, 2, 4, 8, 9, 45
	 Takings
	  	32
	 Temporary Condemnation
	  	32
	 Tenant
	  	1, 2, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
	 Tenant Delays
	  	8
	 Term
	  	1, 2, 4, 7, 8, 9, 10, 12, 13, 14, 16, 19, 21, 24, 27, 31, 32, 33, 41, 44, 45, 46, 47, 48, 50
	 Transfer
	  	32, 33, 34, 35, 36, 39, 42
	 Transfer Notice
	  	33, 34, 35
	 Transfer Premium
	  	35, 36
		
	U	  	
		
	Utilities	  	8, 9, 10, 12, 13, 14, 18
		
	W	  	
		
	Work	  	7, 8, 23, 25, 51

  

  
 Oyster Point Marina
Plaza Lease Table of Defined Terms 
 Page I-iii of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]